<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1505257395
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DOCADEX 20 mg/ml Injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DOCETAXEL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        126.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="S.C Sindan pharma SRL" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            S.C Sindan pharma SRL
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01CD02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The name of this medicine is Docadex. Its common name is docetaxel.</p><p>Docetaxel is a substance derived from the needles of yew trees.<br />Docetaxel belongs to the group of anti-cancer medicines called taxoids.</p><p>Docadex has been prescribed by your doctor for the treatment of breast cancer, special forms of lung cancer (non-small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer:<br />- For the treatment of advanced breast cancer, Docadex could be administered either alone or in combination&nbsp;with doxorubicin, or trastuzumab, or capecitabine.<br />- For the treatment of early breast cancer with or without lymph node involvement, Docadex could be&nbsp;administered in combination with doxorubicin and cyclophosphamide.<br />- For the treatment of lung cancer, Docadex could be administered either alone or in combination with&nbsp;cisplatin.<br />- For the treatment of prostate cancer, Docadex is administered in combination with prednisone or&nbsp;prednisolone.<br />- For the treatment of metastatic gastric cancer, Docadex is administered in combination with cisplatin and 5-fluorouracil.<br />- For the treatment of head and neck cancer, Docadex is administered in combination with cisplatin and 5-fluorouracil.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Docadex:</strong></p><p>- if you are allergic to docetaxel or any of the other ingredients of this medicine (listed in section 6). - if the number of white blood cells is too low.<br />- if you have a severe liver disease.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before using Docadex</p><p>Before each treatment with Docadex, you will have blood tests to check that you have enough blood cells and sufficient liver function to receive Docadex. In case of white blood cells disturbances, you may experience associated fever or infections.</p><p>Tell your doctor, hospital pharmacist or nurse if you have vision problems. In case of vision problems, in particular blurred vision, you should immediately have your eyes and vision examined.</p><p>If you develop acute or worsening problem with your lungs (fever, shortness of breath or cough), please tell your doctor, pharmacist or nurse immediately. Your doctor may stop your treatment immediately.</p><p>You will be asked to take premedication consisting of an oral corticosteroid such as dexamethasone, one day prior to Docadex administration and to continue for one or two days after it in order to minimize certain undesirable effects which may occur after the infusion of Docadex in particular allergic reactions and fluid retention (swelling of the hands, feet, legs or weight gain).</p><p>During treatment, you may be given other medicines to maintain the number of your blood cells.</p><p>Docetaxel contains alcohol. Discuss with your doctor if you suffer from alcohol dependency or liver impairment. See also section &ldquo;Docetaxel contains ethanol (alcohol)&rdquo; below.</p><p><strong>Other medicines and Docadex</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicine. This is because Docadex or the other medicine may not work as well as expected and you may be more likely to get a side effect.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p><strong>Pregnancy</strong><br />Docadex must NOT be administered if you are pregnant unless clearly indicated by your doctor.</p><p>You must not become pregnant during treatment with this medicine and must use an effective method of contraceptive during therapy, because Docadex may be harmful for the unborn baby. If pregnancy occurs during your treatment, you must immediately inform your doctor.</p><p><strong>Breast-feeding</strong><br />You must NOT breast-feed while you are treated with Docadex.</p><p><strong>Fertility</strong><br />If you are a man being treated with Docadex you are advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment because docetaxel may alter male fertility.</p><p><strong>Driving and using machines</strong></p><p>No studies on the effects on the ability to drive and use machines have been performed.<br />There is no reason why you cannot drive between courses of Docadex except if you feel dizzy or are unsure of yourself. In higher doses (7.5 ml concentrate (150 mg) contains 3 g ethanol) the amount of alcohol may impair your ability to drive or use machines.</p><p><strong>Docadex contains ethanol (alcohol)</strong></p><p>4 ml vial:&nbsp;This medicinal product contains 51 vol % ethanol (alcohol), i.e. up to 1.6 g (2.02 ml) per vial, equivalent to 40.4 ml of beer or 16.83 ml wine per vial.</p><p>Harmful for those suffering from alcoholism.</p><p>To be taken into account if you are pregnant or if you are a breast-feeding woman, in children and high-risk groups such as patients with liver disease, or epilepsy.</p><p>The amount of alcohol in this medicinal product may alter the effects of other medicines.<br />The amount of alcohol in this medicinal product may impair your ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Docadex will be administered to you by a healthcare professional.</p><p><strong>Usual dosage</strong></p><p>The dose will depend on your weight and your general condition. Your doctor will calculate your body surface area in square meters (m2) and will determine the dose you should receive.</p><p><strong>Method and route of administration</strong></p><p>Docadex will be given by infusion into one of your veins. The infusion will last approximately one hour during which you will be in the hospital.</p><p><strong>Frequency of administration</strong></p><p>You should usually receive your infusion once every 3 weeks.</p><p>Your doctor may change the dose and frequency of dosing depending on your blood tests, your general condition and your response to Docadex. In particular, please inform your doctor in case of diarrhoea, sores in the mouth, feeling of numbness or pins and needles, fever and give her/him results of your blood tests. Such information will allow her/him to decide whether a dose reduction is needed. If you have any further questions on the use of this product, ask your doctor, or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Your doctor will discuss these with you and will explain the potential risks and benefits of your treatment.</p><p>The most commonly reported adverse reactions of Docadex alone are: decrease in the number of red blood cells or white blood cells, alopecia, nausea, vomiting, sores in the mouth, diarrhea and tiredness.</p><p>The severity of adverse events of Docadex may be increased when Docadex is given in combination with other chemotherapeutic agents.</p><p>During the infusion at the hospital the following allergic reactions (may affect more than 1 in 10 people):<br />&bull; flushing, skin reactions, itching<br />&bull; chest tightness; difficulty in breathing<br />&bull; fever or chills<br />&bull; back pain<br />&bull; low blood pressure<br />More severe reactions may occur.</p><p>The hospital staff will monitor your condition closely during treatment. Tell them immediately if you notice any of these effects.</p><p>Between infusions of Docadex the following may occur, and the frequency may vary with the combinations of medicines that are received:</p><p><strong>Very Common&nbsp;(may affect more than 1 in 10 people):</strong><br />&bull; infections, decrease in the number of red (anemia), or white blood cells (which are important&nbsp;in fighting infection) and platelets,<br />&bull; fever: if this happens you must tell your doctor immediately<br />&bull; allergic reactions as described above<br />&bull; loss of appetite (anorexia)<br />&bull; insomnia<br />&bull; feeling of numbness or pins and needles or pain in the joints or muscles<br />&bull; headache<br />&bull; alteration in sense of taste<br />&bull; inflammation of the eye or increased tearing of the eyes<br />&bull; swelling caused by faulty lymphatic drainage<br />&bull; shortness of breath<br />&bull; nasal drainage; inflammation of the throat and nose; cough<br />&bull; bleeding from the nose<br />&bull; sores in the mouth<br />&bull; stomach upsets including nausea, vomiting and diarrhea, constipation<br />&bull; abdominal pain<br />&bull; indigestion<br />&bull; hair loss (in most cases normal hair growth should return)<br />&bull; redness and swelling of the palms of your hands or soles of your feet which may cause your&nbsp;skin to peel (this may also occur on the arms, face, or body) &bull; change in the color of your nails, which may detach<br />&bull; muscle aches and pains; back pain or bone pain<br />&bull; change or absence of menstrual period<br />&bull; swelling of the hands, feet, legs<br />&bull; tiredness; or flu-like symptoms<br />&bull; weight gain or loss</p><p><strong>Common&nbsp;(may affect up to 1 in 10 people): &bull; oral candidiasis</strong><br />&bull; dehydration<br />&bull; dizziness<br />&bull; hearing impaired<br />&bull; decrease in blood pressure; irregular or rapid heart beat<br />&bull; heart failure<br />&bull; esophagitis<br />&bull; dry mouth<br />&bull; difficulty or painful swallowing<br />&bull; hemorrhage<br />&bull; raised liver enzymes (hence the need for regular blood tests)</p><p><strong>Uncommon&nbsp;(may affect up to 1 in 100 people):</strong><br />&bull; fainting<br />&bull; at the injection site, skin reactions, phlebitis (inflammation of the vein) or swelling &bull; inflammation of the colon, small intestine; intestinal perforation<br />&bull; blood clots</p><p><strong>Frequency unknown:</strong></p><p>&bull;&nbsp;interstitial lung disease (inflammation of the lungs causing coughing and difficulty breathing. Inflammation of the lungs can also develop when docetaxel therapy is used with radiotherapy)</p><ul><li><p>pneumonia (infection of the lungs)</p></li><li><p>pulmonary fibrosis (scarring and thickening in the lungs with shortness of breath)</p></li><li><p>burn like appearance at the injection site may appear several days after the last dose.</p></li><li><p>blurred vision due to swelling of the retina within the eye (cystoid macular edema)</p></li><li><p>decrease of sodium in your blood.</p></li></ul><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed&nbsp;in this leaflet. You can also report side effects directly via the National Pharmacovigilance and Drug Safety Centre (NPC) +966-11-2038222. Exts: 2317-2356-2353-2354-2334-2340. Toll free phone: 8002490000. E- mail: npc.drug@sfda.gov.sa. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton and&nbsp;vial. Store below 30&deg;C.<br />Store in the original package in order to protect from light.</p><p>Do not refrigerate or freeze.</p><p>After opening of the vial:</p><p>Each vial is for single use and should be used immediately after opening. If not used immediately, in- use storage times and conditions are the responsibility of the user.</p><p>Once added to the infusion bag:</p><p>The diluted solution should be used immediately after preparation. If not used immediately the in-use storage times and conditions are the responsibility of the user and would not normally be longer than 3 days when stored between 2-8&deg;C protected from light or 8 hours at room temperature (below 25&deg;C) including the one hour infusion.</p><p>Dispose any unused product or waste material in accordance with local requirements.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substanceis docetaxel. Each ml of docetaxel solution contains 20 mg of&nbsp;docetaxel anhydrous.<br />- The other ingredients are citric acid anhydrous, povidone, ethanol absolute and polysorbate80.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Docadex concentrate for solution for infusion is a clear, pale yellow solution.
Pack sizes:
1 x 4 ml into 8 ml vial (S. C. Sindan-Pharma S.R.L) 1 x 4 ml into 10 ml vial (Actavis Italy S.p.A.)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Tadawy Biomedical company Olaya st<br />Riyadh<br />Saudi Arabia</p><p><strong>Manufacturer</strong></p><p>S. C. Sindan-Pharma S.R.L</p><p>11 Ion Mihalache Blvd,</p><p>011171 Bucharest, Romania</p><p>Actavis Italy S.p.A.<br />Via Pasteur 10<br />20014 Nerviano (MI), Italy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                YYYY
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">اسم هذا الدواء هو&nbsp;<strong>دوكادكس</strong>. واسمه العام هو دوسيتاكسيل. دوسيتاكسيل&nbsp;&nbsp;مادة مشتقة من إبر أشجار الطقسوس الصنوبرية.</p><p dir="RTL">ينتمي دوسيتاكسيل إلى مجموعة الأدوية المضادة للسرطان والمسماة &quot;تاكسوئيدات&quot;.</p><p dir="RTL">تم وصف&nbsp;<strong>دوكادكس</strong>&nbsp;من قبل طبيبك لعلاج سرطان الثدي، وأشكال خاصة من سرطان الرئة (سرطان الرئة ذو الخلايا غير الصغيرة)، سرطان البروستاتا، سرطان المعدة أو سرطان الرأس والعنق:</p><p dir="RTL">- لعلاج سرطان الثدي المتقدم، يمكن إعطاء&nbsp;<strong>دوكادكس</strong>&nbsp;إما بمفرده أو بالاشتراك مع دوكسوروبيسين، أو تراستوزوماب، أو كابيسيتابين.</p><p dir="RTL">- لعلاج سرطان الثدي المبكر مع أو بدون تدخل العقدة الليمفاوية، يمكن إعطاء&nbsp;<strong>دوكادكس</strong>&nbsp;بالمشاركة مع دوكسوروبيسين وسايكلوفوسفاميد.</p><p dir="RTL">- لعلاج سرطان الرئة، يمكن إعطاء&nbsp;<strong>دوكادكس</strong>&nbsp;إما بمفرده أو بالاشتراك مع سيسبلاتين.</p><p dir="RTL">- لعلاج سرطان البروستاتا، يُعطى&nbsp;<strong>دوكادكس</strong>&nbsp;بالاشتراك مع بريدنيزون أو بريدنيزولون.</p><p dir="RTL">- لعلاج سرطان المعدة المتنقل، يُعطى&nbsp;<strong>دوكادكس</strong>&nbsp;بالاشتراك مع سيسبلاتين و 5&nbsp;-&nbsp;فلورويوراسيل.</p><p dir="RTL">- لعلاج سرطان الرأس والرقبة، يُعطى&nbsp;<strong>دوكادكس</strong>&nbsp;بالاشتراك مع سيسبلاتين و 5- فلورويوراسيل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم دوكادكس:</strong></p><p dir="RTL">- إذا كنت تعاني من حساسية تجاه دوسيتاكسيل أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">- إذا كان عدد خلايا الدم البيضاء منخفضاً جداً.</p><p dir="RTL">- إذا كنت تعاني من مرض كبدي حاد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المحاذير والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل استخدام&nbsp;<strong>دوكادكس</strong>.</p><p dir="RTL">قبل كل علاج بدواء&nbsp;<strong>دوكادكس</strong>، سيكون لديك اختبارات دم للتأكد من أن لديك خلايا دم كافية ووظيفة كبد كافية لتلقي دواء&nbsp;<strong>دوكادكس</strong>. في حالة اضطرابات خلايا الدم البيضاء، قد تواجه حمى مرتبطة أو عدوى.</p><p dir="RTL">أخبر طبيبك, صيدلي المستشفى أو الممرضة إذا كنت تعاني من مشاكل في الرؤية. في حالة وجود مشاكل في الرؤية، خاصة عدم وضوح الرؤية، يجب فحص عينيك ورؤيتك على الفور.</p><p dir="RTL">إذا كنت تعاني من مشكلة حادة أو متفاقمة في رئتيك (حمى, ضيق التنفس أو سعال)، يرجى إخبار طبيبك, الصيدلي أو الممرضة على الفور. قد يوقف طبيبك العلاج على الفور.</p><p dir="RTL">سيُطلب منك أن تأخذ مسبقاً أدوية تتكون من كورتيكوستيروئيد عن طريق الفم مثل: ديكساميثازون، قبل يوم واحد من إعطائك&nbsp;<strong>دوكادكس</strong>&nbsp;وأن تستمر لمدة يوم أو يومين بعده من أجل تقليل بعض التأثيرات غير المرغوبة التي قد تحدث بعد تسريب&nbsp;<strong>دوكادكس</strong>&nbsp;بشكل خاص في ردود الفعل التحسسية واحتباس السوائل (تورم اليدين, القدمين, الساقين أو زيادة الوزن).</p><p dir="RTL">أثناء العلاج، قد يتم إعطاؤك أدوية أخرى للحفاظ على عدد خلايا دمك.</p><p dir="RTL">إن دوسيتاكسيل يحتوي على الكحول. تحدَّث مع طبيبك إذا كنت تعاني من إدمان الكحول أو ضعف الكبد. انظر أيضاً القسم &quot;يحتوي دوسيتاكسيل على الإيثانول (الكحول)&quot; أدناه.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى و</strong><strong>&nbsp;دوكادكس</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو أخذت مؤخراً أو قد تأخذ أي دواء آخر. ذلك لأن&nbsp;<strong>دوكادكس</strong>&nbsp;أو الدواء الآخر قد لا يعمل بشكل جيد كما هو متوقع وقد تكون أكثر عرضة لتأثيرات جانبية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل, والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">إذا كنتِ حاملاً أو مرضعةً، تظنينَ أنكِ قد تكوني حاملاً أو أنكِ تُخططينَ لإنجاب طفلٍ، اسألي طبيبكِ للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL"><u>الحمل</u></p><p dir="RTL"><strong>لا</strong>&nbsp;يجب إعطاء&nbsp;<strong>دوكادكس</strong>&nbsp;إذا كنتِ حاملاً إلا إذا أوصى طبيبك ذلك بوضوح.</p><p dir="RTL">يجب ألا تصبحي حاملاً أثناء العلاج بهذا الدواء ويجب أن تستخدمي وسيلة فعالة لمنع الحمل أثناء العلاج، لأن&nbsp;<strong>دوكادكس</strong>&nbsp;قد يكون ضاراً على الجنين. إذا حدث الحمل أثناء علاجكِ، يجب عليكِ إبلاغ طبيبكِ على الفور.</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">يجب عليكِ&nbsp;<strong>عـدم</strong>&nbsp;الرضاعة الطبيعية أثناء علاجكِ بدواء&nbsp;<strong>دوكادكس</strong>.</p><p dir="RTL"><u>الخصوبة</u></p><p dir="RTL">إذا كنتَ رجلاً وتعالج بدواء&nbsp;<strong>دوكادكس</strong>, يُنصح بعدم إنجاب طفل خلال فترة العلاج وحتى فترة تصل إلى 6 أشهر بعد العلاج مع طلب المشورة بشأن حفظ الحيوانات المنوية قبل العلاج لأن دوسيتاكسيل قد يغير خصوبة الذكور.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لم يتم إجراء دراسات حول التأثيرات على القدرة لقيادة واستخدام الآلات.</p><p dir="RTL">لا يوجد سبب يمنعك من القيادة بين جرعات&nbsp;<strong>دوكادكس</strong>&nbsp;إلا إذا كنت تشعر بالدوار أو أنك غير متأكد من نفسك. في الجرعات الكبيرة (7,5 مل تركيز (150 ملغ) تحتوي على 3 غرام إيثانول) قد تؤدي كمية الكحول إلى إضعاف قدرتك على القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي</strong><strong>&nbsp;دوكادكس</strong><strong>&nbsp;على الإيثانول (الكحول)</strong></p><p dir="RTL"><em><u>قارورة سعة 4 مل:</u></em>&nbsp;يحتوي هذا المنتج الطبي على حجم 51٪ من الإيثانول (الكحول)، أي ما يصل إلى 1,6غرام (2,02 مل) لكل قارورة، ما يعادل 40,4 مل من البيرة أو 16,83 مل من النبيذ لكل قارورة.</p><p dir="RTL">فهو ضارٌّ لأولئك الذين يعانون من إدمان الكحول.</p><p dir="RTL">يجب الأخذ بالحسبان فيما إذا كنتِ حاملاً أو إذا كنتِ امرأةً مرضعةً، وفي الأطفال والمجموعات المعرضة للخطر أمثال المرضى الذين يعانون من مرض الكبد, أو الصرع.</p><p dir="RTL">إن كمية الكحول في هذا المنتج الطبي قد تُغير من تأثيرات الأدوية الأخرى.</p><p dir="RTL">وقد تُضعف كمية الكحول في هذا المنتج الطبي قدرتك على القيادة أو استخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سوف يُعطى لك&nbsp;<strong>دوكادكس</strong>&nbsp;من قبل أخصائي الرعاية الصحية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة المعتادة</strong></p><p dir="RTL">تعتمد الجرعة على وزنك وحالتك العامة. سيقوم طبيبك بحساب مساحة سطح جسمك بالأمتار المربعة (م2) وسيحدد الجرعة التي يجب أن تتلقاها.</p><p dir="RTL"><strong>أسلوب وطريق الإعطاء</strong></p><p dir="RTL">سوف يُعطى&nbsp;<strong>دوكادكس&nbsp;</strong>عن طريق الحقن في أحد أوردتك. وسوف يستمر الحقن لمدة ساعة تقريباً تكون خلالها في المستشفى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تكرار الإعطاء</strong></p><p dir="RTL">يجب أن تتلقى الحقن عادة مرة واحدة كل 3 أسابيع.</p><p dir="RTL">قد يغير طبيبك الجرعة وتكرار الجرعات&nbsp;&nbsp;اعتماداً على اختبارات دمك, وحالتك العامة واستجابتك لدواء&nbsp;<strong>دوكادكس</strong>. على وجه الخصوص، يرجى إبلاغ طبيبك في حالة الإسهال، تقرحات في الفم، شعور بالخدر أو وخز الدبابيس والإبر, الحمى وإعطائه نتائج اختبارات دمك. ستسمح هذه المعلومات لطبيبك بتحديد ما إذا كانت هناك حاجة لخفض الجرعة. إذا كان لديك أية أسئلة أخرى حول استخدام هذا المنتج، اسأل طبيبك, أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سوف يُعطى لك&nbsp;<strong>دوكادكس</strong>&nbsp;من قبل أخصائي الرعاية الصحية.</p><p dir="RTL"><strong>الجرعة المعتادة</strong></p><p dir="RTL">تعتمد الجرعة على وزنك وحالتك العامة. سيقوم طبيبك بحساب مساحة سطح جسمك بالأمتار المربعة (م2) وسيحدد الجرعة التي يجب أن تتلقاها.</p><p dir="RTL"><strong>أسلوب وطريق الإعطاء</strong></p><p dir="RTL">سوف يُعطى&nbsp;<strong>دوكادكس&nbsp;</strong>عن طريق الحقن في أحد أوردتك. وسوف يستمر الحقن لمدة ساعة تقريباً تكون خلالها في المستشفى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تكرار الإعطاء</strong></p><p dir="RTL">يجب أن تتلقى عادة الحقن مرة واحدة كل 3 أسابيع.</p><p dir="RTL">قد يغير طبيبك الجرعة وتكرار الجرعات&nbsp;&nbsp;اعتماداً على اختبارات دمك, وحالتك العامة واستجابتك لدواء&nbsp;<strong>دوكادكس</strong>. على وجه الخصوص، يرجى إبلاغ طبيبك في حالة الإسهال، تقرحات في الفم، شعور بالخدر أو وخز الدبابيس والإبر, الحمى وإعطائه نتائج اختبارات دمك. ستسمح هذه المعلومات لطبيبك بتحديد ما إذا كانت هناك حاجة لخفض الجرعة. إذا كانت لديك أية أسئلة أخرى حول استخدام هذا المنتج، اسأل طبيبك, أو الصيدلي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>4- تأثيرات جانبية محتملة</strong></p><p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء تأثيرات جانبية ، وإن كانت لا تحدث لكل شخص.</p><p dir="RTL">سيناقش طبيبك هذه الأمور معك وسوف يشرح المخاطر والفوائد المحتملة لعلاجك.</p><p dir="RTL">التفاعلات الضارة الأكثر شيوعاً التي تم الإبلاغ عنها باستعمال دواء&nbsp;<strong>دوكادكس</strong>&nbsp;لوحده هي: انخفاض عدد خلايا الدم الحمراء أو خلايا الدم البيضاء, سقوط الشعر، غثيان، قيء، قروح في الفم، إسهال وتعب.</p><p dir="RTL">قد تزداد شدة الأحداث الضارة لدواء&nbsp;<strong>دوكادكس</strong>&nbsp;عندما يتم إعطاء&nbsp;<strong>دوكادكس</strong>&nbsp;بالاشتراك مع مواد علاجية كيميائية أخرى.</p><p dir="RTL">أثناء التسريب في المستشفى، ردود الفعل التحسسية التالية (قد تؤثر في أكثر من 1 من كل 10 أشخاص):</p><p dir="RTL">&bull; توَهُّج، ردود فعل الجلد، حكة</p><p dir="RTL">&bull; ضيق صدر؛ صعوبة في التنفس</p><p dir="RTL">&bull; حمى أو قشعريرة</p><p dir="RTL">&bull; ألم الظهر</p><p dir="RTL">&bull; ضغط دم منخفض</p><p dir="RTL">قد تحدث ردود فعل أكثر حدة.</p><p dir="RTL">سيقوم موظفوا المستشفى بمراقبة حالتك عن كثب أثناء العلاج. أخبرهم على الفور إذا لاحظت أيّاً من هذه التأثيرات.</p><p dir="RTL">قد تحدث الحالات التالية بين جرعات&nbsp;<strong>دوكادكس</strong>, وقد يختلف تكرارها مع مشاركة الأدوية التي يتم تلقيها:</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة جداً</strong>&nbsp;(قد يؤثر في أكثر من 1 من كل 10 أشخاص):</p><p dir="RTL">&bull; التهابات، انخفاض عدد خلايا الدم الحمراء (فقر الدم)، أو خلايا الدم البيضاء (والتي تعتبر مهمة في مكافحة العدوى) والصفائح الدموية</p><p dir="RTL">&bull; حمى: إذا حدث ذلك، يجب عليك إخبار طبيبك على الفور</p><p dir="RTL">&bull; ردود فعل تحسسية كما هو موصوف أعلاه</p><p dir="RTL">&bull; فقدان الشهية (أنوريكسيا)</p><p dir="RTL">&bull; أرق</p><p dir="RTL">&bull; شعور بالتنميل أو الدبابيس والإبر أو ألم في المفاصل أو العضلات</p><p dir="RTL">&bull; صداع</p><p dir="RTL">&bull; تغيُّر في حاسة التَّذوُّق</p><p dir="RTL">&bull; التهاب العين أو زيادة دموع العينين</p><p dir="RTL">&bull; تورم ناتج عن خلل في التصريف اللمفاوي</p><p dir="RTL">&bull; ضيق في التنفس</p><p dir="RTL">&bull; سيلان الأنف؛ التهاب الحلق والأنف؛ سعال</p><p dir="RTL">&bull; نزيف من الأنف</p><p dir="RTL">&bull; قروح في الفم</p><p dir="RTL">&bull; اضطرابات في المعدة بما في ذلك الغثيان, القيء, الإسهال, والإمساك</p><p dir="RTL">&bull; وجع بطن</p><p dir="RTL">&bull; عسر الهضم</p><p dir="RTL">&bull; تساقط الشعر (في معظم الحالات يعود نمو الشعر الطبيعي)</p><p dir="RTL">&bull; احمرار وتورم راحة يديك أو باطن قدميك مما قد يسبب لك تقشر الجلد (قد يحدث ذلك أيضاً على الذراعين, الوجه, أو الجسم)</p><p dir="RTL">&bull; تغيُّر في لون أظافرك، والتي قد تنفصل</p><p dir="RTL">&bull; آلام العضلات وآلام؛ آلم الظهر أو آلم العظام</p><p dir="RTL">&bull; تغيُّر أو غياب فترة الحيض</p><p dir="RTL">&bull; تورم اليدين, القدمين, والساقين</p><p dir="RTL">&bull; تعب؛ أو أعراض شبيهة بالانفلونزا</p><p dir="RTL">&bull; زيادة الوزن أو فقدان الوزن</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong>&nbsp;(قد يؤثر حتى في 1 من كل 10 أشخاص):</p><p dir="RTL">&bull; داء المبيضات الفموي</p><p dir="RTL">&bull; تجفاف</p><p dir="RTL">&bull; دوخة</p><p dir="RTL">&bull; ضعف السمع</p><p dir="RTL">&bull; انخفاض في ضغط الدم؛ عدم انتظام أو سرعة ضربات القلب</p><p dir="RTL">&bull; فشل القلب</p><p dir="RTL">&bull; التهاب المريء</p><p dir="RTL">&bull; فم جاف</p><p dir="RTL">&bull; صعوبة أو ألم في البلع</p><p dir="RTL">&bull; نزيف</p><p dir="RTL">&bull; ارتفاع إنزيمات الكبد (والحاجة بالتالي إلى اختبارات دم منتظمة)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير شائعة</strong>&nbsp;(قد يؤثر حتى في 1 من كل 100 شخص):</p><p dir="RTL">&bull; إغماء</p><p dir="RTL">&bull; في موقع الحقن، تفاعلات الجلد، التهاب وريدي (التهاب الوريد) أو تورم</p><p dir="RTL">&bull; التهاب القولون, الأمعاء الدقيقة؛ انثقاب الأمعاء</p><p dir="RTL">&bull; جلطات الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حالات غير معروفة التكرار:</strong></p><p dir="RTL">&bull; مرض الرئة الخلالي (التهاب الرئتين يسبب سعال وصعوبة التنفس.</p><p dir="RTL">يمكن أن يتطور التهاب الرئتين أيضاً عند استخدام دوسيتاكسيل مع العلاج الإشعاعي)</p><p dir="RTL">&bull; التهاب رئوي (التهاب الرئتين)</p><p dir="RTL">&bull; تليف رئوي (تندب وسماكة في الرئتين مع ضيق في التنفس)</p><p dir="RTL">&bull; ظهور ما يشبه الحرق في موقع الحقن ربما تظهر لعدة أيام بعد آخر جرعة.</p><p dir="RTL">&bull; عدم وضوح الرؤية بسبب تورم الشبكية داخل العين (وذمة كيسية بقعية)</p><p dir="RTL">&bull; نقص الصوديوم في دمك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن التأثيرات الجانبية</strong></p><p dir="RTL">إذا حصل معك أية تأثيرات جانبية، تحدَّث إلى طبيبك أو الصيدلي. وهذا يتضمن أية تأثيرات جانبية محتملة غير مذكورة في هذه النشرة. يمكنك أيضاً الإبلاغ عن التأثيرات الجانبية مباشرةً عن طريق المركز الوطني للأدوية والسلامة الدوائية&nbsp;(NPC):</p><p dir="RTL">الهاتــــــف:&nbsp;&nbsp;اتصل بـ&nbsp;&nbsp;+966-11-2038222.</p><p dir="RTL">التحويلات:&nbsp;&nbsp;2317 &ndash; 2356 &ndash; 2353 &ndash; 2354 &ndash; 2334 - 2340.</p><p dir="RTL">الهاتـــف المجاني:&nbsp;8002490000.</p><p dir="RTL">البريد الإلكتروني:&nbsp;&nbsp;E-Mail:&nbsp;npc.drug@sfda.gov.sa.</p><p dir="RTL">إن قيامك بالإبلاغ عن التأثيرات الجانبية يساعد على التزوُّد بالمزيد من معلومات السلامة لهذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن رؤية ومتناول أيدي الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة والقارورة.</p><p dir="RTL">يحفظ بدرجة حرارة دون 30 مئوية.</p><p dir="RTL">يحفظ في العبوة&nbsp;&nbsp;الأصلية من أجل الحماية من الضوء.</p><p dir="RTL">لا تبرده أو تجمده.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>بعد فتح القارورة:</em></strong></p><p dir="RTL">كل قارورة مخصصة للاستخدام مرة واحدة ويجب استخدامها فوراً بعد الفتح. إذا لم تُستخدم على الفور، فإن أوقات وظروف التخزين قيد الاستخدام هي على مسؤولية المستخدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>بمجرد إضافتها إلى كيس التسريب:</em></strong></p><p dir="RTL">يجب استخدام المحلول المخفف مباشرة بعد التحضير. إذا لم يتم استخدامه على الفور، فإن أوقات وظروف التخزين قيد الاستخدام هي على مسؤولية المُستخدم وعادة لن تكون أطول من 3 أيام عند تخزينها بين 2- 8 درجة مئوية محمية من الضوء أو 8 ساعات بدرجة حرارة الغرفة (دون 25 درجة مئوية) بما في ذلك ساعة إعطاء التسريب.</p><p dir="RTL">تخلص من أي منتج غير مُستخدم أو نفايات وفقاً للمتطلبات المحلية.</p><p dir="RTL">لا تتخلص من أية أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. هذه التدابير سوف تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- المادة الفعالة هي دوسيتاكسيل. كل 1 مل من محلول دوسيتاكسيل يحتوي على 20 ملغ من دوسيتاكسيل اللامائي.</p><p dir="RTL">- المكونات الأخرى هي حامض الستريك اللامائي، بوفيدون، إيثانول مطلق وبوليسوربات 80.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>دوكادكس</strong>&nbsp;مركز للحل للتسريب هو محلول ناصع, أصفر شاحب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أحجام العبوة:</strong></p><p dir="RTL">1 &times; 4 مل في قارورة سعة 8 مل&nbsp;(S.C. Sindan-Pharma S.R.L.)</p><p dir="RTL">1 &times; 4 مل في قارورة سعة 10 مل&nbsp;(Actavis Italy S.p.A.)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>- حامل ترخيص التسويق</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;شركة تداوي الطبية الحيوية,</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;شارع عُلايا، الرياض،</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;- الصانع&nbsp;</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;إس. سي. سيندان - فارما إس. آر.إل</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11 شارع ايون ميهالاشي،</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;011171 بوخارست، رومانيا</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;أكتافيس إيطاليا إس. بي. إيه.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10 شارع باستور</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20014 نيرفيانو (إم آي), إيطاليا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة آخر مرة في XXXX
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Docadex
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each single dose vial contains docetaxel 20 mg/ml Each 4 ml single dose vial contains 80 mg docetaxel
Excipient with known effect: Ethanol absolute 400 mg/ml For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion

The concentrate is a clear, pale yellow solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Breast&nbsp;cancer</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Docadex&nbsp;in&nbsp;combination&nbsp;with&nbsp;doxorubicin&nbsp;and&nbsp;cyclophosphamide&nbsp;is&nbsp;indicated&nbsp;for&nbsp;the&nbsp;adjuvant&nbsp;treatment&nbsp;of patients with:</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->operable&nbsp;node-positive&nbsp;breast&nbsp;cancer</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;<!--[endif]-->operable&nbsp;node-negative&nbsp;breast&nbsp;cancer</p><p>&nbsp;</p><p>For&nbsp;patients&nbsp;with&nbsp;operable&nbsp;node-negative&nbsp;breast&nbsp;cancer,&nbsp;adjuvant&nbsp;treatment&nbsp;should&nbsp;be&nbsp;restricted&nbsp;to&nbsp;patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer (see section 5.1).</p><p>&nbsp;</p><p>Docadex&nbsp;in&nbsp;combination&nbsp;with&nbsp;doxorubicin&nbsp;is&nbsp;indicated&nbsp;for&nbsp;the&nbsp;treatment of patients&nbsp;with&nbsp;locally&nbsp;advanced&nbsp;or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.</p><p>&nbsp;</p><p>Docadex monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.</p><p>&nbsp;</p><p>Docadex in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer&nbsp;whosetumors&nbsp;over&nbsp;express&nbsp;HER2&nbsp;and&nbsp;who&nbsp;previously&nbsp;have&nbsp;not&nbsp;received&nbsp;chemotherapy&nbsp;for&nbsp;metastatic&nbsp;disease.</p><p>&nbsp;</p><p>Docadex&nbsp;in&nbsp;combination&nbsp;with&nbsp;capecitabine&nbsp;is&nbsp;indicated&nbsp;for&nbsp;the&nbsp;treatment of patients&nbsp;with&nbsp;locally&nbsp;advanced&nbsp;or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an&nbsp;anthracycline.</p><p>&nbsp;</p><p><strong><em>Non-small&nbsp;cell&nbsp;lung&nbsp;cancer</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Docadex&nbsp;is&nbsp;indicated&nbsp;for&nbsp;the&nbsp;treatment of patients&nbsp;with&nbsp;locally&nbsp;advanced&nbsp;or&nbsp;metastatic&nbsp;non-small&nbsp;cell lung cancer after failure of prior chemotherapy.</p><p>&nbsp;</p><p>Docadex&nbsp;in&nbsp;combination&nbsp;with&nbsp;cisplatin&nbsp;is&nbsp;indicated&nbsp;for&nbsp;the&nbsp;treatment of patients&nbsp;with&nbsp;unresectable,&nbsp;locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.</p><p>&nbsp;</p><p><strong><em>Prostate&nbsp;cancer</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Docadex&nbsp;in&nbsp;combination&nbsp;with&nbsp;prednisone&nbsp;or&nbsp;prednisolone&nbsp;is&nbsp;indicated&nbsp;for&nbsp;the&nbsp;treatment&nbsp;of&nbsp;patients&nbsp;with hormone refractory metastatic prostate cancer.</p><p>&nbsp;</p><p><strong><em>Gastric&nbsp;Adenocarcinoma</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Docadex in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastaticgastric&nbsp;adenocarcinoma,&nbsp;including&nbsp;adenocarcinoma&nbsp;of&nbsp;the&nbsp;gastroesophageal&nbsp;junction,&nbsp;who&nbsp;have not received prior chemotherapy for metastatic disease.</p><p>&nbsp;</p><p><strong><em>Head&nbsp;and&nbsp;neck&nbsp;cancer</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Docadex&nbsp;in&nbsp;combination&nbsp;with&nbsp;cisplatin&nbsp;and&nbsp;5-fluorouracil&nbsp;is&nbsp;indicated&nbsp;for the&nbsp;induction&nbsp;treatment of&nbsp;patients with locally advanced squamous cell carcinoma of the head and neck.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The&nbsp;use&nbsp;of docetaxel should&nbsp;be&nbsp;confined&nbsp;to&nbsp;units&nbsp;specialised&nbsp;in&nbsp;the&nbsp;administration&nbsp;of cytotoxic&nbsp;chemotherapy and it should only be administered under the supervision of a physician qualified in the use of anticancer chemotherapy (see section 6.6).</p><p>&nbsp;</p><p><strong><em>Recommended&nbsp;dosage</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>For breast, non-small cell lung, gastric, and head and neck cancers, premedication consisting of an oral corticosteroid, such as dexamethasone 16 mg per day (e.g. 8 mg BID) for 3 days starting 1 day prior to docetaxel&nbsp;administration,unless&nbsp;contraindicated,&nbsp;can&nbsp;be&nbsp;used&nbsp;(see&nbsp;section&nbsp;4.4).&nbsp;Prophylactic&nbsp;G-CSF&nbsp;may&nbsp;be used to mitigate the risk of hematological toxicities.</p><p>For prostate&nbsp;cancer,&nbsp;given&nbsp;the concurrent use&nbsp;of prednisone&nbsp;or prednisolone&nbsp;the&nbsp;recommended&nbsp;premedication regimen&nbsp;is oral dexamethasone 8&nbsp;mg,&nbsp;12&nbsp;hours, 3&nbsp;hours and&nbsp;1 hour before&nbsp;the docetaxel infusion&nbsp;(see section&nbsp;4.4).</p><p>&nbsp;</p><p>Docetaxel&nbsp;is&nbsp;administered&nbsp;as&nbsp;a&nbsp;one-hour&nbsp;infusion&nbsp;every&nbsp;three&nbsp;weeks.</p><p>&nbsp;</p><p><em>Breast&nbsp;cancer</em></p><p>In the adjuvant treatment of operable node-positive and node-negative breast cancer, the recommended dose ofdocetaxel&nbsp;is&nbsp;75&nbsp;mg/m<sup>2</sup>&nbsp;administered&nbsp;1-hour&nbsp;after&nbsp;doxorubicin&nbsp;50&nbsp;mg/m<sup>2</sup>&nbsp;and&nbsp;cyclophosphamide&nbsp;500&nbsp;mg/m<sup>2</sup>&nbsp;every 3 weeks for 6 cycles (TAC regiment) (see also Dosage adjustments during treatment).</p><p>For the treatment of patients with locally advanced or metastatic breast cancer, the recommended dosage of docetaxel is 100 mg/m<sup>2</sup>&nbsp;in monotherapy. In first-line treatment, docetaxel 75 mg/m<sup>2</sup>&nbsp;is given in combination therapy with doxorubicin (50 mg/m<sup>2</sup>).</p><p>&nbsp;</p><p>In&nbsp;combination&nbsp;with&nbsp;trastuzumab&nbsp;the&nbsp;recommended&nbsp;dose&nbsp;of&nbsp;docetaxel&nbsp;is&nbsp;100&nbsp;mg/m<sup>2</sup>&nbsp;every&nbsp;three&nbsp;weeks,&nbsp;with trastuzumab administered weekly. In the pivotal study the initial docetaxel infusion was started the day following the first dose of trastuzumab. The subsequent docetaxel doses were administered immediately after completion of the trastuzumab infusion, if the preceding dose of trastuzumab was well tolerated. For trastuzumab dosage and administration, see trastuzumab summary of product characteristics.</p><p>In&nbsp;combination&nbsp;with&nbsp;capecitabine,&nbsp;the&nbsp;recommended&nbsp;dose&nbsp;of docetaxel&nbsp;is&nbsp;75&nbsp;mg/m<sup>2</sup>&nbsp;every&nbsp;three&nbsp;weeks, combined with capecitabine at 1250 mg/m<sup>2</sup>&nbsp;twice daily (within 30 minutes after a meal) for 2 weeks followed by 1-week rest period. For capecitabine dose calculation according to body surface area, see capecitabine summary of product characteristics.</p><p>&nbsp;</p><p><em>Non-small&nbsp;cell&nbsp;lung&nbsp;cancer</em></p><p>In chemotherapy na&iuml;ve patients treated for non-small cell lung cancer, the recommended dose regimen is docetaxel 75 mg/m<sup>2</sup>&nbsp;immediately followed by cisplatin 75 mg/m<sup>2</sup>&nbsp;over 30-60 minutes. For treatment after failure of prior platinum-based chemotherapy, the recommended dose is 75 mg/m&sup2; as a single agent.</p><p>&nbsp;</p><p><em>Prostate&nbsp;cancer</em></p><p>The&nbsp;recommended&nbsp;dose&nbsp;of&nbsp;docetaxel is&nbsp;75&nbsp;mg/m<sup>2</sup>.&nbsp;Prednisone&nbsp;or prednisolone&nbsp;5&nbsp;mg&nbsp;orally&nbsp;twice&nbsp;daily&nbsp;is administered continuously (see section 5.1).</p><p>&nbsp;</p><p><em>Gastric&nbsp;adenocarcinoma</em></p><p>The&nbsp;recommended&nbsp;dose&nbsp;of&nbsp;docetaxel is&nbsp;75&nbsp;mg/m<sup>2</sup>&nbsp;as&nbsp;a&nbsp;1&nbsp;hour infusion,&nbsp;followed&nbsp;by&nbsp;cisplatin&nbsp;75&nbsp;mg/m<sup>2</sup>,&nbsp;as&nbsp;a 1&nbsp;to&nbsp;3hour infusion&nbsp;(both&nbsp;on&nbsp;day&nbsp;1&nbsp;only),&nbsp;followed&nbsp;by&nbsp;5-fluorouracil 750&nbsp;mg/m<sup>2</sup>&nbsp;per day&nbsp;given&nbsp;as&nbsp;a&nbsp;24-hour continuous infusion for 5 days, starting at the end of the cisplatin infusion.</p><p>Treatment is repeated every three weeks. Patients must receive premedication with antiemetics and appropriatehydration&nbsp;for&nbsp;cisplatin&nbsp;administration.&nbsp;Prophylactic&nbsp;G-CSF&nbsp;should&nbsp;be&nbsp;used&nbsp;to&nbsp;mitigate&nbsp;the&nbsp;risk&nbsp;of hematological toxicities (See also Dosage adjustments during treatment).</p><p>&nbsp;</p><p><em>Head&nbsp;and&nbsp;neck&nbsp;cancer</em></p><p>Patients&nbsp;must&nbsp;receive&nbsp;premedication&nbsp;with&nbsp;antiemetics&nbsp;and&nbsp;appropriate&nbsp;hydration&nbsp;(prior&nbsp;to&nbsp;and&nbsp;after&nbsp;cisplatin administration). Prophylactic G-CSF may be used to mitigate the risk of hematological toxicities. All patients on the docetaxel-containing arm of the TAX 323 and TAX 324 studies, received prophylactic&nbsp;antibiotics.</p><p>&nbsp;</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Induction&nbsp;chemotherapy&nbsp;followed&nbsp;by&nbsp;radiotherapy&nbsp;(TAX&nbsp;323)</p><p>For the induction treatment of inoperable locally advanced squamous cell carcinoma of the head and neck (SCCHN), the recommended dose of docetaxel is 75 mg/m<sup>2</sup>&nbsp;as a 1 hour infusion followed by cisplatin&nbsp;75&nbsp;mg/m<sup>2</sup>over 1&nbsp;hour,&nbsp;on&nbsp;day&nbsp;one,&nbsp;followed&nbsp;by&nbsp;5-fluorouracil&nbsp;as&nbsp;a&nbsp;continuous&nbsp;infusion&nbsp;at&nbsp;750 mg/m<sup>2</sup>&nbsp;per day for five days. This regimen is administered every 3 weeks for 4 cycles. Following chemotherapy, patients should receive radiotherapy.</p><p>&nbsp;</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Induction&nbsp;chemotherapy&nbsp;followed&nbsp;by&nbsp;chemoradiotherapy&nbsp;(TAX&nbsp;324)</p><p>For the induction treatment of patients with locally advanced (technically unresectable, low probability of surgical cure, and aiming at organ preservation) squamous cell carcinoma of the head and&nbsp;neck&nbsp;(SCCHN),&nbsp;therecommended&nbsp;dose&nbsp;of&nbsp;docetaxel is&nbsp;75&nbsp;mg/m<sup>2</sup>&nbsp;as&nbsp;a&nbsp;1&nbsp;hour intravenous&nbsp;infusion on day 1, followed by cisplatin 100 mg/m<sup>2</sup>&nbsp;administered as a 30-minute to 3 hour infusion, followed by 5-fluorouracil 1000 mg/m<sup>2</sup>/day as a continuous infusion from day 1 to day 4. This regimen is administered every 3 weeks for 3 cycles. Following chemotherapy, patients should receive&nbsp;chemoradiotherapy.</p><p>&nbsp;</p><p>For&nbsp;cisplatin&nbsp;and&nbsp;5-fluorouracil&nbsp;dose&nbsp;modifications,&nbsp;see&nbsp;the&nbsp;corresponding&nbsp;summary&nbsp;of&nbsp;product&nbsp;characteristics.</p><p>&nbsp;</p><p><strong><em>Dose&nbsp;adjustments&nbsp;during&nbsp;treatment</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><em>General</em></p><p>Docetaxel should be administered when the neutrophil count is &ge; 1,500 cells/mm<sup>3</sup>. In patients who experienced&nbsp;either febrile&nbsp;neutropenia, neutrophil&nbsp;&lt; 500 cells/mm<sup>3</sup>&nbsp;for&nbsp;more&nbsp;than&nbsp;one week,&nbsp;severe&nbsp;or cumulative&nbsp;cutaneous&nbsp;reactions&nbsp;orsevere&nbsp;peripheral&nbsp;neuropathy&nbsp;during&nbsp;docetaxel&nbsp;therapy,&nbsp;the&nbsp;dose&nbsp;of docetaxel should&nbsp;be reduced from 100 mg/m<sup>2</sup>&nbsp;to&nbsp;75mg/m<sup>2</sup>&nbsp;and/or from 75&nbsp;to 60&nbsp;mg/m&sup2;. If&nbsp;the patient continues to experience these reactions at 60 mg/m&sup2;, the treatment should be discontinued.</p><p><em>Adjuvant&nbsp;therapy&nbsp;for&nbsp;breast&nbsp;cancer</em></p><p>Primary G-CSF prophylaxis should be considered in patients who receive docetaxel, doxorubicin and cyclophosphamide (TAC) adjuvant therapy for breast cancer. Patients who experience febrile neutropenia and/or neutropenic&nbsp;infections&nbsp;should&nbsp;have&nbsp;their docetaxel dose&nbsp;reduced&nbsp;to&nbsp;60&nbsp;mg/m<sup>2</sup>&nbsp;in&nbsp;all subsequent&nbsp;cycles (see&nbsp;sections 4.4 and&nbsp;4.8).&nbsp;Patients who experience Grade 3 or&nbsp;4 stomatitis&nbsp;should&nbsp;have&nbsp;their dose decreased to 60 mg/m&sup2;.</p><p>&nbsp;</p><p><em>In&nbsp;combination&nbsp;with&nbsp;cisplatin</em></p><p>For patients&nbsp;who&nbsp;are&nbsp;dosed&nbsp;initially&nbsp;at docetaxel&nbsp;75&nbsp;mg/m<sup>2</sup>&nbsp;in&nbsp;combination&nbsp;with&nbsp;cisplatin&nbsp;and&nbsp;whose&nbsp;nadir of platelet count during the previous course of therapy is &lt; 25,000 cells/mm<sup>3</sup>, or in patients who experience febrile neutropenia, or in patients with serious non-hematologic toxicities, the docetaxel dosage in subsequent cycles should be reduced to 65 mg/m<sup>2</sup>. For cisplatin dosage adjustments, see manufacturer&rsquo;s summary of product characteristics.</p><p>&nbsp;</p><p><em>In&nbsp;combination&nbsp;with&nbsp;capecitabine</em></p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;<!--[endif]-->For&nbsp;capecitabine&nbsp;dose&nbsp;modifications,&nbsp;see&nbsp;capecitabine&nbsp;summary&nbsp;of&nbsp;product&nbsp;characteristics.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->For patients developing the first appearance of Grade 2 toxicity, which persists at the time of the next docetaxel/capecitabine&nbsp;treatment,&nbsp;delay&nbsp;treatment&nbsp;until&nbsp;resolved&nbsp;to&nbsp;Grade&nbsp;0-1,&nbsp;and&nbsp;resume&nbsp;at 100%&nbsp;of&nbsp;the original dose.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->For patients developing the second appearance of Grade 2 toxicity, or the first appearance of a Grade 3 toxicity, at any time during the treatment cycle, delay treatment until resolved to Grade 0-1, then resume treatment with docetaxel 55 mg/m&sup2;.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;<!--[endif]-->For&nbsp;any&nbsp;subsequent&nbsp;appearances&nbsp;of&nbsp;toxicities,&nbsp;or&nbsp;any&nbsp;Grade&nbsp;4&nbsp;toxicities,&nbsp;discontinue&nbsp;the&nbsp;docetaxel&nbsp;dose.</p><p>&nbsp;</p><p>For&nbsp;trastuzumab&nbsp;dose&nbsp;modifications,&nbsp;see&nbsp;trastuzumab&nbsp;summary&nbsp;of&nbsp;product&nbsp;characteristics</p><p>&nbsp;</p><p><em>In&nbsp;combination&nbsp;with&nbsp;cisplatin&nbsp;and&nbsp;5-fluorouracil</em></p><p>If&nbsp;an&nbsp;episode&nbsp;of&nbsp;febrile&nbsp;neutropenia,&nbsp;prolonged&nbsp;neutropenia&nbsp;or&nbsp;neutropenic&nbsp;infection&nbsp;occurs&nbsp;despite&nbsp;G-CSF use, the docetaxel dose should be reduced from 75 to 60 mg/m<sup>2</sup>. If subsequent episodes of</p><p>complicated&nbsp;neutropenia&nbsp;occur&nbsp;the&nbsp;docetaxel dose&nbsp;should&nbsp;be&nbsp;reduced&nbsp;from 60&nbsp;to&nbsp;45&nbsp;mg/m<sup>2</sup>.&nbsp;In&nbsp;case&nbsp;of Grade 4 thrombocytopenia the docetaxel dose should be reduced from 75 to 60 mg/m<sup>2</sup>. Patients should not be retreated with subsequent cycles of docetaxel until neutrophils recover to a level &gt; 1,500 cells/mm<sup>3</sup>&nbsp;and platelets recover to a level &gt; 100,000 cells/mm<sup>3</sup>. Discontinue treatment if these toxicities persist. (See section 4.4).</p><p>Recommended&nbsp;dose&nbsp;modifications&nbsp;for gastrointestinal&nbsp;toxicities&nbsp;in&nbsp;patients&nbsp;treated&nbsp;with&nbsp;docetaxel&nbsp;in combination with cisplatin and 5-fluorouracil (5-FU):</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Toxicity</strong></p></td><td style="vertical-align:top"><p><strong>Dosage&nbsp;adjustment</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea&nbsp;grade&nbsp;3</p></td><td style="vertical-align:top"><p>First&nbsp;episode:&nbsp;reduce&nbsp;5-FU&nbsp;dose&nbsp;by&nbsp;20%.</p><p>Second&nbsp;episode:&nbsp;then&nbsp;reduce&nbsp;docetaxel&nbsp;dose&nbsp;by&nbsp;20%.</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea&nbsp;grade&nbsp;4</p></td><td style="vertical-align:top"><p>First&nbsp;episode:&nbsp;reduce&nbsp;docetaxel&nbsp;and&nbsp;5-FU&nbsp;doses&nbsp;by&nbsp;20%. Second episode: discontinue treatment.</p></td></tr><tr><td style="vertical-align:top"><p>Stomatitis/mucositis&nbsp;grade 3</p></td><td style="vertical-align:top"><p>First&nbsp;episode:&nbsp;reduce&nbsp;5-FU&nbsp;dose&nbsp;by&nbsp;20%.</p><p>Second&nbsp;episode:&nbsp;stop&nbsp;5-FU&nbsp;only,&nbsp;at&nbsp;all&nbsp;subsequent&nbsp;cycles. Third episode: reduce docetaxel dose by 20%.</p></td></tr><tr><td style="vertical-align:top"><p>Stomatitis/mucositis&nbsp;grade 4</p></td><td style="vertical-align:top"><p>First&nbsp;episode:&nbsp;stop&nbsp;5-FU&nbsp;only,&nbsp;at&nbsp;all&nbsp;subsequent&nbsp;cycles. Second episode: reduce docetaxel dose by 20%.</p></td></tr></tbody></table><p>For&nbsp;cisplatin&nbsp;and&nbsp;5-fluorouracil&nbsp;dose&nbsp;adjustments,&nbsp;see&nbsp;the&nbsp;corresponding&nbsp;summary&nbsp;of&nbsp;product&nbsp;characteristics.</p><p>&nbsp;</p><p>In the pivotal SCCHN studies patients who experienced complicated neutropenia (including prolonged neutropenia,febrile&nbsp;neutropenia,&nbsp;or&nbsp;infection),&nbsp;it was&nbsp;recommended&nbsp;to&nbsp;use&nbsp;G-CSF&nbsp;to&nbsp;provide&nbsp;prophylactic coverage (eg, day 6-15) in all subsequent cycles.</p><p><strong><em>Special&nbsp;populations</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><em>Patients&nbsp;with&nbsp;hepatic&nbsp;impairment</em></p><p>Based on pharmacokinetic data with docetaxel at 100 mg/m&sup2; as single agent, patients who have both elevations of transaminase (ALT and/or AST) greater than 1.5 times the upper limit of the normal range (ULN) and alkaline phosphatase greater than 2.5 times the ULN, the recommended dose of docetaxel is 75 mg/m<sup>2</sup>&nbsp;(see&nbsp;sections&nbsp;4.4&nbsp;and5.2).&nbsp;For&nbsp;those&nbsp;patients&nbsp;with&nbsp;serum&nbsp;bilirubin&nbsp;&gt;&nbsp;ULN&nbsp;and/or ALT&nbsp;and&nbsp;AST&nbsp;&gt;&nbsp;3.5 times the ULN associated with alkaline phosphatase &gt; 6 times the ULN, no dose-reduction can be recommended, and docetaxel should not be used unless strictly indicated.</p><p>In&nbsp;combination&nbsp;with&nbsp;cisplatin&nbsp;and&nbsp;5-fluorouracil&nbsp;for&nbsp;the&nbsp;treatment&nbsp;of&nbsp;patients&nbsp;with&nbsp;gastric&nbsp;adenocarcinoma, the pivotal clinical trial excluded patients with ALT and/or AST &gt; 1.5 &times; ULN associated with alkaline phosphatase &gt; 2.5 &times; ULN, and bilirubin &gt; 1 x ULN; for these patients, no dose-reductions can be recommended and docetaxel should not be used unless strictly indicated. No data are available in patients with hepatic impairment treated by docetaxel in combination in the other indications.</p><p>&nbsp;</p><p>This&nbsp;medicinal product contains&nbsp;400&nbsp;mg&nbsp;ethanol per ml concentrate.&nbsp;This&nbsp;has&nbsp;to&nbsp;be&nbsp;taken&nbsp;into&nbsp;account&nbsp;in high-risk groups such as patients with liver disease.</p><p>&nbsp;</p><p><em>Pediatric&nbsp;population</em></p><p>The safety and efficacy of Docadex in nasopharyngeal carcinoma in children aged 1 month to less than 18 years have not yet been established.</p><p>There is no relevant use of Docadex in the pediatric population in the indications breast cancer, non-small cell lung cancer, prostate cancer, gastric carcinoma and head and neck cancer, not including type II and III less differentiated nasopharyngeal carcinoma.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Based&nbsp;on&nbsp;a&nbsp;population&nbsp;pharmacokinetic&nbsp;analysis,&nbsp;there&nbsp;are&nbsp;no&nbsp;special&nbsp;instructions&nbsp;for use&nbsp;in&nbsp;the&nbsp;elderly. In combination with capecitabine, for patients 60 years of age or more, a starting dose reduction of capecitabine to 75% is recommended (see capecitabine summary of product characteristics)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Docetaxel must not be used in patients with baseline neutrophil count of < 1,500 cells/mm3.
Docetaxel must not be used in patients with severe liver impairment since there is no data available (see sections 4.2 and 4.4).
Contraindications for other medicinal products also apply, when combined with docetaxel.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For breast and non-small cell lung cancers, premedication consisting of an oral corticosteroid, such as dexamethasone 16&nbsp;mg&nbsp;per&nbsp;day (e.g. 8&nbsp;mg BID) for 3 days starting 1 day prior to docetaxel administration, unless contraindicated, can reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity&nbsp;reactions.&nbsp;For&nbsp;prostatecancer,&nbsp;the&nbsp;premedication&nbsp;is&nbsp;oral&nbsp;dexamethasone&nbsp;8&nbsp;mg,&nbsp;12&nbsp;hours,&nbsp;3 hours and 1 hour before the docetaxel infusion (see section 4.2).</p><p>&nbsp;</p><p><em>Hematology</em></p><p>Neutropenia is the most frequent adverse reaction&nbsp;of docetaxel. Neutrophil nadirs occurred&nbsp;at a median of 7 days,&nbsp;butthis&nbsp;interval may&nbsp;be&nbsp;shorter&nbsp;in&nbsp;heavily&nbsp;pre-treated&nbsp;patients.&nbsp;Frequent monitoring&nbsp;of&nbsp;complete&nbsp;blood counts should be conducted on all patients receiving docetaxel. Patients should be retreated with docetaxel when neutrophils recover to a level &ge; 1,500 cells/mm<sup>3</sup>&nbsp;(see section 4.2).</p><p>&nbsp;</p><p>In&nbsp;the&nbsp;case&nbsp;of severe&nbsp;neutropenia&nbsp;(&lt;&nbsp;500&nbsp;cells/mm<sup>3</sup>&nbsp;for&nbsp;seven&nbsp;days&nbsp;or&nbsp;more) during&nbsp;a&nbsp;course&nbsp;of docetaxel therapy, a reduction in dose for subsequent courses of therapy or the use of appropriate symptomatic measures are recommended (see section 4.2).</p><p>In&nbsp;patients&nbsp;treated&nbsp;with&nbsp;docetaxel&nbsp;in&nbsp;combination&nbsp;with&nbsp;cisplatin&nbsp;and&nbsp;5-fluorouracil&nbsp;(TCF),&nbsp;febrile neutropenia&nbsp;andneutropenic&nbsp;infection&nbsp;occurred&nbsp;at&nbsp;lower&nbsp;rates&nbsp;when&nbsp;patients&nbsp;received&nbsp;prophylactic&nbsp;G-CSF.</p><p>Patients treated with TCF should receive prophylactic G-CSF to mitigate the risk of complicated neutropenia&nbsp;(febrileneutropenia,&nbsp;prolonged&nbsp;neutropenia,&nbsp;or&nbsp;neutropenic&nbsp;infection).&nbsp;Patients&nbsp;receiving&nbsp;TCF should be closely monitored, (see sections 4.2 and 4.8).</p><p>&nbsp;</p><p>In patients treated with docetaxel in combination with doxorubicin and cyclophosphamide (TAC), febrile neutropenia and/or neutropenic infection occurred at lower rates when patients received primary G-CSF prophylaxis. Primary G-CSF prophylaxis should be considered in patients who receive adjuvant therapy with&nbsp;TAC&nbsp;for&nbsp;breast&nbsp;cancer&nbsp;tomitigate&nbsp;the&nbsp;risk&nbsp;of&nbsp;complicated&nbsp;neutropenia&nbsp;(febrile&nbsp;neutropenia,&nbsp;prolonged neutropenia, or neutropenic infection). Patients receiving TAC should be closely monitored (see section 4.2 and 4.8).</p><p>&nbsp;</p><p><em>Hypersensitivity&nbsp;reactions</em></p><p>Patients should be observed closely for hypersensitivity reactions especially during the first and second infusions.Hypersensitivity&nbsp;reactions&nbsp;may&nbsp;occur within&nbsp;a&nbsp;few&nbsp;minutes&nbsp;following&nbsp;the&nbsp;initiation&nbsp;of&nbsp;the&nbsp;infusion of docetaxel, thus facilities for the treatment of hypotension and bronchospasm should be available. If hypersensitivity reactions occur, minor symptoms such as flushing or localized cutaneous reactions do not require interruption of therapy. However, severe reactions, such as severe hypotension, bronchospasm or generalized rash/erythema require immediate discontinuation of docetaxel and appropriate therapy. Patients who have developed severe hypersensitivity reactions should not be re-challenged with docetaxel.</p><p>&nbsp;</p><p><em>Cutaneous&nbsp;reactions</em></p><p>Localized skin erythema of&nbsp;the extremities (palms&nbsp;of&nbsp;the hands and&nbsp;soles of the feet) with edema&nbsp;followed bydesquamation&nbsp;has&nbsp;been&nbsp;observed.&nbsp;Severe&nbsp;symptoms&nbsp;such&nbsp;as&nbsp;eruptions&nbsp;followed&nbsp;by&nbsp;desquamation&nbsp;which lead to interruption or discontinuation of docetaxel treatment were reported (see section 4.2).</p><p>&nbsp;</p><p><em>Fluid&nbsp;retention</em></p><p>Patients&nbsp;with&nbsp;severe&nbsp;fluid&nbsp;retention&nbsp;such&nbsp;as&nbsp;pleural effusion,&nbsp;pericardial&nbsp;effusion&nbsp;and&nbsp;ascites&nbsp;should&nbsp;be monitored closely.</p><p>&nbsp;</p><p><em>Respiratory&nbsp;disorders</em></p><p>Acute&nbsp;respiratory&nbsp;distress&nbsp;syndrome,&nbsp;interstitial&nbsp;pneumonia/pneumonitis,&nbsp;interstitial&nbsp;lung&nbsp;disease,&nbsp;pulmonary fibrosis and respiratory failure have been reported and may be associated with fatal outcome. Cases of radiation pneumonitis have been reported in patients receiving concomitant radiotherapy.</p><p>If new or worsening pulmonary symptoms develop, patients should be closely monitored, promptly investigated,&nbsp;andappropriately&nbsp;treated.&nbsp;Interruption&nbsp;of&nbsp;docetaxel&nbsp;therapy&nbsp;is&nbsp;recommended&nbsp;until&nbsp;diagnosis&nbsp;is available. Early use of supportive care measures may help improve the condition. The benefit of resuming docetaxel treatment must be carefully evaluated.</p><p>&nbsp;</p><p><em>Patients&nbsp;with&nbsp;liver&nbsp;impairment</em></p><p>In patients treated with docetaxel at 100 mg/m<sup>2</sup>&nbsp;as single agent who have serum transaminase levels (ALT and/orAST)&nbsp;greater&nbsp;than&nbsp;1.5&nbsp;times&nbsp;the&nbsp;ULN&nbsp;concurrent&nbsp;with&nbsp;serum&nbsp;alkaline&nbsp;phosphatase&nbsp;levels&nbsp;greater&nbsp;than</p><p>2.5 times the ULN, there is a higher risk of developing severe adverse reactions such as toxic deaths including sepsis and gastrointestinal hemorrhage which can be fatal, febrile neutropenia, infections, thrombocytopenia,&nbsp;stomatitis,&nbsp;andasthenia.&nbsp;Therefore,&nbsp;the&nbsp;recommended&nbsp;dose&nbsp;of&nbsp;docetaxel&nbsp;in&nbsp;those&nbsp;patients with elevated liver function test (LFTs) is 75 mg/m<sup>2</sup>&nbsp;and LFTs should be measured at baseline and before each cycle (see section 4.2).</p><p>For patients&nbsp;with&nbsp;serum bilirubin&nbsp;levels&nbsp;&gt;&nbsp;ULN&nbsp;and/or&nbsp;ALT&nbsp;and&nbsp;AST&nbsp;&gt;&nbsp;3.5&nbsp;times&nbsp;the&nbsp;ULN&nbsp;concurrent with serum alkaline phosphatase levels &gt; 6 times the ULN, no dose-reduction can be recommended, and docetaxel should not be used unless strictly indicated.</p><p>In&nbsp;combination&nbsp;with&nbsp;cisplatin&nbsp;and&nbsp;5-fluorouracil&nbsp;for&nbsp;the&nbsp;treatment&nbsp;of&nbsp;patients&nbsp;with&nbsp;gastric&nbsp;adenocarcinoma, the pivotal clinical study excluded patients with ALT and/or AST &gt; 1.5 &times; ULN associated with alkaline phosphatase &gt; 2.5 &times; ULN, and bilirubin&gt; 1 x ULN; for these patients, no dose-reductions can be recommended and docetaxel should not be used unless strictly indicated. No data are available in patients with hepatic impairment treated by docetaxel in combination in the other indications.</p><p>&nbsp;</p><p><em>Patients&nbsp;with&nbsp;renal&nbsp;impairment</em></p><p>There&nbsp;are&nbsp;no&nbsp;data&nbsp;available&nbsp;in&nbsp;patients&nbsp;with&nbsp;severely&nbsp;impaired&nbsp;renal&nbsp;function&nbsp;treated&nbsp;with&nbsp;docetaxel.</p><p>&nbsp;</p><p><em>Nervous&nbsp;system</em></p><p>The development of severe peripheral neurotoxicity requires a reduction of dose (see section 4.2).&nbsp;Since Docadexcontains&nbsp;ethanol&nbsp;(400&nbsp;mg&nbsp;ethanol&nbsp;per&nbsp;ml&nbsp;concentrate),&nbsp;consideration&nbsp;should&nbsp;be&nbsp;given&nbsp;to&nbsp;possible central nervous system and other effects.</p><p>&nbsp;</p><p><em>Cardiac&nbsp;toxicity</em></p><p>Heart failure has been observed in patients receiving docetaxel in combination with trastuzumab, particularlyfollowing&nbsp;anthracycline&nbsp;(doxorubicin&nbsp;or&nbsp;epirubicin)&nbsp;containing&nbsp;chemotherapy.&nbsp;This&nbsp;may&nbsp;be moderate to severe and has been associated with death (see section 4.8).</p><p>&nbsp;</p><p>When patients are candidates for treatment with docetaxel in combination with trastuzumab, they should undergobaseline&nbsp;cardiac&nbsp;assessment.&nbsp;Cardiac&nbsp;function&nbsp;should&nbsp;be&nbsp;further&nbsp;monitored&nbsp;during&nbsp;treatment&nbsp;(e.g. every three months) to help identify patients who may develop cardiac dysfunction. For more details see Summary of Product Characteristics of trastuzumab.</p><p>&nbsp;</p><p><em>Eye&nbsp;disorders</em></p><p>Cystoid&nbsp;macular&nbsp;edema&nbsp;(CMO)&nbsp;has&nbsp;been&nbsp;reported&nbsp;in&nbsp;patients&nbsp;treated&nbsp;with&nbsp;docetaxel.&nbsp;Patients&nbsp;with&nbsp;impaired vision should undergo a prompt and complete ophthalmologic examination. In case CMO is diagnosed, docetaxel treatment should be discontinued, and appropriate treatment initiated (see section 4.8).</p><p>&nbsp;</p><p><em>Others</em></p><p>Contraceptive&nbsp;measures&nbsp;must be&nbsp;taken&nbsp;by&nbsp;both&nbsp;men&nbsp;and&nbsp;women&nbsp;during&nbsp;treatment&nbsp;and&nbsp;for&nbsp;men&nbsp;at&nbsp;least 6 months after cessation of therapy (see section 4.6).</p><p>&nbsp;</p><p>The concomitant use of docetaxel with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin,indinavir,&nbsp;nefazodone,&nbsp;nelfinavir,&nbsp;ritonavir,&nbsp;saquinavir,&nbsp;telithromycin&nbsp;and&nbsp;voriconazole) should be avoided (see section 4.5).</p><p>&nbsp;</p><p><em>Ethanol</em></p><p>Docadex&nbsp;contains&nbsp;400&nbsp;mg&nbsp;ethanol&nbsp;per&nbsp;ml&nbsp;concentrate. Harmful for those suffering from alcoholism.</p><p>To&nbsp;be&nbsp;taken&nbsp;into&nbsp;account&nbsp;in&nbsp;pregnant&nbsp;or&nbsp;breast-feeding&nbsp;women,&nbsp;children&nbsp;and&nbsp;high-risk&nbsp;groups&nbsp;such&nbsp;as patients with liver disease or epilepsy.</p><p>&nbsp;</p><p>The&nbsp;amount&nbsp;of&nbsp;alcohol&nbsp;in&nbsp;this&nbsp;medicinal&nbsp;product&nbsp;may&nbsp;alter&nbsp;the&nbsp;effects&nbsp;of&nbsp;other&nbsp;medicinal&nbsp;products.</p><p>The&nbsp;amount&nbsp;of&nbsp;alcohol&nbsp;in&nbsp;this&nbsp;medicinal&nbsp;product&nbsp;may&nbsp;impair&nbsp;the&nbsp;patient&rsquo;s&nbsp;ability&nbsp;to&nbsp;drive&nbsp;of&nbsp;use&nbsp;machines.</p><p><strong><em>Additional&nbsp;cautions&nbsp;for&nbsp;use&nbsp;in&nbsp;adjuvant&nbsp;treatment&nbsp;of&nbsp;breast&nbsp;cancer</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><em>Complicated&nbsp;neutropenia</em></p><p>For&nbsp;patients&nbsp;who&nbsp;experience&nbsp;complicated&nbsp;neutropenia&nbsp;(prolonged&nbsp;neutropenia,&nbsp;febrile&nbsp;neutropenia,&nbsp;or infection), G-CSF and dose reduction should be considered (see section 4.2).</p><p>&nbsp;</p><p><em>Gastrointestinal&nbsp;reactions</em></p><p>Symptoms&nbsp;such&nbsp;as&nbsp;early&nbsp;abdominal&nbsp;pain&nbsp;and&nbsp;tenderness,&nbsp;fever,&nbsp;diarrhea,&nbsp;with&nbsp;or&nbsp;without&nbsp;neutropenia,&nbsp;may be early manifestations of serious gastrointestinal toxicity and should be evaluated and treated promptly.</p><p>&nbsp;</p><p><em>Congestive&nbsp;heart&nbsp;failure&nbsp;(CHF)</em></p><p>Patients&nbsp;should&nbsp;be&nbsp;monitored&nbsp;for&nbsp;symptoms&nbsp;of&nbsp;congestive&nbsp;heart&nbsp;failure&nbsp;during&nbsp;therapy&nbsp;and&nbsp;during&nbsp;the&nbsp;follow up period. In patients treated with the TAC regimen for node positive breast cancer, the risk of CHF has been shown to be higher during the first year after treatment (see sections 4.8 and 5.1).</p><p>&nbsp;</p><p><em>Leukemia</em></p><p>In&nbsp;the&nbsp;docetaxel,&nbsp;doxorubicin,&nbsp;and&nbsp;cyclophosphamide&nbsp;(TAC)&nbsp;treated&nbsp;patients,&nbsp;the&nbsp;risk&nbsp;of&nbsp;delayed myelodysplasia or myeloid leukemia requires hematological follow-up.</p><p>&nbsp;</p><p><em>Patients&nbsp;with&nbsp;4+&nbsp;nodes</em></p><p>As the benefit observed in patient with 4+ nodes was not statistically significant on disease-free survival (DFS) andoverall survival&nbsp;(OS),&nbsp;the&nbsp;positive&nbsp;benefit/risk&nbsp;ratio&nbsp;for TAC&nbsp;in&nbsp;patients&nbsp;with&nbsp;4+&nbsp;nodes&nbsp;was&nbsp;not fully demonstrated at the final analysis (see section 5.1).</p><p>&nbsp;</p><p><em>Elderly&nbsp;patients</em></p><p>There&nbsp;are&nbsp;limited&nbsp;data&nbsp;available&nbsp;in&nbsp;patients&nbsp;&gt;&nbsp;70&nbsp;years&nbsp;of age&nbsp;on&nbsp;docetaxel use&nbsp;in&nbsp;combination&nbsp;with doxorubicin and cyclophosphamide.</p><p>&nbsp;</p><p>Of the&nbsp;333&nbsp;patients&nbsp;treated&nbsp;with&nbsp;docetaxel every&nbsp;three&nbsp;weeks&nbsp;in&nbsp;a&nbsp;prostate&nbsp;cancer study,&nbsp;209&nbsp;patients&nbsp;were&nbsp;65 years of age or greater and 68 patients were older than 75 years. In patients treated with docetaxel every three weeks, the incidence of related nail changes occurred at a rate &ge; 10% higher in patients who were 65 years of&nbsp;age or greater compared&nbsp;to younger patients.&nbsp;The incidence&nbsp;of&nbsp;related fever, diarrhea, anorexia, and peripheral edema occurred at rates &ge; 10% higher in patients who were 75 years of age or greater versus less than 65 years.</p><p>&nbsp;</p><p>Among&nbsp;the 300 (221 patients in the phase III&nbsp;part of the study and&nbsp;79 patients in the phase II&nbsp;part) patients treated&nbsp;withdocetaxel in&nbsp;combination&nbsp;with&nbsp;cisplatin&nbsp;and&nbsp;5-fluorouracil&nbsp;in&nbsp;the&nbsp;gastric&nbsp;cancer study,&nbsp;74&nbsp;were 65 years of age or older and 4 patients were 75 years of age or older. The incidence of serious adverse events was higher in the elderly patients compared to younger patients. The incidence of the following adverse events (all grades): lethargy, stomatitis, neutropenic infection occurred at rates &ge; 10% higher in patients who were 65 years of age or older compared to younger patients.</p><p>Elderly&nbsp;patients&nbsp;treated&nbsp;with&nbsp;TCF&nbsp;should&nbsp;be&nbsp;closely&nbsp;monitored.</p><p>&nbsp;</p><p>During&nbsp;the&nbsp;post marketing&nbsp;experience&nbsp;a&nbsp;high&nbsp;number of delayed&nbsp;infusion&nbsp;site&nbsp;adverse&nbsp;reactions&nbsp;were&nbsp;reported for docetaxel, concentrate for solution&nbsp;for infusion. Although the mechanism of these reactions is not known at present it was observed that they occur close to the infusion site, several days of the last docetaxel cycle and have a &ldquo;burn-like&rdquo; appearance. In some cases, vesicles and vein hyperpigmentation were reported. No correlation with docetaxel cycle number was noted&nbsp;and&nbsp;re-occurrence was not always seen with&nbsp;re-exposure. In most of the cases the patients recovered or were recovering at the time of reporting.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>In vitro&nbsp;</em>studies have shown that the metabolism of docetaxel may be modified by the concomitant administration&nbsp;ofcompounds&nbsp;which&nbsp;induce,&nbsp;inhibit or&nbsp;are&nbsp;metabolized&nbsp;by&nbsp;(and&nbsp;thus&nbsp;may&nbsp;inhibit&nbsp;the&nbsp;enzyme competitively) cytochrome P450-3A such as cyclosporine, ketoconazole and erythromycin. As a result, caution should be exercised when treating patients with these medicinal products as concomitant therapy since there is a potential for a significant interaction.</p><p>&nbsp;</p><p>In&nbsp;case&nbsp;of&nbsp;combination&nbsp;with&nbsp;CYP3A4&nbsp;inhibitors,&nbsp;the&nbsp;occurrence&nbsp;of&nbsp;docetaxel&nbsp;adverse&nbsp;reactions&nbsp;may&nbsp;increase, as a result of reduced metabolism. If the concomitant use of a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a dose- adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor (see section</p><p>4.4).&nbsp;In&nbsp;a&nbsp;pharmacokinetic&nbsp;study&nbsp;with&nbsp;7&nbsp;patients,&nbsp;the&nbsp;co-administration&nbsp;of docetaxel&nbsp;with&nbsp;the&nbsp;strong&nbsp;CYP3A4 inhibitor ketoconazole leads to a significant decrease in docetaxel clearance by 49%.</p><p>Docetaxel pharmacokinetics in the presence of prednisone was studied in patients with metastatic prostate cancer.Docetaxel&nbsp;is&nbsp;metabolized&nbsp;by&nbsp;CYP3A4&nbsp;and&nbsp;prednisone&nbsp;is&nbsp;known&nbsp;to&nbsp;induce&nbsp;CYP3A4.&nbsp;No&nbsp;statistically significant effect of prednisone on the pharmacokinetics of docetaxel was observed.</p><p>&nbsp;</p><p>Docetaxel is highly protein bound (&gt; 95%). Although the possible&nbsp;<em>in vivo&nbsp;</em>interaction of docetaxel with concomitantlyadministered&nbsp;medication&nbsp;has&nbsp;not&nbsp;been&nbsp;investigated&nbsp;formally,&nbsp;<em>in&nbsp;vitro&nbsp;</em>interactions&nbsp;with&nbsp;tightly&nbsp;protein-bound agents such as erythromycin, diphenhydramine, propranolol, propafenone, phenytoin, salicylate,sulfamethoxazole&nbsp;and&nbsp;sodium&nbsp;valproate&nbsp;did&nbsp;not&nbsp;affect&nbsp;protein&nbsp;binding&nbsp;of&nbsp;docetaxel.&nbsp;In&nbsp;addition, dexamethasone did not affect protein binding of docetaxel. Docetaxel did not influence the binding of&nbsp;digitoxin.</p><p>&nbsp;</p><p>The pharmacokinetics of docetaxel, doxorubicin and cyclophosphamide were not influenced by their coadministration. Limited data from a single uncontrolled study were suggestive of an interaction between docetaxel and&nbsp;carboplatin.When&nbsp;combined&nbsp;to&nbsp;docetaxel,&nbsp;the&nbsp;clearance&nbsp;of carboplatin&nbsp;was&nbsp;about&nbsp;50% higher than values previously reported for carboplatin monotherapy.</p><p>&nbsp;</p><p>Docadex&nbsp;contains&nbsp;400&nbsp;mg&nbsp;ethanol per&nbsp;ml&nbsp;concentrate.&nbsp;In&nbsp;higher doses&nbsp;(7.5&nbsp;ml concentrate&nbsp;(150&nbsp;mg) contains 3 g ethanol) the amount of alcohol may alter the effects of other medicines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There&nbsp;is&nbsp;no&nbsp;information&nbsp;on&nbsp;the&nbsp;use&nbsp;of docetaxel&nbsp;in&nbsp;pregnant women.&nbsp;Docetaxel has&nbsp;been&nbsp;shown&nbsp;to&nbsp;be&nbsp;both embryotoxic and fetotoxic in rabbits and rats, and to reduce fertility in rats. As with other cytotoxic medicinal products, docetaxel may cause fetal harm when administered to pregnant women. Therefore, docetaxel must not be used during pregnancy unless clearly indicated.</p><p>Women&nbsp;of childbearing&nbsp;age&nbsp;receiving&nbsp;docetaxel should&nbsp;be&nbsp;advised&nbsp;to&nbsp;avoid&nbsp;becoming&nbsp;pregnant,&nbsp;and&nbsp;to inform the treating physician immediately should this occur.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>Docetaxel&nbsp;is&nbsp;a lipophilic&nbsp;substance, but&nbsp;it&nbsp;is not known&nbsp;whether it&nbsp;is excreted in&nbsp;human&nbsp;milk. Consequently, because&nbsp;of the&nbsp;potential&nbsp;for&nbsp;adverse&nbsp;reactions&nbsp;in&nbsp;nursing&nbsp;infants,&nbsp;breast&nbsp;feeding&nbsp;must be&nbsp;discontinued&nbsp;for&nbsp;the duration of docetaxel therapy.</p><p>&nbsp;</p><p><u>Contraception&nbsp;in&nbsp;males&nbsp;and&nbsp;females</u></p><p>An&nbsp;effective&nbsp;method&nbsp;of&nbsp;contraception&nbsp;should&nbsp;be&nbsp;used&nbsp;during&nbsp;treatment.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>In non-clinical studies, docetaxel has genotoxic effects and may alter male fertility (see section 5.3). Therefore,&nbsp;men being&nbsp;treated with&nbsp;docetaxel&nbsp;are&nbsp;advised not&nbsp;to father&nbsp;a child&nbsp;during and up&nbsp;to 6&nbsp;months&nbsp;after treatment and to seek advice on conservation of sperm prior to treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No&nbsp;studies&nbsp;on&nbsp;the&nbsp;effects&nbsp;on&nbsp;the&nbsp;ability&nbsp;to&nbsp;drive&nbsp;and&nbsp;use&nbsp;machines&nbsp;have&nbsp;been&nbsp;performed.</p><p>Docadex contains 400 mg ethanol per ml concentrate.</p><p>In higher doses (7.5 ml concentrate (150 mg docetaxel)&nbsp;contains3&nbsp;g&nbsp;ethanol)&nbsp;the&nbsp;amount of&nbsp;alcohol&nbsp;may&nbsp;impair&nbsp;the&nbsp;ability&nbsp;to&nbsp;drive or use&nbsp;machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary&nbsp;of&nbsp;the&nbsp;safety&nbsp;profile&nbsp;for&nbsp;all&nbsp;indications</p><p>&nbsp;</p><p>The&nbsp;adverse&nbsp;reactions&nbsp;considered&nbsp;to&nbsp;be&nbsp;possibly&nbsp;or probably&nbsp;related&nbsp;to&nbsp;the&nbsp;administration&nbsp;of&nbsp;docetaxel&nbsp;have been obtained in:</p><ul><li><img width="2" height="2" src="blob:https://sdi.sfda.gov.sa/7aa3b4c0-e82c-40ab-80ec-cc40c238cd73" />1312&nbsp;and&nbsp;121&nbsp;patients&nbsp;who&nbsp;received&nbsp;100&nbsp;mg/m&sup2;&nbsp;and&nbsp;75&nbsp;mg/m&sup2;&nbsp;of&nbsp;docetaxel&nbsp;as&nbsp;a&nbsp;single&nbsp;agent&nbsp;respectively</li><li><img width="2" height="2" src="blob:https://sdi.sfda.gov.sa/7aa3b4c0-e82c-40ab-80ec-cc40c238cd73" /><img width="2" height="2" src="blob:https://sdi.sfda.gov.sa/7aa3b4c0-e82c-40ab-80ec-cc40c238cd73" />258&nbsp;patients&nbsp;who&nbsp;received&nbsp;docetaxel&nbsp;in&nbsp;combination&nbsp;with&nbsp;doxorubicin 406 patients who received docetaxel in combination with cisplatin</li><li><img width="2" height="2" src="blob:https://sdi.sfda.gov.sa/7aa3b4c0-e82c-40ab-80ec-cc40c238cd73" />92&nbsp;patients&nbsp;treated&nbsp;with&nbsp;docetaxel&nbsp;in&nbsp;combination&nbsp;with&nbsp;trastuzumab,</li><li><img width="2" height="1" src="blob:https://sdi.sfda.gov.sa/0e9f1608-06fb-42df-9222-47e8752aca21" />255&nbsp;patients&nbsp;who&nbsp;received&nbsp;docetaxel&nbsp;in&nbsp;combination&nbsp;with&nbsp;capecitabine,</li><li><img width="2" height="2" src="blob:https://sdi.sfda.gov.sa/0e9f1608-06fb-42df-9222-47e8752aca21" />332&nbsp;patients&nbsp;who&nbsp;received&nbsp;docetaxel&nbsp;in&nbsp;combination&nbsp;with&nbsp;prednisone&nbsp;or&nbsp;prednisolone&nbsp;(clinically important treatment related adverse events are presented).</li><li><img width="2" height="2" src="blob:https://sdi.sfda.gov.sa/0e9f1608-06fb-42df-9222-47e8752aca21" />1276 patients (744 and&nbsp;532&nbsp;in TAX&nbsp;316 and GEICAM 9805 respectively) who received&nbsp;docetaxel&nbsp;in combination&nbsp;with&nbsp;doxorubicin&nbsp;and&nbsp;cyclophosphamide&nbsp;(clinically&nbsp;important&nbsp;treatment&nbsp;related&nbsp;adverse events are presented).</li><li><img width="2" height="1" src="blob:https://sdi.sfda.gov.sa/0e9f1608-06fb-42df-9222-47e8752aca21" />300&nbsp;gastric&nbsp;adenocarcinoma&nbsp;patients&nbsp;(221&nbsp;patients&nbsp;in&nbsp;the&nbsp;phase&nbsp;III&nbsp;part of the&nbsp;study&nbsp;and&nbsp;79&nbsp;patients in the phase II part) who received docetaxel in combination with cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented).</li><li><img width="2" height="2" src="blob:https://sdi.sfda.gov.sa/0e9f1608-06fb-42df-9222-47e8752aca21" />174&nbsp;and&nbsp;251&nbsp;head&nbsp;and&nbsp;neck&nbsp;cancer&nbsp;patients&nbsp;who&nbsp;received&nbsp;docetaxel&nbsp;in&nbsp;combination&nbsp;with&nbsp;cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented).</li></ul><p>&nbsp;</p><p>These&nbsp;reactions&nbsp;were&nbsp;described&nbsp;using&nbsp;the&nbsp;NCI&nbsp;Common&nbsp;Toxicity&nbsp;Criteria&nbsp;(grade&nbsp;3&nbsp;=&nbsp;G3; grade3-4&nbsp;=&nbsp;G3/4; grade 4 = G4), the COSTART and the MedDRA terms. Frequencies are defined as: very common (&ge; 1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from available data).</p><p>Within&nbsp;each&nbsp;frequency&nbsp;grouping,&nbsp;undesirable&nbsp;effects&nbsp;are&nbsp;presented&nbsp;in&nbsp;order&nbsp;of&nbsp;decreasing&nbsp;seriousness.</p><p>The&nbsp;most commonly&nbsp;reported adverse&nbsp;reactions of docetaxel&nbsp;alone&nbsp;are:&nbsp;neutropenia (which&nbsp;was&nbsp;reversible and not cumulative; the median day to nadir was 7 days and the median duration of severe neutropenia</p><p>(&lt; 500 cells/mm<sup>3</sup>) was 7 days), anemia, alopecia, nausea, vomiting, stomatitis, diarrhea and asthenia. The severity&nbsp;of adverse&nbsp;events&nbsp;of docetaxel may&nbsp;be&nbsp;increased&nbsp;when&nbsp;docetaxel is&nbsp;given&nbsp;in&nbsp;combination&nbsp;with&nbsp;other chemotherapeutic agents.</p><p>&nbsp;</p><p>For&nbsp;combination&nbsp;with&nbsp;trastuzumab,&nbsp;adverse&nbsp;events&nbsp;(all&nbsp;grades)&nbsp;reported&nbsp;in&nbsp;&ge;&nbsp;10%&nbsp;are&nbsp;displayed.&nbsp;There&nbsp;was an increased incidence of SAEs (40% vs. 31%) and Grade 4 AEs (34% vs. 23%) in the trastuzumab combination arm compared to docetaxel monotherapy.</p><p>&nbsp;</p><p>For&nbsp;combination&nbsp;with&nbsp;capecitabine,&nbsp;the&nbsp;most&nbsp;frequent&nbsp;treatment-related&nbsp;undesirable&nbsp;effects&nbsp;(&ge;&nbsp;5%)&nbsp;reported in a phaseIII&nbsp;study in breast cancer&nbsp;patients&nbsp;failing&nbsp;anthracycline&nbsp;treatment&nbsp;are&nbsp;presented&nbsp;(see capecitabine summary of product characteristics).</p><p>&nbsp;</p><p><strong>The&nbsp;following&nbsp;adverse&nbsp;reactions&nbsp;are&nbsp;frequently&nbsp;observed&nbsp;with&nbsp;docetaxel:</strong></p><p>&nbsp;</p><p><em>Nervous&nbsp;system&nbsp;disorders</em></p><p>The&nbsp;development&nbsp;of&nbsp;severe&nbsp;peripheral&nbsp;neurotoxicity&nbsp;requires&nbsp;a&nbsp;reduction&nbsp;of&nbsp;dose&nbsp;(see&nbsp;sections&nbsp;4.2&nbsp;and&nbsp;4.4). Mild to moderate neuro-sensory signs are characterized by paresthesia, dysesthesia or pain including burning. Neuro-motor events are mainly characterized by weakness.</p><p>&nbsp;</p><p><em>Skin&nbsp;and&nbsp;subcutaneous&nbsp;tissue&nbsp;disorder</em>s</p><p>Reversible cutaneous reactions have been observed and were generally considered as mild to moderate. Reactions were characterized by a rash including localized eruptions mainly on the feet and hands (including&nbsp;severe&nbsp;hand&nbsp;andfoot&nbsp;syndrome),&nbsp;but&nbsp;also&nbsp;on&nbsp;the&nbsp;arms,&nbsp;face&nbsp;or&nbsp;thorax,&nbsp;and&nbsp;frequently&nbsp;associated with pruritus. Eruptions generallyoccurred within one week after the docetaxel infusion. Less frequently, severe symptoms such as eruptions followed by desquamation which rarely lead to interruption or discontinuation of docetaxel treatment were reported (see sections 4.2 and 4.4). Severe nail disorders are characterized by hypo- or hyperpigmentation and sometimes pain and onycholysis.</p><p>&nbsp;</p><p><em>General&nbsp;disorders&nbsp;and&nbsp;administration&nbsp;site&nbsp;conditions</em></p><p>Infusion site reactions were generally mild and consisted of hyper pigmentation, inflammation, redness or dryness&nbsp;of the&nbsp;skin,&nbsp;phlebitis&nbsp;or extravasation&nbsp;and&nbsp;swelling&nbsp;of the&nbsp;vein.&nbsp;Fluid&nbsp;retention&nbsp;includes&nbsp;events&nbsp;such as peripheral&nbsp;edema and less frequently pleural&nbsp;effusion, pericardial&nbsp;effusion,&nbsp;ascites, and&nbsp;weight gain. The peripheral&nbsp;edema&nbsp;usually starts at the lower extremities&nbsp;and may become generalized with a weight gain of 3 kg or more. Fluid retention is cumulative in incidence and severity (see section 4.4).</p><p><em>Immune&nbsp;system&nbsp;disorders</em></p><p>Hypersensitivity reactions have generally occurred within a few minutes following the start of the infusion ofdocetaxel&nbsp;and&nbsp;were&nbsp;usually&nbsp;mild&nbsp;to&nbsp;moderate.&nbsp;The&nbsp;most&nbsp;frequently&nbsp;reported&nbsp;symptoms&nbsp;were&nbsp;flushing,&nbsp;rash with or without pruritus, chest tightness, back pain, dyspnea and fever or chills. Severe reactions were characterized by hypotension and/or bronchospasm or generalized rash/erythema (see section 4.4).</p><p>&nbsp;</p><p><strong><em>Tabulated&nbsp;list&nbsp;of&nbsp;adverse&nbsp;reactions&nbsp;in&nbsp;breast&nbsp;cancer&nbsp;for&nbsp;docetaxel&nbsp;100&nbsp;mg/m&sup2;&nbsp;single&nbsp;agent:</em></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:956px"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRASystem Organ classes</strong></p></td><td style="vertical-align:top"><p><strong>Very common adverse&nbsp;reactions</strong></p></td><td style="vertical-align:top"><p><strong>Common&nbsp;adverse&nbsp;reactions</strong></p></td><td style="vertical-align:top; width:150px"><p><strong>Uncommon&nbsp;adverse&nbsp;reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>G3/4&nbsp;Blood&nbsp;bilirubin increased (&lt;5%); G3/4 Blood alkaline&nbsp;phosphatase&nbsp;increased (&lt;4%); G3/4 AST increased&nbsp;(&lt;3%);</p><p>G3/4&nbsp;ALT&nbsp;increased&nbsp;(&lt;2%)</p></td><td style="vertical-align:top; width:150px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac&nbsp;disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arrhythmia&nbsp;(G3/4:&nbsp;0.7%)</p></td><td style="vertical-align:top; width:150px"><p>Cardiac&nbsp;failure</p></td></tr><tr><td style="vertical-align:top"><p>Blood&nbsp;and&nbsp;lymphaticsystem</p><p>disorders</p></td><td style="vertical-align:top"><p>Neutropenia&nbsp;(G4:&nbsp;76.4%);</p><p>Anemia&nbsp;(G3/4:&nbsp;8.9%);</p><p>Febrile&nbsp;neutropenia</p></td><td style="vertical-align:top"><p>Thrombocytopenia&nbsp;(G4: 0.2%)</p></td><td style="vertical-align:top; width:150px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top"><p>Peripheral&nbsp;sensory&nbsp;neuropathy</p><p>(G3:&nbsp;4.1%);</p><p>Peripheral motor neuropathy(G3/4:&nbsp;4%)</p><p>Dysgeusia(severe&nbsp;0.07%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:150px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory,&nbsp;thoracic</p><p>and&nbsp;mediastinal&nbsp;disorders</p></td><td style="vertical-align:top"><p>Dyspnea&nbsp;(severe&nbsp;2.7%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:150px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Stomatitis&nbsp;(G3/4:&nbsp;5.3%);</p><p>Diarrhea&nbsp;(G3/4:&nbsp;4%);</p><p>Nausea&nbsp;(G3/4:&nbsp;4%);</p><p>Vomiting&nbsp;(G3/4:&nbsp;3%)</p></td><td style="vertical-align:top"><p>Constipation&nbsp;(severe 0.2%); Abdominal</p><p>pain (severe 1%);&nbsp;GastrointestinalHemorrhage&nbsp;(severe&nbsp;0.3%)</p></td><td style="vertical-align:top; width:150px"><p>Esophagitis(severe:&nbsp;0.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneoustissue&nbsp;disorders</p></td><td style="vertical-align:top"><p>Alopecia.</p><p>Skin&nbsp;reaction&nbsp;(G3/4:&nbsp;5.9%);</p><p>Nail&nbsp;disorders (severe&nbsp;2.6%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:150px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal&nbsp;and</p><p>connective&nbsp;tissue&nbsp;disorders</p></td><td style="vertical-align:top"><p>Myalgia&nbsp;(severe&nbsp;1.4%)</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top; width:150px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutritiondisorders</p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:150px"><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:168px"><p>Infections&nbsp;and&nbsp;infestations</p></td><td style="vertical-align:top; width:173px"><p>Infections (G3/4: 5.7%; including sepsis and pneumonia,&nbsp;fatal&nbsp;in</p><p>1.7%)</p></td><td style="vertical-align:top; width:465px"><p>Infection associated with G4 neutropenia (G3/4: 4.6%)</p></td><td style="vertical-align:top; width:148px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:168px"><p>Vascular&nbsp;disorders</p></td><td style="vertical-align:top; width:173px"><p>&nbsp;</p></td><td style="vertical-align:top; width:465px"><p>Hypotension; Hypertension. Hemorrhage</p></td><td style="vertical-align:top; width:148px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:168px"><p>General disorders&nbsp;andadministrationsite&nbsp;conditions</p></td><td style="vertical-align:top; width:173px"><p>Fluid retention (severe: 6.5%) Asthenia&nbsp;(severe&nbsp;11.2%);</p><p>Pain</p></td><td style="vertical-align:top; width:465px"><p>Infusion&nbsp;site&nbsp;reaction; Non-cardiac chest pain (severe</p><p>0.4%)</p></td><td style="vertical-align:top; width:148px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:168px"><p>Immune&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top; width:173px"><p>Hypersensitivity&nbsp;(G3/4: 5.3%)</p></td><td style="vertical-align:top; width:465px"><p>&nbsp;</p></td><td style="vertical-align:top; width:148px"><p>&nbsp;</p></td></tr></tbody></table><p><strong><em>Description&nbsp;of&nbsp;selected&nbsp;adverse&nbsp;reactions&nbsp;in&nbsp;breast&nbsp;cancer&nbsp;for&nbsp;docetaxel&nbsp;100&nbsp;mg/m2&nbsp;single&nbsp;agent:</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><em>Blood&nbsp;and&nbsp;Lymphatic&nbsp;system&nbsp;disorders</em></p><p>Rare:&nbsp;bleeding&nbsp;episodes&nbsp;associated&nbsp;with&nbsp;grade&nbsp;3/4&nbsp;thrombocytopenia</p><p>&nbsp;</p><p><em>Nervous&nbsp;system&nbsp;disorders</em></p><p>Reversibility&nbsp;data&nbsp;are&nbsp;available&nbsp;among&nbsp;35.3%&nbsp;of&nbsp;patients&nbsp;who&nbsp;developed&nbsp;neurotoxicity&nbsp;following&nbsp;docetaxel treatment at 100 mg/m&sup2; as single agent. The events were spontaneously reversible within 3 months.</p><p>&nbsp;</p><p><em>Skin&nbsp;and&nbsp;subcutaneous&nbsp;tissue&nbsp;disorders</em></p><p>Very&nbsp;rare: one&nbsp;case&nbsp;of alopecia&nbsp;non-reversible&nbsp;at&nbsp;the&nbsp;end&nbsp;of&nbsp;the&nbsp;study.&nbsp;73% of&nbsp;the&nbsp;cutaneous&nbsp;reactions&nbsp;were reversible within 21 days.</p><p>&nbsp;</p><p><em>General&nbsp;disorders&nbsp;and&nbsp;administration&nbsp;site&nbsp;conditions</em></p><p>The&nbsp;median&nbsp;cumulative&nbsp;dose&nbsp;to&nbsp;treatment&nbsp;discontinuation&nbsp;was&nbsp;more&nbsp;than&nbsp;1,000&nbsp;mg/m<sup>2</sup>&nbsp;and&nbsp;the&nbsp;median&nbsp;time to fluid retention reversibility was 16.4 weeks (range 0 to 42 weeks). The onset of moderate and severe retention&nbsp;is delayed(median cumulative dose: 818.9&nbsp;mg/m<sup>2</sup>) in&nbsp;patients with premedication compared with patients without premedication (median cumulative dose: 489.7 mg/m<sup>2</sup>); however, it has been reported in some patients during the early courses of therapy.</p><p>&nbsp;</p><p><strong><em>Tabulated&nbsp;list&nbsp;of&nbsp;adverse&nbsp;reactions&nbsp;in&nbsp;non-small&nbsp;cell&nbsp;lung&nbsp;cancer&nbsp;for&nbsp;docetaxel&nbsp;75mg/m&sup2;&nbsp;single&nbsp;agent:</em></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:842px"><tbody><tr><td style="vertical-align:top; width:313px"><p><strong>MedDRA&nbsp;System&nbsp;Organ&nbsp;classes</strong></p></td><td style="vertical-align:top; width:349px"><p><strong>Very&nbsp;common&nbsp;adverse&nbsp;reactions</strong></p></td><td style="vertical-align:top; width:179px"><p><strong>Common&nbsp;adverse&nbsp;reactions</strong></p></td></tr><tr><td style="vertical-align:top; width:313px"><p>Investigations</p></td><td style="vertical-align:top; width:349px"><p>&nbsp;</p></td><td style="vertical-align:top; width:179px"><p>G3/4&nbsp;Blood&nbsp;bilirubin&nbsp;increased&nbsp;(&lt;2%)</p></td></tr><tr><td style="vertical-align:top; width:313px"><p>Cardiac&nbsp;disorders</p></td><td style="vertical-align:top; width:349px"><p>&nbsp;</p></td><td style="vertical-align:top; width:179px"><p>Arrhythmia&nbsp;(no&nbsp;severe);</p></td></tr><tr><td style="vertical-align:top; width:313px"><p>Blood&nbsp;and&nbsp;lymphatic&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top; width:349px"><p>Neutropenia&nbsp;(G4:&nbsp;54.2%);</p><p>Anemia&nbsp;(G3/4:&nbsp;10.8%);</p><p>Thrombocytopenia&nbsp;(G4:&nbsp;1.7%)</p></td><td style="vertical-align:top; width:179px"><p>Febrile&nbsp;neutropenia</p></td></tr><tr><td style="vertical-align:top; width:313px"><p>Nervous&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top; width:349px"><p>Peripheral&nbsp;sensory&nbsp;neuropathy (G3/4: 0.8%)</p></td><td style="vertical-align:top; width:179px"><p>Peripheral&nbsp;motor&nbsp;neuropathy (G3/4: 2.5%)</p></td></tr><tr><td style="vertical-align:top; width:313px"><p>Gastrointestinal&nbsp;disorders</p></td><td style="vertical-align:top; width:349px"><p>Nausea&nbsp;(G3/4:&nbsp;3.3%);</p><p>Stomatitis&nbsp;(G3/4:&nbsp;1.7%);</p><p>Vomiting&nbsp;(G3/4:&nbsp;0.8%);</p><p>Diarrhea&nbsp;(G3/4:&nbsp;1.7%)</p></td><td style="vertical-align:top; width:179px"><p>Constipation</p></td></tr><tr><td style="vertical-align:top; width:313px"><p>Skin&nbsp;and&nbsp;subcutaneous&nbsp;tissue&nbsp;disorders</p></td><td style="vertical-align:top; width:349px"><p>Alopecia.</p><p>Skin&nbsp;reaction&nbsp;(G3/4:&nbsp;0.8%)</p></td><td style="vertical-align:top; width:179px"><p>Nail&nbsp;disorders&nbsp;(severe&nbsp;0.8%)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Musculoskeletal&nbsp;and&nbsp;connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism&nbsp;and&nbsp;nutritiondisorders</p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Infections&nbsp;and&nbsp;infestations</p></td><td style="vertical-align:top"><p>Infections&nbsp;(G3/4:&nbsp;5%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular&nbsp;disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration&nbsp;site&nbsp;conditions</p></td><td style="vertical-align:top"><p>Asthenia (severe 12.4%); Fluid&nbsp;retention&nbsp;(severe&nbsp;0.8%);&nbsp;Pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity&nbsp;(no&nbsp;severe)</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><em>Tabulated&nbsp;list&nbsp;of&nbsp;adverse&nbsp;reactions&nbsp;in&nbsp;breast&nbsp;cancer&nbsp;for&nbsp;docetaxel&nbsp;75mg/m&sup2;&nbsp;in&nbsp;combination&nbsp;with&nbsp;doxorubicin:</em></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRASystem Organ classes</strong></p></td><td style="vertical-align:top"><p><strong>Very&nbsp;common&nbsp;adverse&nbsp;reactions</strong></p></td><td style="vertical-align:top"><p><strong>Commonadverse&nbsp;reactions</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon&nbsp;adverse&nbsp;reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>G3/4 Blood bilirubin increased (&lt;2.5%); G3/4 Blood alkaline phosphataseincreased</p><p>(&lt;2.5%)</p></td><td style="vertical-align:top"><p>G3/4&nbsp;AST&nbsp;increased&nbsp;(&lt;1%);</p><p>G3/4&nbsp;ALT&nbsp;increased&nbsp;(&lt;1%)</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac&nbsp;disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cardiac failure; Arrhythmia&nbsp;(no&nbsp;severe)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood&nbsp;and&nbsp;lymphatic system disorders</p></td><td style="vertical-align:top"><p>Neutropenia&nbsp;(G4:&nbsp;91.7%);</p><p>Anemia (G3/4: 9.4%); Febrile neutropenia; Thrombocytopenia(G4:&nbsp;0.8%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top"><p>Peripheral sensory neuropathy&nbsp;(G3:&nbsp;0.4%)</p></td><td style="vertical-align:top"><p>Peripheral motor neuropathy&nbsp;(G3/4:&nbsp;0.4%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea&nbsp;(G3/4:&nbsp;5%);</p><p>Stomatitis&nbsp;(G3/4:&nbsp;7.8%);</p><p>Diarrhea&nbsp;(G3/4:&nbsp;6.2%);</p><p>Vomiting&nbsp;(G3/4:&nbsp;5%);&nbsp;Constipation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin&nbsp;and&nbsp;subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Alopecia.</p><p>Nail&nbsp;disorders&nbsp;(severe</p><p>0.4%);&nbsp;Skin&nbsp;reaction&nbsp;(no&nbsp;severe)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletaland connective tissue&nbsp;disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutritiondisorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Infections&nbsp;and&nbsp;infestations</p></td><td style="vertical-align:top"><p>Infection&nbsp;(G3/4:&nbsp;7.8%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular&nbsp;disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension</p></td></tr><tr><td style="vertical-align:top"><p>General&nbsp;disorders&nbsp;and</p></td><td style="vertical-align:top"><p>Asthenia&nbsp;(severe&nbsp;8.1%);</p></td><td style="vertical-align:top"><p>Infusion&nbsp;site&nbsp;reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:956px"><tbody><tr><td style="vertical-align:top; width:196px"><p>administrationsite&nbsp;conditions</p></td><td style="vertical-align:top; width:288px"><p>Fluid&nbsp;retention&nbsp;(severe&nbsp;1.2%);</p><p>Pain</p></td><td style="vertical-align:top; width:324px"><p>&nbsp;</p></td><td style="vertical-align:top; width:147px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:196px"><p>Immune&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top; width:288px"><p>&nbsp;</p></td><td style="vertical-align:top; width:324px"><p>Hypersensitivity(G3/4:&nbsp;1.2%)</p></td><td style="vertical-align:top; width:147px"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><em>Tabulated&nbsp;list&nbsp;of&nbsp;adverse&nbsp;reactions&nbsp;in&nbsp;non-small&nbsp;cell&nbsp;lung&nbsp;cancer&nbsp;for&nbsp;docetaxel&nbsp;75mg/m&sup2;&nbsp;in&nbsp;combination with cisplatin</em></strong><em>:</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:958px"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRASystem Organ classes</strong></p></td><td style="vertical-align:top"><p><strong>Very&nbsp;common&nbsp;adverse&nbsp;reactions</strong></p></td><td style="vertical-align:top"><p><strong>Commonadverse&nbsp;reactions</strong></p></td><td style="vertical-align:top; width:194px"><p><strong>Uncommon&nbsp;adverse&nbsp;reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>G3/4&nbsp;Blood&nbsp;bilirubin increased (2.1%); G3/4 ALT increased&nbsp;(1.3%)</p></td><td style="vertical-align:top; width:194px"><p>G3/4&nbsp;AST&nbsp;increased&nbsp;(0.5%);</p><p>G3/4 Blood alkaline phosphatase&nbsp;increased&nbsp;(0.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac&nbsp;disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arrhythmia(G3/4:&nbsp;0.7%)</p></td><td style="vertical-align:top; width:194px"><p>Cardiac&nbsp;failure</p></td></tr><tr><td style="vertical-align:top"><p>Blood&nbsp;and&nbsp;lymphatic system disorders</p></td><td style="vertical-align:top"><p>Neutropenia&nbsp;(G4:&nbsp;51.5%);</p><p>Anemia&nbsp;(G3/4:&nbsp;6.9%);&nbsp;Thrombocytopenia (G4:0.5%)</p></td><td style="vertical-align:top"><p>Febrile&nbsp;neutropenia</p></td><td style="vertical-align:top; width:194px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top"><p>Peripheral sensory neuropathy&nbsp;(G3:&nbsp;3.7%); Peripheral motor neuropathy (G3/4: 2%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:194px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea&nbsp;(G3/4:&nbsp;9.6%);</p><p>Vomiting&nbsp;(G3/4:&nbsp;7.6%);</p><p>Diarrhea&nbsp;(G3/4:&nbsp;6.4%);</p><p>Stomatitis&nbsp;(G3/4:&nbsp;2%)</p></td><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top; width:194px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin&nbsp;and&nbsp;subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Alopecia.</p><p>Nail&nbsp;disorders&nbsp;(severe 0.7%); Skin reaction</p><p>(G3/4:&nbsp;0.2%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:194px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal&nbsp;and</p><p>connective&nbsp;tissue&nbsp;disorders</p></td><td style="vertical-align:top"><p>Myalgia&nbsp;(severe&nbsp;0.5%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:194px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutritiondisorders</p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:194px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Infections&nbsp;and&nbsp;infestations</p></td><td style="vertical-align:top"><p>Infection&nbsp;(G3/4:&nbsp;5.7%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:194px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular&nbsp;disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension(G3/4:&nbsp;0.7%)</p></td><td style="vertical-align:top; width:194px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General&nbsp;disorders&nbsp;and administration site&nbsp;conditions</p></td><td style="vertical-align:top"><p>Asthenia&nbsp;(severe&nbsp;9.9%); Fluid retention (severe&nbsp;0.7%);</p><p>Fever&nbsp;(G3/4:&nbsp;1.2%)</p></td><td style="vertical-align:top"><p>Infusion&nbsp;site&nbsp;reaction;&nbsp;Pain</p></td><td style="vertical-align:top; width:194px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity(G3/4:&nbsp;2.5%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:194px"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><em>Tabulated&nbsp;list&nbsp;of&nbsp;adverse&nbsp;reactions&nbsp;in&nbsp;breast&nbsp;cancer&nbsp;for&nbsp;docetaxel&nbsp;100mg/m&sup2;&nbsp;in&nbsp;combination&nbsp;with&nbsp;trastuzumab:</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA&nbsp;System&nbsp;Organ&nbsp;classes</strong></p></td><td style="vertical-align:top"><p><strong>Very&nbsp;common&nbsp;adverse&nbsp;reactions</strong></p></td><td style="vertical-align:top"><p><strong>Common&nbsp;adverse&nbsp;reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Weight&nbsp;increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac&nbsp;disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cardiac&nbsp;failure</p></td></tr><tr><td style="vertical-align:top"><p>Blood&nbsp;and&nbsp;lymphatic&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top"><p>Neutropenia&nbsp;(G3/4:&nbsp;32%);&nbsp;Febrile neutropenia&nbsp;(includes&nbsp;neutropenia associated with fever and antibiotic use) or neutropenic&nbsp;sepsis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top"><p>Paresthesia; Headache; Dysgeusia;Hypoesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye&nbsp;disorders</p></td><td style="vertical-align:top"><p>Lacrimation&nbsp;increased.Conjunctivitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory,&nbsp;thoracic, and mediastinal&nbsp;disorders</p></td><td style="vertical-align:top"><p>Epistaxis;&nbsp;Pharyngolaryngeal</p><p>pain;&nbsp;Nasopharyngitis;&nbsp;Dyspnea; Cough; Rhinorrhea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal&nbsp;disorders</p></td><td style="vertical-align:top"><p>Nausea;&nbsp;Diarrhea;&nbsp;Vomiting; Constipation; Stomatitis.</p><p>Dyspepsia;&nbsp;Abdominal&nbsp;pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin&nbsp;and&nbsp;subcutaneous&nbsp;tissue&nbsp;disorders</p></td><td style="vertical-align:top"><p>Alopecia;&nbsp;Erythema;&nbsp;Rash;&nbsp;Nail&nbsp;disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal&nbsp;and&nbsp;connective tissue disorders</p></td><td style="vertical-align:top"><p>Myalgia; Arthralgia; Pain in extremity;&nbsp;Bone&nbsp;pain;&nbsp;Back&nbsp;pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism&nbsp;and&nbsp;nutrition&nbsp;disorders</p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular&nbsp;disorders</p></td><td style="vertical-align:top"><p>Lymphoedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration&nbsp;site&nbsp;conditions</p></td><td style="vertical-align:top"><p>Asthenia; Edema peripheral; Pyrexia; Fatigue; Mucosal inflammation;&nbsp;Pain;&nbsp;Influenza&nbsp;like illness; Chest pain; Chills</p></td><td style="vertical-align:top"><p>Lethargy</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric&nbsp;disorders</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><em>Description&nbsp;of selected&nbsp;adverse&nbsp;reactions&nbsp;in&nbsp;breast cancer&nbsp;for&nbsp;docetaxel 100&nbsp;mg/m&sup2;&nbsp;in&nbsp;combination&nbsp;with&nbsp;trastuzumab</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><em>Cardiac&nbsp;disorders</em></p><p>Symptomatic cardiac failure was reported in 2.2% of the patients who received docetaxel plus trastuzumab comparedto&nbsp;0%&nbsp;of&nbsp;patients&nbsp;given&nbsp;docetaxel&nbsp;alone.&nbsp;In&nbsp;the&nbsp;docetaxel&nbsp;plus&nbsp;trastuzumab&nbsp;arm,&nbsp;64%&nbsp;had&nbsp;received a prior anthracycline as adjuvant therapy compared with 55% in the docetaxel arm alone.</p><p>&nbsp;</p><p><em>Blood&nbsp;and&nbsp;lymphatic&nbsp;system&nbsp;disorders</em></p><p>Very common: Hematological toxicity was increased in patients receiving trastuzumab and docetaxel, compared&nbsp;withdocetaxel&nbsp;alone&nbsp;(32%&nbsp;grade&nbsp;3/4&nbsp;neutropenia&nbsp;versus&nbsp;22%,&nbsp;using&nbsp;NCI-CTC&nbsp;criteria).&nbsp;Note&nbsp;that this is likely to be an underestimate since docetaxel alone at a dose of 100 mg/m<sup>2</sup>&nbsp;is known to result in neutropenia in 97% of patients, 76% grade 4, based on nadir blood counts. The incidence of febrile neutropenia/neutropenic sepsis was also increased in patients treated with Herceptin plus docetaxel (23% versus 17% for patients treated with docetaxel alone).</p><p>&nbsp;</p><p><strong><em>Tabulated&nbsp;list&nbsp;of&nbsp;adverse&nbsp;reactions&nbsp;in&nbsp;breast&nbsp;cancer&nbsp;for&nbsp;docetaxel&nbsp;75mg/m&sup2;&nbsp;in&nbsp;combination&nbsp;with&nbsp;capecitabine:</em></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:958px"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA&nbsp;System&nbsp;Organ&nbsp;classes</strong></p></td><td style="vertical-align:top"><p><strong>Very&nbsp;common&nbsp;adverse&nbsp;reactions</strong></p></td><td style="vertical-align:top; width:299px"><p><strong>Common&nbsp;adverse&nbsp;reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:299px"><p>Weight&nbsp;decreased.</p><p>G3/4&nbsp;Blood&nbsp;bilirubin&nbsp;increased&nbsp;(9%)</p></td></tr><tr><td style="vertical-align:top"><p>Blood&nbsp;and&nbsp;lymphatic&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top"><p>Neutropenia&nbsp;(G3/4:&nbsp;63%);</p><p>Anemia&nbsp;(G3/4:&nbsp;10%)</p></td><td style="vertical-align:top; width:299px"><p>Thrombocytopenia&nbsp;(G3/4:&nbsp;3%)</p></td></tr><tr><td style="vertical-align:top"><p>Nervous&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top"><p>Dysgeusia&nbsp;(G3/4:&nbsp;&lt;1%);</p><p>Paranesthesia&nbsp;(G3/4:&nbsp;&lt;1%)</p></td><td style="vertical-align:top; width:299px"><p>Dizziness.</p><p>Headache&nbsp;(G3/4:&nbsp;&lt;1%); Neuropathy peripheral</p></td></tr><tr><td style="vertical-align:top"><p>Eye&nbsp;disorders</p></td><td style="vertical-align:top"><p>Lacrimation&nbsp;increased</p></td><td style="vertical-align:top; width:299px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory,&nbsp;thoracic&nbsp;and mediastinal disorders</p></td><td style="vertical-align:top"><p>Pharyngolaryngealpain (G3/4: 2%)</p></td><td style="vertical-align:top; width:299px"><p>Dyspnea&nbsp;(G3/4:&nbsp;1%);</p><p>Cough&nbsp;(G3/4:&nbsp;&lt;1%);</p><p>Epistaxis&nbsp;(G3/4:&nbsp;&lt;1%)</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal&nbsp;disorders</p></td><td style="vertical-align:top"><p>Stomatitis&nbsp;(G3/4:&nbsp;18%);</p><p>Diarrhea&nbsp;(G3/4:&nbsp;14%);</p><p>Nausea&nbsp;(G3/4:&nbsp;6%);</p><p>Vomiting&nbsp;(G3/4:&nbsp;4%);</p><p>Constipation&nbsp;(G3/4:&nbsp;1%);</p><p>Abdominal&nbsp;pain&nbsp;(G3/4:&nbsp;2%);&nbsp;Dyspepsia</p></td><td style="vertical-align:top; width:299px"><p>Abdominal&nbsp;pain&nbsp;upper; Dry mouth</p></td></tr><tr><td style="vertical-align:top"><p>Skin&nbsp;and&nbsp;subcutaneous&nbsp;tissue&nbsp;disorders</p></td><td style="vertical-align:top"><p>Hand-foot&nbsp;syndrome&nbsp;(G3/4:&nbsp;24%) Alopecia (G3/4: 6%);</p><p>Nail&nbsp;disorders&nbsp;(G3/4:&nbsp;2%)</p></td><td style="vertical-align:top; width:299px"><p>Dermatitis.</p><p>Rash&nbsp;erythematous&nbsp;(G3/4:&nbsp;&lt;1%); Nail discoloration.</p><p>Onycholysis&nbsp;(G3/4:&nbsp;1%)</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal&nbsp;and&nbsp;connective tissue disorders</p></td><td style="vertical-align:top"><p>Myalgia&nbsp;(G3/4:&nbsp;2%);</p><p>Arthralgia&nbsp;(G3/4:&nbsp;1%)</p></td><td style="vertical-align:top; width:299px"><p>Pain&nbsp;in&nbsp;extremity&nbsp;(G3/4:&nbsp;&lt;1%); Back pain (G3/4: 1%);</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism&nbsp;and&nbsp;nutrition&nbsp;disorders</p></td><td style="vertical-align:top"><p>Anorexia&nbsp;(G3/4:&nbsp;1%); Decreased appetite</p></td><td style="vertical-align:top; width:299px"><p>Dehydration&nbsp;(G3/4:&nbsp;2%);</p></td></tr><tr><td style="vertical-align:top"><p>Infections&nbsp;and&nbsp;infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:299px"><p>Oral&nbsp;candidiasis&nbsp;(G3/4:&nbsp;&lt;1%)</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration&nbsp;site&nbsp;conditions</p></td><td style="vertical-align:top"><p>Asthenia&nbsp;(G3/4:&nbsp;3%);</p><p>Pyrexia&nbsp;(G3/4:&nbsp;1%);</p><p>Fatigue/&nbsp;weakness&nbsp;(G3/4:&nbsp;5%); Edema peripheral (G3/4: 1%);</p></td><td style="vertical-align:top; width:299px"><p>Lethargy;&nbsp;Pain</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><em>Tabulated&nbsp;list of adverse&nbsp;reactions&nbsp;in&nbsp;prostate&nbsp;cancer&nbsp;for&nbsp;docetaxel 75mg/m&sup2; in&nbsp;combination&nbsp;with prednisone or prednisolone:</em></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA&nbsp;System&nbsp;Organ&nbsp;classes</strong></p></td><td style="vertical-align:top"><p><strong>Very&nbsp;common&nbsp;adverse&nbsp;reactions</strong></p></td><td style="vertical-align:top"><p><strong>Common&nbsp;adverse&nbsp;reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cardiac&nbsp;disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cardiac&nbsp;left&nbsp;ventricular&nbsp;function decrease (G3/4: 0.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Blood&nbsp;and&nbsp;lymphatic&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top"><p>Neutropenia&nbsp;(G3/4:&nbsp;32%);</p><p>Anemia&nbsp;(G3/4:&nbsp;4.9%)</p></td><td style="vertical-align:top"><p>Thrombocytopenia;&nbsp;(G3/4:&nbsp;0.6%); Febrile neutropenia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top"><p>Peripheral&nbsp;sensory&nbsp;neuropathy (G3/4: 1.2%);</p><p>Dysgeusia&nbsp;(G3/4:&nbsp;0%)</p></td><td style="vertical-align:top"><p>Peripheral&nbsp;motor&nbsp;neuropathy (G3/4: 0%)</p></td></tr><tr><td style="vertical-align:top"><p>Eye&nbsp;disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lacrimation&nbsp;increased&nbsp;(G3/4:&nbsp;0.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory,&nbsp;thoracic&nbsp;and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Epistaxis&nbsp;(G3/4:&nbsp;0%);</p><p>Dyspnea&nbsp;(G3/4:&nbsp;0.6%);</p><p>Cough&nbsp;(G3/4:&nbsp;0%)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:873px"><tbody><tr><td style="vertical-align:top; width:283px"><p>Gastrointestinal&nbsp;disorders</p></td><td style="vertical-align:top; width:263px"><p>Nausea&nbsp;(G3/4:&nbsp;2.4%);</p><p>Diarrhea (G3/4: 1.2%); Stomatitis/Pharyngitis(G3/4:&nbsp;0.9%);</p><p>Vomiting&nbsp;(G3/4:&nbsp;1.2%)</p></td><td style="vertical-align:top; width:326px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:283px"><p>Skin&nbsp;and&nbsp;subcutaneous&nbsp;tissue&nbsp;disorders</p></td><td style="vertical-align:top; width:263px"><p>Alopecia.</p><p>Nail&nbsp;disorders&nbsp;(no&nbsp;severe)</p></td><td style="vertical-align:top; width:326px"><p>Exfoliative&nbsp;rash&nbsp;(G3/4:&nbsp;0.3%)</p></td></tr><tr><td style="vertical-align:top; width:283px"><p>Musculoskeletal&nbsp;and&nbsp;connective tissue disorders</p></td><td style="vertical-align:top; width:263px"><p>&nbsp;</p></td><td style="vertical-align:top; width:326px"><p>Arthralgia&nbsp;(G3/4:&nbsp;0.3%);</p><p>Myalgia&nbsp;(G3/4:&nbsp;0.3%)</p></td></tr><tr><td style="vertical-align:top; width:283px"><p>Metabolism&nbsp;and&nbsp;nutrition&nbsp;disorders</p></td><td style="vertical-align:top; width:263px"><p>Anorexia&nbsp;(G3/4:&nbsp;0.6%)</p></td><td style="vertical-align:top; width:326px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:283px"><p>Infections&nbsp;and&nbsp;infestations</p></td><td style="vertical-align:top; width:263px"><p>Infection&nbsp;(G3/4:&nbsp;3.3%)</p></td><td style="vertical-align:top; width:326px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:283px"><p>General disorders and administration&nbsp;site&nbsp;conditions</p></td><td style="vertical-align:top; width:263px"><p>Fatigue&nbsp;(G3/4:&nbsp;3.9%);</p><p>Fluid&nbsp;retention&nbsp;(severe&nbsp;0.6%)</p></td><td style="vertical-align:top; width:326px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:283px"><p>Immune&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top; width:263px"><p>&nbsp;</p></td><td style="vertical-align:top; width:326px"><p>Hypersensitivity&nbsp;(G3/4:&nbsp;0.6%)</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><em>Tabulated list of adverse reactions in breast cancer for adjuvant therapy with docetaxel 75mg/m&sup2; in combinationwith&nbsp;doxorubicin&nbsp;and&nbsp;cyclophosphamide&nbsp;in&nbsp;patients&nbsp;with&nbsp;node-positive&nbsp;(TAX316)&nbsp;and&nbsp;node negative (GEICAM9805) breast cancer &ndash; pooled data:</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRASystem Organ classes</strong></p></td><td style="vertical-align:top"><p><strong>Very&nbsp;common&nbsp;adverse&nbsp;reactions</strong></p></td><td style="vertical-align:top"><p><strong>Commonadverse&nbsp;reactions</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon&nbsp;adverse&nbsp;reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections&nbsp;and&nbsp;infestations</p></td><td style="vertical-align:top"><p>Infection&nbsp;(G3/4:&nbsp;2.4%);</p><p>Neutropenic&nbsp;infection (G3/4: 2.6%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood&nbsp;and&nbsp;lymphatic system disorders</p></td><td style="vertical-align:top"><p>Anemia&nbsp;(G3/4:&nbsp;3%); Neutropenia (G3/4:&nbsp;59.2%);</p><p>Thrombocytopenia&nbsp;(G3/4: 1.6%);</p><p>Febrile&nbsp;neutropenia</p><p>(G3/4:&nbsp;NA)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity(G3/4:&nbsp;0.6%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism&nbsp;and&nbsp;nutrition&nbsp;disorders</p></td><td style="vertical-align:top"><p>Anorexia&nbsp;(G3/4:&nbsp;1.5%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top"><p>Dysgeusia&nbsp;(G3/4:&nbsp;0.6%); Peripheral sensory neuropathy (G3/4:</p><p>&lt;0.1%)</p></td><td style="vertical-align:top"><p>Peripheral motor neuropathy&nbsp;(G3/4:&nbsp;0%);</p></td><td style="vertical-align:top"><p>Syncope (G3/4: 0%) Neurotoxicity(G3/4):&nbsp;0%)</p><p>Somnolence&nbsp;(G3/4:0%)</p></td></tr><tr><td style="vertical-align:top"><p>Eye&nbsp;disorders</p></td><td style="vertical-align:top"><p>Conjunctivitis&nbsp;(G3/4:</p><p>&lt;0.1%)</p></td><td style="vertical-align:top"><p>Lacrimationincreased (G3/4: &lt;0.1%);</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac&nbsp;disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arrhythmia(G3/4:&nbsp;0.2%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular&nbsp;disorders</p></td><td style="vertical-align:top"><p>Hot&nbsp;flush&nbsp;(G3/4:&nbsp;0.5%)</p></td><td style="vertical-align:top"><p>Hypotension(G3/4:&nbsp;0%);</p><p>Phlebitis&nbsp;(G3/4:&nbsp;0%)</p></td><td style="vertical-align:top"><p>Lymphoedema&nbsp;(G3/4:&nbsp;0%)</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory,&nbsp;thoracic&nbsp;and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cough&nbsp;(G3/4:&nbsp;0%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea&nbsp;(G3/4:&nbsp;5.0%);</p><p>Stomatitis&nbsp;(G3/4:&nbsp;6.0%);</p><p>Vomiting&nbsp;(G3/4:&nbsp;4.2%);</p><p>Diarrhea&nbsp;(G3/4:&nbsp;3.4%); Constipation (G3/4:&nbsp;0.5%)</p></td><td style="vertical-align:top"><p>Abdominal&nbsp;pain&nbsp;(G3/4:&nbsp;0.4%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:955px"><tbody><tr><td style="vertical-align:top; width:231px"><p>Skin&nbsp;and&nbsp;subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:297px"><p>Alopecia&nbsp;(persisting:</p><p>&lt;3%);</p><p>Skin&nbsp;disorder&nbsp;(G3/4:&nbsp;0.6%);</p><p>Nail&nbsp;disorders&nbsp;(G3/4:&nbsp;0.4%)</p></td><td style="vertical-align:top; width:205px"><p>&nbsp;</p></td><td style="vertical-align:top; width:221px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:231px"><p>Musculoskeletaland connective tissue&nbsp;disorders</p></td><td style="vertical-align:top; width:297px"><p>Myalgia&nbsp;(G3/4:&nbsp;0.7%);</p><p>Arthralgia&nbsp;(G3/4:&nbsp;0.2%)</p></td><td style="vertical-align:top; width:205px"><p>&nbsp;</p></td><td style="vertical-align:top; width:221px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:231px"><p>Reproductive&nbsp;system&nbsp;and breast disorders</p></td><td style="vertical-align:top; width:297px"><p>Amenorrhea(G3/4:&nbsp;NA)</p></td><td style="vertical-align:top; width:205px"><p>&nbsp;</p></td><td style="vertical-align:top; width:221px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:231px"><p>General&nbsp;disorders&nbsp;and administration site&nbsp;conditions</p></td><td style="vertical-align:top; width:297px"><p>Asthenia&nbsp;(G3/4:&nbsp;10.0%); Fever (G3/4: NA); Edema peripheral</p><p>(G3/4:&nbsp;0.2%)</p></td><td style="vertical-align:top; width:205px"><p>&nbsp;</p></td><td style="vertical-align:top; width:221px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:231px"><p>Investigations</p></td><td style="vertical-align:top; width:297px"><p>&nbsp;</p></td><td style="vertical-align:top; width:205px"><p>Weight&nbsp;increased&nbsp;(G3/4:&nbsp;0%;</p><p>Weight&nbsp;decreased&nbsp;(G3/4:&nbsp;0.2%)</p></td><td style="vertical-align:top; width:221px"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><em>Description&nbsp;of selected&nbsp;adverse&nbsp;reactions&nbsp;for&nbsp;adjuvant&nbsp;therapy&nbsp;with&nbsp;docetaxel 75&nbsp;mg/m&sup2; in&nbsp;combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><em>Cardiac&nbsp;disorders</em></p><p>In&nbsp;study&nbsp;TAX316,&nbsp;26&nbsp;patients&nbsp;(3.5%)&nbsp;in&nbsp;the&nbsp;TAC&nbsp;arm&nbsp;and&nbsp;17&nbsp;patients&nbsp;(2.3%)&nbsp;in&nbsp;the&nbsp;FAC&nbsp;arm experienced congestive heart failure. All except one patient in each arm were diagnosed with CHF more than 30 days after the treatment period. Two patients in the TAC arm and 4 patients in the FAC arm died because of cardiac failure.</p><p>In&nbsp;GEICAM&nbsp;9805&nbsp;study,&nbsp;3&nbsp;patients&nbsp;(0.6&nbsp;%)&nbsp;in&nbsp;TAC&nbsp;arm and&nbsp;3&nbsp;patients&nbsp;(0.6&nbsp;%) in&nbsp;FAC&nbsp;arm developed congestive heart failure during the follow-up period. One patient in TAC arm died because of dilated&nbsp;cardiomyopathy.</p><p>&nbsp;</p><p><em>Nervous&nbsp;system&nbsp;disorders</em></p><p>Peripheral&nbsp;sensory&nbsp;neuropathy&nbsp;was&nbsp;observed&nbsp;to&nbsp;be&nbsp;ongoing&nbsp;during&nbsp;follow-up&nbsp;in10&nbsp;patients&nbsp;out of&nbsp;the&nbsp;84 patients with peripheral sensory neuropathy at the end of the chemotherapy in the node positive breast cancer study (TAX316).</p><p>&nbsp;</p><p><em>Skin&nbsp;and&nbsp;subcutaneous&nbsp;tissue&nbsp;disorders</em></p><p>In study TAX316, alopecia persisting into the follow-up period after the end of chemotherapy was reported in 687 of 744 TAC patients and 645 of 736 FAC patients. At the end of the follow-up period (actual median follow-up time of 96 months), alopecia was observed to be ongoing in 29 TAC patients (3.9%) and 16 FAC patients (2.2%).</p><p>In GEICAM 9805 study, alopecia persisted into the follow-up period (median follow-up time of 10 years and&nbsp;5months)&nbsp;and&nbsp;was&nbsp;observed&nbsp;to&nbsp;be&nbsp;ongoing&nbsp;in&nbsp;49&nbsp;patients&nbsp;(9.2&nbsp;%) in&nbsp;TAC&nbsp;arm&nbsp;and&nbsp;35&nbsp;patients&nbsp;(6.7&nbsp;%)&nbsp;in FAC&nbsp;arm.Alopecia&nbsp;related&nbsp;to&nbsp;study&nbsp;drug&nbsp;started&nbsp;or&nbsp;worsened&nbsp;during&nbsp;the&nbsp;follow-up&nbsp;period&nbsp;in&nbsp;42&nbsp;patients&nbsp;(7.9</p><p>%)&nbsp;in&nbsp;TAC&nbsp;arm&nbsp;and&nbsp;30&nbsp;patients&nbsp;(5.8&nbsp;%)&nbsp;in&nbsp;FAC&nbsp;arm.</p><p>&nbsp;</p><p><em>General&nbsp;disorders&nbsp;and&nbsp;administration&nbsp;site&nbsp;conditions</em></p><p>In study TAX316, peripheral edema was observed to be ongoing in 19 patients out of the 119 patients with peripheral edema in the TAC arm and 4 patients out of the 23 patients with peripheral edema in the FAC&nbsp;arm. In study GEICAM 9805, lymphoedema was observed to be ongoing in 4 of the 5 patients in TAC arm and&nbsp;in&nbsp;1&nbsp;ofthe&nbsp;2&nbsp;patients&nbsp;in&nbsp;FAC&nbsp;arm&nbsp;at&nbsp;the&nbsp;end&nbsp;of the&nbsp;chemotherapy,&nbsp;and&nbsp;did&nbsp;not&nbsp;resolve&nbsp;during&nbsp;the&nbsp;follow- up period (median follow-up time of 10 years and 5 months). Asthenia persisted into the follow-up period (median follow-up time&nbsp;of&nbsp;10 years and 5&nbsp;months) and&nbsp;was observed to&nbsp;be ongoing in 12&nbsp;patients&nbsp;(2.3&nbsp;%)&nbsp;in TAC arm and 4 patients (0.8 %) in FAC arm.</p><p>&nbsp;</p><p><em>Reproductive&nbsp;system&nbsp;and&nbsp;breast&nbsp;disorders</em></p><p>Amenorrhea&nbsp;was&nbsp;observed&nbsp;to&nbsp;be&nbsp;ongoing&nbsp;during&nbsp;follow-up&nbsp;in&nbsp;121&nbsp;patients&nbsp;out&nbsp;of&nbsp;the&nbsp;202&nbsp;patients&nbsp;with amenorrhea at the end of the chemotherapy in study TAX316.</p><p>In GEICAM 9805 study, amenorrhea persisted into the follow-up period (median follow-up time of 10 years&nbsp;and&nbsp;5months)&nbsp;and&nbsp;was&nbsp;observed&nbsp;to&nbsp;be&nbsp;ongoing&nbsp;in&nbsp;18&nbsp;patients&nbsp;(3.4&nbsp;%) in&nbsp;TAC&nbsp;arm&nbsp;and&nbsp;5&nbsp;patients&nbsp;(1.0</p><p>%)&nbsp;in&nbsp;FAC&nbsp;arm.</p><p>&nbsp;</p><p><em>Acute&nbsp;leukemia&nbsp;/&nbsp;Myelodysplastic&nbsp;syndrome</em></p><p>After 10&nbsp;years&nbsp;of&nbsp;follow&nbsp;up&nbsp;in&nbsp;study&nbsp;TAX316,&nbsp;acute&nbsp;leukemia&nbsp;was&nbsp;reported&nbsp;in&nbsp;4&nbsp;of&nbsp;744&nbsp;TAC&nbsp;patients&nbsp;and&nbsp;in 1 of 736 FAC patients. Myelodysplastic syndrome was reported in 2 of 744 TAC patients and in 1 of 736 FAC patients.</p><p>After 10&nbsp;years&nbsp;of&nbsp;follow-up&nbsp;in&nbsp;GEICAM&nbsp;9805&nbsp;study,&nbsp;acute&nbsp;leukemia&nbsp;occurred&nbsp;in&nbsp;1&nbsp;of 532&nbsp;(0.2%)&nbsp;patients&nbsp;in TAC arm. No cases were reported in patients in FAC arm. No patient was diagnosed with myelodysplastic syndrome in either treatment groups.</p><p>&nbsp;</p><p><em>Neutropenic&nbsp;complications</em></p><p><em>Table&nbsp;below&nbsp;shows&nbsp;that the&nbsp;incidence&nbsp;of Grade&nbsp;4&nbsp;neutropenia,&nbsp;febrile&nbsp;neutropenia&nbsp;and&nbsp;neutropenic&nbsp;infection was decreased in patients who received primary G-CSF prophylaxis after it was made mandatory in the TAC arm &ndash; GEICAM study.</em></p><p><em>&nbsp;</em></p><p><u>Neutropenic&nbsp;complications&nbsp;in&nbsp;patients&nbsp;receiving&nbsp;TAC&nbsp;with&nbsp;or&nbsp;without&nbsp;primary&nbsp;G-CSF&nbsp;prophylaxis</u>&nbsp;<u>(GEICAM 9805)</u></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Without&nbsp;primary&nbsp;G_CSF prophylaxis (n=111)</strong></p><p><strong>n&nbsp;(%)</strong></p></td><td style="vertical-align:top"><p><strong>With&nbsp;primary&nbsp;G-CSF prophylaxis (n=421) n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia&nbsp;(Grade&nbsp;4)</p></td><td style="vertical-align:top"><p>104&nbsp;(93.7)</p></td><td style="vertical-align:top"><p>135&nbsp;(32.1)</p></td></tr><tr><td style="vertical-align:top"><p>Febrile&nbsp;neutropenia</p></td><td style="vertical-align:top"><p>28&nbsp;(25.2)</p></td><td style="vertical-align:top"><p>23&nbsp;(5.5)</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenic&nbsp;infection</p></td><td style="vertical-align:top"><p>14&nbsp;(12.6)</p></td><td style="vertical-align:top"><p>21&nbsp;(5.0)</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenic&nbsp;infection&nbsp;(Grade&nbsp;3-4)</p></td><td style="vertical-align:top"><p>2&nbsp;(1.8)</p></td><td style="vertical-align:top"><p>5&nbsp;(1.2)</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><em>Tabulated&nbsp;list&nbsp;of&nbsp;adverse&nbsp;reactions&nbsp;in&nbsp;gastric&nbsp;adenocarcinoma&nbsp;cancer&nbsp;for&nbsp;docetaxel&nbsp;75mg/m&sup2;&nbsp;in combination with cisplatin and 5-fluorouracil</em></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:957px"><tbody><tr><td style="vertical-align:top; width:281px"><p><strong>MedDRA&nbsp;System&nbsp;Organ&nbsp;classes</strong></p></td><td style="vertical-align:top; width:251px"><p><strong>Very&nbsp;common&nbsp;adverse&nbsp;reactions</strong></p></td><td style="vertical-align:top; width:422px"><p><strong>Common&nbsp;adverse&nbsp;reactions</strong></p></td></tr><tr><td style="vertical-align:top; width:281px"><p>Cardiac&nbsp;disorders</p></td><td style="vertical-align:top; width:251px"><p>&nbsp;</p></td><td style="vertical-align:top; width:422px"><p>Arrhythmia&nbsp;(G3/4:&nbsp;1.0%).</p></td></tr><tr><td style="vertical-align:top; width:281px"><p>Blood&nbsp;and&nbsp;lymphatic&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top; width:251px"><p>Anemia&nbsp;(G3/4:&nbsp;20.9%);</p><p>Neutropenia&nbsp;(G3/4:&nbsp;83.2%);</p><p>Thrombocytopenia&nbsp;(G3/4:&nbsp;8.8%); Febrile neutropenia.</p></td><td style="vertical-align:top; width:422px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:281px"><p>Nervous&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top; width:251px"><p>Peripheral&nbsp;sensory&nbsp;neuropathy (G3/4: 8.7%).</p></td><td style="vertical-align:top; width:422px"><p>Dizziness&nbsp;(G3/4:&nbsp;2.3%);</p><p>Peripheral&nbsp;motor&nbsp;neuropathy (G3/4: 1.3%).</p></td></tr><tr><td style="vertical-align:top; width:281px"><p>Eye&nbsp;disorders</p></td><td style="vertical-align:top; width:251px"><p>&nbsp;</p></td><td style="vertical-align:top; width:422px"><p>Lacrimation&nbsp;increased&nbsp;(G3/4:&nbsp;0%).</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Ear&nbsp;and&nbsp;labyrinth&nbsp;disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hearing&nbsp;impaired&nbsp;(G3/4:&nbsp;0%).</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal&nbsp;disorders</p></td><td style="vertical-align:top"><p>Diarrhea&nbsp;(G3/4:&nbsp;19.7%);</p><p>Nausea&nbsp;(G3/4:&nbsp;16%);</p><p>Stomatitis&nbsp;(G3/4:&nbsp;23.7%);</p><p>Vomiting&nbsp;(G3/4:&nbsp;14.3%).</p></td><td style="vertical-align:top"><p>Constipation&nbsp;(G3/4:&nbsp;1.0&nbsp;%); Gastrointestinal&nbsp;pain&nbsp;(G3/4:&nbsp;1.0%);</p><p>Esophagitis/dysphagia/odynophagi</p><p>a&nbsp;(G3/4:&nbsp;0.7%).</p></td></tr><tr><td style="vertical-align:top"><p>Skin&nbsp;and&nbsp;subcutaneous&nbsp;tissue&nbsp;disorders</p></td><td style="vertical-align:top"><p>Alopecia&nbsp;(G3/4:&nbsp;4.0%).</p></td><td style="vertical-align:top"><p>Rash pruritus (G3/4: 0.7%); Nail&nbsp;disorders&nbsp;(G3/4:0.7%); Skin&nbsp;exfoliation(G3/4:&nbsp;0%).</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism&nbsp;and&nbsp;nutrition&nbsp;disorders</p></td><td style="vertical-align:top"><p>Anorexia&nbsp;(G3/4:&nbsp;11.7%).</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Infections&nbsp;and&nbsp;infestations</p></td><td style="vertical-align:top"><p>Neutropenic&nbsp;infection;&nbsp;Infection (G3/4: 11.7%).</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration&nbsp;site&nbsp;conditions</p></td><td style="vertical-align:top"><p>Lethargy&nbsp;(G3/4:&nbsp;19.0%);</p><p>Fever&nbsp;(G3/4:&nbsp;2.3%);</p><p>Fluid&nbsp;retention&nbsp;(severe/life threatening: 1%).</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity&nbsp;(G3/4:&nbsp;1.7).</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong><em>Description&nbsp;of selected&nbsp;adverse&nbsp;reactions&nbsp;in&nbsp;gastric&nbsp;adenocarcinoma&nbsp;cancer&nbsp;for&nbsp;docetaxel&nbsp;75&nbsp;mg/m2&nbsp;in combination with cisplatin and 5-fluorouracil</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><em>Blood&nbsp;and&nbsp;lymphatic&nbsp;system&nbsp;disorders</em></p><p>Febrile neutropenia and neutropenic infection occurred in 17.2% and 13.5% of patients respectively, regardless of G-CSF use. G-CSF was used for secondary prophylaxis in 19.3% of patients (10.7% of the cycles).&nbsp;Febrile&nbsp;neutropeniaand&nbsp;neutropenic&nbsp;infection&nbsp;occurred&nbsp;respectively&nbsp;in&nbsp;12.1% and&nbsp;3.4% of&nbsp;patients when patients received prophylactic G-CSF, in 15.6% and 12.9% of patients without prophylactic G-CSF, (see section 4.2).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>Tabulated&nbsp;list of adverse&nbsp;reactions&nbsp;in&nbsp;head&nbsp;and&nbsp;neck&nbsp;cancer&nbsp;for&nbsp;docetaxel 75mg/m&sup2; in&nbsp;combination&nbsp;with cisplatin and 5-fluorouracil</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><img width="2" height="2" src="blob:https://sdi.sfda.gov.sa/31d149de-08b4-4f21-bbae-55b7b733d814" />Induction&nbsp;chemotherapy&nbsp;followed&nbsp;by&nbsp;radiotherapy&nbsp;(TAX&nbsp;323)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRASystem Organ classes</strong></p></td><td style="vertical-align:top"><p><strong>Very&nbsp;common&nbsp;adverse&nbsp;reactions</strong></p></td><td style="vertical-align:top"><p><strong>Commonadverse&nbsp;reactions</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon&nbsp;adverse&nbsp;reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Weight&nbsp;increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac&nbsp;disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myocardialischemia&nbsp;(G3/4:1.7%)</p></td><td style="vertical-align:top"><p>Arrhythmia&nbsp;(G3/4:0.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Blood&nbsp;and&nbsp;lymphatic&nbsp;system</p><p>disorders</p></td><td style="vertical-align:top"><p>Neutropenia (G3/4:76.3%)</p><p>Anemia&nbsp;(G3/4:9.2)</p><p>Thrombocytopenia&nbsp;(G3/4:5.2%)</p></td><td style="vertical-align:top"><p>Febrile&nbsp;neutropenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top"><p>Dysgeusia/Parosmia</p><p>Peripheral sensory neuropathy&nbsp;(G3/4:0.6%)</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye&nbsp;disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lacrimation&nbsp;increased&nbsp;Conjunctivitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ear&nbsp;and&nbsp;labyrinth&nbsp;disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hearing&nbsp;impaired</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal&nbsp;disorders</p></td><td style="vertical-align:top"><p>Nausea&nbsp;(G3/4:0.6%)Stomatitis (G3/4;4.0%) Diarrhea (G3/4:2.9%) Vomiting (G3/4:0.6%)</p></td><td style="vertical-align:top"><p>Constipation&nbsp;<br />&nbsp;</p><p>Esophagitis/dysphagia/ odynophagia (G3/4:0.6%)</p><p>Abdominal&nbsp;pain&nbsp;Dyspepsia Gastrointestinal hemorrhage</p><p>(G3/4:0.6%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:957px"><tbody><tr><td style="vertical-align:top; width:161px"><p>Skin&nbsp;and&nbsp;subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:381px"><p>Alopecia&nbsp;(G3/4:10.9%).</p></td><td style="vertical-align:top; width:250px"><p>Rash&nbsp;pruritic Dry skin</p><p>Skin&nbsp;exfoliative&nbsp;(G3/4:0.6%)</p></td><td style="vertical-align:top; width:162px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:161px"><p>Musculoskeletal&nbsp;and</p><p>connective&nbsp;tissue&nbsp;disorders</p></td><td style="vertical-align:top; width:381px"><p>&nbsp;</p></td><td style="vertical-align:top; width:250px"><p>Myalgia&nbsp;(G3/4:0.6%)</p></td><td style="vertical-align:top; width:162px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:161px"><p>Metabolism and nutritiondisorders</p></td><td style="vertical-align:top; width:381px"><p>Anorexia&nbsp;(G3/4:0.6%)</p></td><td style="vertical-align:top; width:250px"><p>&nbsp;</p></td><td style="vertical-align:top; width:162px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:161px"><p>Infections&nbsp;and&nbsp;infestations</p></td><td style="vertical-align:top; width:381px"><p>Infection(G3/4:6.3%) Neutropenic&nbsp;infection</p></td><td style="vertical-align:top; width:250px"><p>&nbsp;</p></td><td style="vertical-align:top; width:162px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:161px"><p>Neoplasms&nbsp;benign, malignant and&nbsp;unspecified</p><p>(incl&nbsp;cysts&nbsp;and&nbsp;polyps)</p></td><td style="vertical-align:top; width:381px"><p>&nbsp;</p></td><td style="vertical-align:top; width:250px"><p>Cancer&nbsp;pain&nbsp;(G3/4:&nbsp;0.6%)</p></td><td style="vertical-align:top; width:162px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:161px"><p>Vascular&nbsp;disorders</p></td><td style="vertical-align:top; width:381px"><p>&nbsp;</p></td><td style="vertical-align:top; width:250px"><p>Venous&nbsp;disorder&nbsp;(G3/4:0.6%)</p></td><td style="vertical-align:top; width:162px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:161px"><p>General&nbsp;disorders&nbsp;and administration site&nbsp;conditions</p></td><td style="vertical-align:top; width:381px"><p>Lethargy(G3/4:3.4%) Pyrexia (G3/4:0.6%)</p><p>Fluid&nbsp;retention&nbsp;Edema</p></td><td style="vertical-align:top; width:250px"><p>&nbsp;</p></td><td style="vertical-align:top; width:162px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:161px"><p>Immune&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top; width:381px"><p>&nbsp;</p></td><td style="vertical-align:top; width:250px"><p>Hypersensitivity(no&nbsp;severe)</p></td><td style="vertical-align:top; width:162px"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><img width="2" height="2" src="blob:https://sdi.sfda.gov.sa/a9bdbbb8-459e-40a3-aa30-968fdd848740" />Induction&nbsp;chemotherapy&nbsp;followed&nbsp;by&nbsp;chemoradiotherapy&nbsp;(TAX&nbsp;324)&nbsp;</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRASystem Organ classes</strong></p></td><td style="vertical-align:top"><p><strong>Very&nbsp;common&nbsp;adverse&nbsp;reactions</strong></p></td><td style="vertical-align:top"><p><strong>Commonadverse&nbsp;reactions</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon&nbsp;adverse&nbsp;reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Weight&nbsp;decreased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Weight&nbsp;increased</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac&nbsp;disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arrhythmia&nbsp;(G3/4:2.0%)</p></td><td style="vertical-align:top"><p>Ischemia&nbsp;myocardial</p></td></tr><tr><td style="vertical-align:top"><p>Blood&nbsp;and&nbsp;lymphaticsystem</p><p>disorders</p></td><td style="vertical-align:top"><p>Neutropenia (G3/4:83.5%)</p><p>Anemia(G3/4:12.4%)&nbsp;Thrombocytopenia (G3/4:4.0%)</p><p>Febrile&nbsp;neutropenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top"><p>Dysgeusia/Parosmia (G3/4:0.4%);</p><p>Peripheral sensory neuropathy(G3/4:1.2%)</p></td><td style="vertical-align:top"><p>Dizziness (G3/4:2.0%); Peripheral motor neuropathy(G3/4:0.4%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye&nbsp;disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lacrimation&nbsp;increased</p></td><td style="vertical-align:top"><p>Conjunctivitis</p></td></tr><tr><td style="vertical-align:top"><p>Ear&nbsp;and&nbsp;labyrinth&nbsp;disorders</p></td><td style="vertical-align:top"><p>Hearing&nbsp;impaired&nbsp;(G3/4:1.2%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal&nbsp;disorders</p></td><td style="vertical-align:top"><p>Nausea&nbsp;(G3/4:&nbsp;13.9%);</p><p>Stomatitis(G3/4:20.7%); Vomiting (G3/4:8.4%); Diarrhea (G3/4: 6.8%);&nbsp;Esophagitis/dysphagia/ odynophagia (G3/4:12.0%);</p><p>Constipation (G3/4:0.4%)</p></td><td style="vertical-align:top"><p>Dyspepsia&nbsp;(G3/4:0.8%);</p><p>Gastrointestinal&nbsp;pain (G3/4: 1.2%);</p><p>Gastrointestinal hemorrhage (G3/4:0.4%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:162px"><p>Skin&nbsp;and&nbsp;subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:427px"><p>Alopecia(G3/4:4.0%); Rash pruritic</p></td><td style="vertical-align:top; width:233px"><p>Dry&nbsp;skin;&nbsp;Desquamation</p></td><td style="vertical-align:top; width:132px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:162px"><p>Musculoskeletal&nbsp;and</p><p>connective&nbsp;tissue&nbsp;disorders</p></td><td style="vertical-align:top; width:427px"><p>&nbsp;</p></td><td style="vertical-align:top; width:233px"><p>Myalgia&nbsp;(G3/4:0.4%)</p></td><td style="vertical-align:top; width:132px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:162px"><p>Metabolism and nutritiondisorders</p></td><td style="vertical-align:top; width:427px"><p>Anorexia&nbsp;(G3/4:12.0%)</p></td><td style="vertical-align:top; width:233px"><p>&nbsp;</p></td><td style="vertical-align:top; width:132px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:162px"><p>Infections&nbsp;and&nbsp;infestations</p></td><td style="vertical-align:top; width:427px"><p>Infection&nbsp;(G3/4:3.6%)</p></td><td style="vertical-align:top; width:233px"><p>Neutropenic&nbsp;infection</p></td><td style="vertical-align:top; width:132px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:162px"><p>Neoplasms&nbsp;benign, malignant and&nbsp;unspecified</p><p>(incl&nbsp;cysts&nbsp;and&nbsp;polyps)</p></td><td style="vertical-align:top; width:427px"><p>&nbsp;</p></td><td style="vertical-align:top; width:233px"><p>Cancer&nbsp;pain&nbsp;(G3/4:&nbsp;1.2%)</p></td><td style="vertical-align:top; width:132px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:162px"><p>Vascular&nbsp;disorders</p></td><td style="vertical-align:top; width:427px"><p>&nbsp;</p></td><td style="vertical-align:top; width:233px"><p>&nbsp;</p></td><td style="vertical-align:top; width:132px"><p>Venous&nbsp;disorder</p></td></tr><tr><td style="vertical-align:top; width:162px"><p>General&nbsp;disorders&nbsp;and administration site&nbsp;conditions</p></td><td style="vertical-align:top; width:427px"><p>Lethargy(G3/4:4.0%) Pyrexia (G3/4:3.6%) Fluid retention&nbsp;(G3/4:1.2)</p><p>Edema&nbsp;(G3/4:1.2%)</p></td><td style="vertical-align:top; width:233px"><p>&nbsp;</p></td><td style="vertical-align:top; width:132px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:162px"><p>Immune&nbsp;system&nbsp;disorders</p></td><td style="vertical-align:top; width:427px"><p>&nbsp;</p></td><td style="vertical-align:top; width:233px"><p>&nbsp;</p></td><td style="vertical-align:top; width:132px"><p>Hypersensitivity</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><em>Post-Marketing&nbsp;Experience:</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><em>Cardiac&nbsp;disorders</em></p><p>Rare&nbsp;cases&nbsp;of&nbsp;myocardial&nbsp;infarction&nbsp;have&nbsp;been&nbsp;reported.</p><p>&nbsp;</p><p><em>Blood&nbsp;and&nbsp;lymphatic&nbsp;system&nbsp;disorders</em></p><p>Bone marrow suppression and other hematologic adverse reactions have been reported. Disseminated intravascular coagulation&nbsp;(DIC),&nbsp;often&nbsp;in&nbsp;association&nbsp;with&nbsp;sepsis&nbsp;or&nbsp;multiorgan&nbsp;failure,&nbsp;has&nbsp;been&nbsp;reported.</p><p>&nbsp;</p><p><em>Nervous&nbsp;system&nbsp;disorders</em></p><p>Rare cases of convulsion or transient loss of consciousness have been observed with docetaxel administration.&nbsp;Thesereactions&nbsp;sometimes&nbsp;appear&nbsp;during&nbsp;the&nbsp;infusion&nbsp;of&nbsp;the&nbsp;medicinal&nbsp;product.</p><p>&nbsp;</p><p><em>Eye&nbsp;disorders</em></p><p>Very rare cases of transient visual disturbances (flashes, flashing lights, scotomata) typically occurring during infusion of the medicinal product and in association with hypersensitivity reactions have been reported. These were reversible upon discontinuation of the infusion. Cases of lacrimation with or without conjunctivitis,&nbsp;as&nbsp;cases&nbsp;of&nbsp;lacrimal ductobstruction&nbsp;resulting&nbsp;in&nbsp;excessive&nbsp;tearing&nbsp;have&nbsp;been&nbsp;rarely&nbsp;reported. Cases of cystoid macular oedema (CMO) have been reported in patients treated with docetaxel.</p><p>&nbsp;</p><p><em>Ear&nbsp;and&nbsp;labyrinth&nbsp;disorders</em></p><p>Rare&nbsp;cases&nbsp;of&nbsp;ototoxicity,&nbsp;hearing&nbsp;impaired&nbsp;and/or&nbsp;hearing&nbsp;loss&nbsp;have&nbsp;been&nbsp;reported.</p><p><em>Respiratory,&nbsp;thoracic&nbsp;and&nbsp;mediastinal&nbsp;disorders</em></p><p>Acute respiratory distress syndrome and cases of interstitial pneumonia/ pneumonitis, interstitial lung disease,pulmonary&nbsp;fibrosis&nbsp;and&nbsp;respiratory&nbsp;failure&nbsp;sometimes&nbsp;fatal have&nbsp;rarely&nbsp;been&nbsp;reported.&nbsp;Rare&nbsp;cases&nbsp;of radiation pneumonitis have been reported in patients receiving concomitant radiotherapy.</p><p>&nbsp;</p><p><em>Gastrointestinal&nbsp;disorders</em></p><p>Rare occurrences of dehydration as a consequence of gastrointestinal events, gastrointestinal perforation, colitisischemic,&nbsp;colitis&nbsp;and&nbsp;neutropenic&nbsp;enterocolitis&nbsp;have&nbsp;been&nbsp;reported.&nbsp;Rare&nbsp;cases&nbsp;of&nbsp;ileus&nbsp;and&nbsp;intestinal obstruction have been reported.</p><p>&nbsp;</p><p><em>Skin&nbsp;and&nbsp;subcutaneous&nbsp;tissue&nbsp;disorders</em></p><p>Very&nbsp;rare&nbsp;cases&nbsp;of cutaneous&nbsp;lupus&nbsp;erythematosus&nbsp;and&nbsp;bullous&nbsp;eruptions&nbsp;such&nbsp;as&nbsp;erythema&nbsp;multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, have been reported with docetaxel. In some cases,&nbsp;concomitantfactors&nbsp;may&nbsp;have&nbsp;contributed&nbsp;to&nbsp;the&nbsp;development&nbsp;of&nbsp;these&nbsp;effects.&nbsp;Scleroderma&nbsp;like changes usually preceded by peripheral lymphoedema have been reported with docetaxel. Cases of persisting alopecia have been reported.</p><p>&nbsp;</p><p><em>Neoplasms&nbsp;benign,&nbsp;malignant&nbsp;and&nbsp;unspecified&nbsp;(incl&nbsp;cysts&nbsp;and&nbsp;polyps)</em></p><p>Cases&nbsp;of acute&nbsp;myeloid&nbsp;leukemia&nbsp;and&nbsp;myelodysplastic&nbsp;syndrome&nbsp;have&nbsp;been&nbsp;reported&nbsp;in&nbsp;association&nbsp;with docetaxel when used in combination with other chemotherapy agents and/or radiotherapy.</p><p>&nbsp;</p><p><em>Vascular&nbsp;disorders</em></p><p>Venous&nbsp;thromboembolic&nbsp;events&nbsp;have&nbsp;rarely&nbsp;been&nbsp;reported.</p><p>&nbsp;</p><p><em>Renal&nbsp;and&nbsp;urinary&nbsp;disorders</em></p><p>Renal&nbsp;insufficiency&nbsp;and&nbsp;renal failure&nbsp;have&nbsp;been&nbsp;reported.&nbsp;In&nbsp;about&nbsp;20%&nbsp;of&nbsp;these&nbsp;cases&nbsp;there&nbsp;were&nbsp;no&nbsp;risk factors for acute renal failure such as concomitant nephrotoxic medicinal products and gastrointestinal&nbsp;disorders<em>.</em></p><p><em>&nbsp;</em></p><p><em>General&nbsp;disorders&nbsp;and&nbsp;administration&nbsp;site&nbsp;conditions</em></p><p>Radiation&nbsp;recall&nbsp;phenomena&nbsp;have&nbsp;rarely&nbsp;been&nbsp;reported.</p><p>Fluid&nbsp;retention&nbsp;has&nbsp;not&nbsp;been&nbsp;accompanied&nbsp;by&nbsp;acute&nbsp;episodes&nbsp;of&nbsp;oliguria&nbsp;or&nbsp;hypotension.&nbsp;Dehydration&nbsp;and pulmonary edema have rarely been reported.</p><p>Cases&nbsp;of delayed&nbsp;infusion&nbsp;site&nbsp;adverse&nbsp;reactions&nbsp;with&nbsp;a&nbsp;&ldquo;burn-like&rdquo;&nbsp;appearance&nbsp;have&nbsp;been&nbsp;reported&nbsp;with unknown frequency.</p><p>&nbsp;</p><p><em>Metabolism&nbsp;and&nbsp;nutrition&nbsp;disorders</em></p><p>Cases&nbsp;of&nbsp;hyponatremia&nbsp;have&nbsp;been&nbsp;reported,&nbsp;mostly&nbsp;associated&nbsp;with&nbsp;dehydration,&nbsp;vomiting&nbsp;and&nbsp;pneumonia.</p><p>&nbsp;</p><p><em>Immune&nbsp;system&nbsp;disorders</em></p><p>Some&nbsp;cases&nbsp;of&nbsp;anaphylactic&nbsp;shock,&nbsp;sometimes&nbsp;fatal,&nbsp;have&nbsp;been&nbsp;reported.</p><p>&nbsp;</p><p><em>Hepato-biliary&nbsp;disorders</em></p><p>Very&nbsp;rare&nbsp;cases&nbsp;of&nbsp;hepatitis,&nbsp;sometimes&nbsp;fatal&nbsp;primarily&nbsp;in&nbsp;patients&nbsp;with&nbsp;pre-existing&nbsp;liver&nbsp;disorders,&nbsp;have been reported.</p><p>&nbsp;</p><p>To&nbsp;reports&nbsp;any&nbsp;side&nbsp;effect(s):</p><p><strong>Saudi&nbsp;Arabia:</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->The&nbsp;National&nbsp;Pharmacovigilance&nbsp;Centre&nbsp;(NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fax:&nbsp;+966-11-205-7662</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Call&nbsp;NPC&nbsp;at&nbsp;+966-11-2038222,&nbsp;Ext&nbsp;2317-2356-2340</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->SFDA&nbsp;Call&nbsp;Center:&nbsp;19999</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->E-mail:&nbsp;npc.drug@sfda.gov.sa</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Website:&nbsp;https://ade.sfda.gov.sa/</p><p><strong>Other&nbsp;GCC&nbsp;States:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>Please&nbsp;contact&nbsp;the&nbsp;relevant&nbsp;competent&nbsp;authority.</em></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There were a few reports of overdose. There is no known antidote for docetaxel overdose. In case of overdose, the patient should be kept in a specialized unit and vital functions closely monitored. In cases of overdose, exacerbation of adverse events may be expected. The primary anticipated complications of overdose&nbsp;would&nbsp;consist&nbsp;of&nbsp;bone&nbsp;marrowsuppression,&nbsp;peripheral&nbsp;neurotoxicity&nbsp;and&nbsp;mucositis.&nbsp;Patients&nbsp;should receive therapeutic G-CSF as soon as possible after discovery of overdose. Other appropriate symptomatic measures should be taken, as needed.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic&nbsp;group:&nbsp;Antineoplastic&nbsp;agents,&nbsp;ATC&nbsp;Code:&nbsp;L01CD&nbsp;02</p><p>&nbsp;</p><p><strong><em>Preclinical&nbsp;data</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><u>Mechanism&nbsp;of&nbsp;action</u></p><p>&nbsp;</p><p>Docetaxel is an antineoplastic agent which acts by promoting the assembly of tubulin into stable microtubules&nbsp;andinhibits&nbsp;their&nbsp;disassembly&nbsp;which&nbsp;leads&nbsp;to&nbsp;a&nbsp;marked&nbsp;decrease&nbsp;of&nbsp;free&nbsp;tubulin.&nbsp;The&nbsp;binding&nbsp;of docetaxel to microtubules does not alter the number of protofilaments.</p><p>&nbsp;</p><p>Docetaxel&nbsp;has&nbsp;been&nbsp;shown&nbsp;<em>in&nbsp;vitro&nbsp;</em>to&nbsp;disrupt&nbsp;the&nbsp;microtubular network&nbsp;in&nbsp;cells&nbsp;which&nbsp;is&nbsp;essential for vital mitotic and interphase cellular functions.</p><p>&nbsp;</p><p><u>Pharmacodynamic&nbsp;effects</u></p><p>&nbsp;</p><p>Docetaxel was found to be cytotoxic&nbsp;<em>in vitro&nbsp;</em>against various murine and human tumor cell lines and against freshlyexcised&nbsp;human&nbsp;tumor cells&nbsp;in&nbsp;clonogenic&nbsp;assays.&nbsp;Docetaxel achieves&nbsp;high&nbsp;intracellular&nbsp;concentrations with a long cell residence time. In addition, docetaxel was found to be active on some but not all cell lines over expressing the p-glycoprotein which is encoded by the multidrug resistance gene.&nbsp;<em>In vivo</em>, docetaxel is schedule independent and has a broad spectrum of experimental antitumor activity against advanced murine and human grafted tumors.</p><p>&nbsp;</p><p><strong><em>Clinical&nbsp;efficacy&nbsp;and&nbsp;safety</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><em>Breast&nbsp;cancer</em></p><p><em>&nbsp;</em></p><p><em>Docetaxel&nbsp;in&nbsp;combination&nbsp;with&nbsp;doxorubicin&nbsp;and&nbsp;cyclophosphamide:&nbsp;adjuvant&nbsp;therapy</em></p><p><em>&nbsp;</em></p><p><u>Patients&nbsp;with&nbsp;operable&nbsp;node-positive&nbsp;breast&nbsp;cancer&nbsp;(TAX&nbsp;316)</u></p><p>&nbsp;</p><p>Data&nbsp;from a&nbsp;multicenter open&nbsp;label&nbsp;randomized&nbsp;study&nbsp;support the&nbsp;use&nbsp;of&nbsp;docetaxel&nbsp;for&nbsp;the&nbsp;adjuvant treatment of&nbsp;patientswith&nbsp;operable&nbsp;node-positive&nbsp;breast&nbsp;cancer&nbsp;and&nbsp;KPS&nbsp;&ge;&nbsp;80%,&nbsp;between&nbsp;18&nbsp;and&nbsp;70&nbsp;years&nbsp;of&nbsp;age.&nbsp;After stratification according to the number of positive lymph nodes (1-3, 4+), 1491 patients were randomized to receive either docetaxel 75 mg/m<sup>2</sup>&nbsp;administered 1-hour after doxorubicin 50 mg/m<sup>2</sup>&nbsp;and cyclophosphamide 500 mg/m<sup>2</sup>&nbsp;(TAC arm), or doxorubicin 50 mg/m<sup>2</sup>&nbsp;followed by fluorouracil 500 mg/m<sup>2</sup>&nbsp;and cyclophosphamide 500 mg/m<sup>2</sup>&nbsp;(FAC arm). Both regimens were administered once every 3 weeks for 6 cycles. Docetaxel was administered as a 1-hour infusion, all other medicinal products were given as intravenous bolus on day one. G-CSF was administered as secondary prophylaxis to patients who experienced complicated neutropenia (febrile neutropenia, prolonged neutropenia, or infection). Patients on the TAC arm received antibiotic prophylaxis with ciprofloxacin 500 mg orally twice daily for 10 days starting on day 5 of each cycle, or equivalent. In both arms, after the last cycle of chemotherapy, patients with positive estrogen and/or progesterone receptors received tamoxifen 20 mg daily for up to 5 years. Adjuvant radiation therapy was prescribed according to guidelines in place at participating institutions and&nbsp;was given to 69% of patients who received TAC and 72% of patients who received FAC. Two interims analyses and one final analysis were performed. The first interim analysis was planned 3 years after the date when&nbsp;half of study&nbsp;enrollment was&nbsp;done.&nbsp;Thesecond&nbsp;interim analysis&nbsp;was&nbsp;done&nbsp;after&nbsp;400&nbsp;DFS&nbsp;events&nbsp;had&nbsp;been recorded overall, which led to a median follow-up of 55 months. The final analysis was performed when all patients had reached their 10-year follow-up visit (unless they had a DFS event or were lost to follow- up before). Disease-free survival (DFS) was the primary efficacy endpoint and Overall survival (OS) was the secondary efficacy endpoint.</p><p>&nbsp;</p><p>A final analysis was performed with an actual median follow up of 96 months. Significantly longer disease- freesurvival&nbsp;for&nbsp;the&nbsp;TAC&nbsp;arm&nbsp;compared&nbsp;to&nbsp;the&nbsp;FAC&nbsp;arm was&nbsp;demonstrated.&nbsp;Incidence&nbsp;of relapses&nbsp;at 10&nbsp;years was reduced in patients receiving TAC compared to those who received FAC (39% versus 45%, respectively) i.e. an absolute risk reduction by 6% (p=0.0043). Overall survival at 10 years was also significantly increased with TAC compared to FAC (76% versus 69%, respectively) i.e. an absolute reduction of the risk of death by 7% (p = 0.002). As the benefit observed in patients with 4+ nodes were not statistically&nbsp;significant on&nbsp;DFS and OS, the positive benefit/risk&nbsp;ratio&nbsp;for TAC in&nbsp;patients with 4+ nodes was not fully&nbsp;demonstrated&nbsp;at&nbsp;the&nbsp;final&nbsp;analysis.&nbsp;Overall,&nbsp;the&nbsp;study&nbsp;results&nbsp;demonstrate&nbsp;apositive&nbsp;benefit risk&nbsp;ratio for TAC compared to FAC. TAC-treated patient subsets according to prospectively defined major&nbsp;prognostic&nbsp;factors&nbsp;were&nbsp;analyzed.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Disease&nbsp;Free&nbsp;Survival</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Overall&nbsp;Survival</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Patient&nbsp;subset</strong></p></td><td style="vertical-align:top"><p><strong>Number</strong></p><p><strong>of&nbsp;patients</strong></p></td><td style="vertical-align:top"><p><strong>Hazard&nbsp;ratio*</strong></p></td><td style="vertical-align:top"><p><strong>95%&nbsp;CI</strong></p></td><td style="vertical-align:top"><p><strong>P=</strong></p></td><td style="vertical-align:top"><p><strong>Hazard&nbsp;ratio*</strong></p></td><td style="vertical-align:top"><p><strong>95%&nbsp;CI</strong></p></td><td style="vertical-align:top"><p><strong>P=</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>No&nbsp;of&nbsp;positive</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>nodes</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Overall</p></td><td style="vertical-align:top"><p>745</p></td><td style="vertical-align:top"><p>0.80</p></td><td style="vertical-align:top"><p>0.68-0.93</p></td><td style="vertical-align:top"><p>0.0043</p></td><td style="vertical-align:top"><p>0.74</p></td><td style="vertical-align:top"><p>0.61-0.90</p></td><td style="vertical-align:top"><p>0.0020</p></td></tr><tr><td style="vertical-align:top"><p>1-3</p></td><td style="vertical-align:top"><p>467</p></td><td style="vertical-align:top"><p>0.72</p></td><td style="vertical-align:top"><p>0.58-0.91</p></td><td style="vertical-align:top"><p>0.0047</p></td><td style="vertical-align:top"><p>0.62</p></td><td style="vertical-align:top"><p>0.46-0.82</p></td><td style="vertical-align:top"><p>0.0008</p></td></tr><tr><td style="vertical-align:top"><p>4+</p></td><td style="vertical-align:top"><p>278</p></td><td style="vertical-align:top"><p>0.87</p></td><td style="vertical-align:top"><p>0.70-1.09</p></td><td style="vertical-align:top"><p>0.2290</p></td><td style="vertical-align:top"><p>0.87</p></td><td style="vertical-align:top"><p>0.67-1.12</p></td><td style="vertical-align:top"><p>0.2746</p></td></tr></tbody></table><p>*a&nbsp;hazard&nbsp;ratio&nbsp;of&nbsp;less&nbsp;than&nbsp;1&nbsp;indicates&nbsp;that TAC&nbsp;is&nbsp;associated&nbsp;with&nbsp;a&nbsp;longer disease-free&nbsp;survival and&nbsp;overall survival compared to FAC</p><p>&nbsp;</p><p><u>Patients&nbsp;with&nbsp;operable&nbsp;node-negative&nbsp;breast&nbsp;cancer&nbsp;eligible&nbsp;to&nbsp;receive&nbsp;chemotherapy&nbsp;(GEICAM&nbsp;9805)</u></p><p>&nbsp;</p><p>Data from a multicenter open label randomized trial support the use of docetaxel for the adjuvant treatment of patients with operable node-negative breast cancer eligible to receive chemotherapy. 1060 patients were randomized to receive either docetaxel 75 mg/m<sup>2</sup>&nbsp;administered 1-hour after doxorubicin 50 mg/m<sup>2</sup>&nbsp;and cyclophosphamide&nbsp;500&nbsp;mg/m<sup>2</sup>&nbsp;(539patients&nbsp;in&nbsp;TAC&nbsp;arm),&nbsp;or&nbsp;doxorubicin&nbsp;50&nbsp;mg/m<sup>2</sup>&nbsp;followed&nbsp;by&nbsp;fluorouracil 500 mg/m<sup>2</sup>&nbsp;and cyclophosphamide 500 mg/m<sup>2</sup>(521 patients in FAC arm), as adjuvant treatment of operable node-negative breast cancer patients with high risk of relapse according to 1998 St. Gallen criteria (tumor size &gt;2 cm and/or negative ER and PR and/or high histological/nuclear grade (grade 2 to 3) and /or age&nbsp;&lt;35 years). Both regimens were administered once every 3 weeks for 6 cycles. Docetaxel was administered as a 1-hour infusion, all other drugs were given intravenously on day 1 every three weeks. Primary prophylactic&nbsp;G-CSF&nbsp;was&nbsp;mademandatory&nbsp;in&nbsp;TAC&nbsp;arm&nbsp;after&nbsp;230&nbsp;patients&nbsp;were&nbsp;randomized.&nbsp;The&nbsp;incidence&nbsp;of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis (see section 4.8). In both arms, after the last cycle of chemotherapy, patients with ER+ and/or PgR+ tumors received tamoxifen 20 mg once a day for up to 5 years. Adjuvant radiation therapy was administered according to guidelines in place at participating institutions and was given to 57.3% of patients who received TAC and 51.2% of patients who received FAC.</p><p>&nbsp;</p><p>One primary analysis and one updated analysis were performed. The primary analysis was done when all patients&nbsp;had&nbsp;afollow-up&nbsp;of&nbsp;greater&nbsp;than&nbsp;5&nbsp;years&nbsp;(median&nbsp;follow-up&nbsp;time&nbsp;of&nbsp;77&nbsp;months).&nbsp;The&nbsp;updated&nbsp;analysis was performed when all patients had reached their 10-year (median follow up time of 10 years and 5 months) follow-up visit (unless they had a DFS event or were lost to follow-up previously). Disease-free survival (DFS) was the primary efficacy endpoint and Overall survival (OS) was the secondary efficacy&nbsp;endpoint.</p><p>At the median follow-up time of 77 months, significantly longer disease-free survival for the TAC arm compared to the FAC arm was demonstrated. TAC-treated patients had a 32% reduction in the risk of relapse compared to those treated with FAC (hazard ratio = 0.68, 95% CI (0.49-0.93), p = 0.01). At the median&nbsp;follow up&nbsp;time&nbsp;of 10 years and 5months, TAC&nbsp;treated patients had&nbsp;a 16,5% reduction in&nbsp;the&nbsp;risk of relapse&nbsp;compared&nbsp;to&nbsp;those&nbsp;treated&nbsp;with&nbsp;FAC&nbsp;(hazardratio&nbsp;=&nbsp;0.84,&nbsp;95% CI&nbsp;(0.65-1.08),&nbsp;p=0.1646).&nbsp;DFS&nbsp;data were not statistically significant but were still associated with a positive trend in favors of TAC.</p><p>&nbsp;</p><p>At the median follow-up time of 77 months, overall survival (OS) was longer in the TAC arm with TAC- treated patients having a 24% reduction in the risk of death compared to FAC (hazard ratio = 0.76, 95% CI (0.46-1.26, p = 0.29). However, the distribution of OS was not significantly different between the 2 groups. At the&nbsp;median&nbsp;follow&nbsp;uptime&nbsp;of 10&nbsp;years&nbsp;and&nbsp;5&nbsp;months,&nbsp;TAC-treated&nbsp;patients&nbsp;had&nbsp;a&nbsp;9%&nbsp;reduction&nbsp;in&nbsp;the&nbsp;risk of death compared to FAC-treated patients (hazard ratio = 0.91, 95% CI&nbsp;(0.63-1.32)).</p><p>The&nbsp;survival&nbsp;rate&nbsp;was&nbsp;93.7% in&nbsp;the&nbsp;TAC&nbsp;arm and&nbsp;91.4&nbsp;% in&nbsp;the&nbsp;FAC&nbsp;arm,&nbsp;at the&nbsp;8-year follow-up&nbsp;timepoint, and 91.3 % in the TAC arm and 89 % in the FAC arm, at the 10-year follow-up timepoint.</p><p>&nbsp;</p><p>The&nbsp;positive&nbsp;benefit&nbsp;risk&nbsp;ratio&nbsp;for&nbsp;TAC&nbsp;compared&nbsp;to&nbsp;FAC&nbsp;remained&nbsp;unchanged.</p><p>&nbsp;</p><p>TAC-treated&nbsp;patient&nbsp;subsets&nbsp;according&nbsp;to&nbsp;prospectively&nbsp;defined&nbsp;major&nbsp;prognostic&nbsp;factors&nbsp;were&nbsp;analyzed&nbsp;in the primary analysis (at the median follow-up time of 77 months) (see table below):</p><p>&nbsp;</p><p><u>Subset&nbsp;analyses-Adjuvant&nbsp;Therapy&nbsp;in&nbsp;Patients&nbsp;with&nbsp;Node-negative&nbsp;Breast&nbsp;Cancer&nbsp;Study</u>&nbsp;<u>(Intent-tp-Treat Analysis)</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Patieth&nbsp;subset</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Number&nbsp;of&nbsp;patients&nbsp;in TAC group</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Disease&nbsp;Free&nbsp;Survival</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Hazard&nbsp;ratio*</strong></p></td><td style="vertical-align:top"><p><strong>95%&nbsp;CI</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall</strong></p></td><td style="vertical-align:top"><p>539</p></td><td style="vertical-align:top"><p>0.68</p></td><td style="vertical-align:top"><p>0.49-0.93</p></td></tr><tr><td style="vertical-align:top"><p><strong>Age&nbsp;category&nbsp;1</strong></p><p>&lt;50&nbsp;years</p><p>&ge;50&nbsp;years</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>260</p><p>279</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.67</p><p>0.67</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.43-1.05</p><p>0.43-1.05</p></td></tr><tr><td style="vertical-align:top"><p><strong>Age&nbsp;category&nbsp;2</strong></p><p>&lt;35&nbsp;years</p><p>&ge;35&nbsp;years</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>42</p><p>497</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.31</p><p>0.73</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.11-0.89</p><p>0.52-1.01</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hormonal&nbsp;receptor&nbsp;status</strong></p><p>Negative Postitive</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>195</p><p>344</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>0.7</p><p>0.62</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>0.45-1.1</p><p>0.4-0.97</p></td></tr><tr><td style="vertical-align:top"><p><strong>Tumour&nbsp;size</strong></p><p>&le;2&nbsp;cm</p><p>&gt;2&nbsp;cm</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>285</p><p>254</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.69</p><p>0.68</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.43-1.1</p><p>0.45-1.04</p></td></tr><tr><td style="vertical-align:top"><p><strong>Histological&nbsp;grade</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;1&nbsp;(includes&nbsp;grade</p></td><td style="vertical-align:top"><p>64</p></td><td style="vertical-align:top"><p>0.79</p></td><td style="vertical-align:top"><p>0.24-2.6</p></td></tr><tr><td style="vertical-align:top"><p>not&nbsp;assessed)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;2</p></td><td style="vertical-align:top"><p>216</p></td><td style="vertical-align:top"><p>0.77</p></td><td style="vertical-align:top"><p>0.46-1.3</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;3</p></td><td style="vertical-align:top"><p>259</p></td><td style="vertical-align:top"><p>0.59</p></td><td style="vertical-align:top"><p>0.39-0.9</p></td></tr><tr><td style="vertical-align:top"><p><strong>Menopausalstatus&nbsp;</strong>Pre-menopausal Post-menopausal</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>285</p><p>254</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.64</p><p>0.72</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.40-1</p><p>0.47-1.12</p></td></tr></tbody></table><p>*a&nbsp;hazard&nbsp;ratio&nbsp;(TAC/FAC)&nbsp;of less&nbsp;than&nbsp;1&nbsp;indicates&nbsp;that&nbsp;TAC&nbsp;is&nbsp;associated&nbsp;with&nbsp;a&nbsp;longer&nbsp;disease&nbsp;free survival compared to FAC,</p><p>&nbsp;</p><p><u>Exploratory&nbsp;subgroup&nbsp;analyses&nbsp;for&nbsp;disease-free&nbsp;survival&nbsp;for&nbsp;patients&nbsp;who&nbsp;meet&nbsp;the&nbsp;2009&nbsp;St.&nbsp;Gallen</u><u>chemotherapy criteria &ndash;(ITT population) were performed and presented here below.</u></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:504px"><tbody><tr><td style="vertical-align:top; width:191px"><p>&nbsp;</p></td><td style="vertical-align:top; width:63px"><p>TAC</p></td><td style="vertical-align:top; width:64px"><p>FAC</p></td><td style="vertical-align:top; width:122px"><p>Hazard&nbsp;ratio&nbsp;(TAC/FAC)</p></td><td style="vertical-align:top; width:63px"><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Subgroups</p></td><td style="vertical-align:top"><p>(n=539)</p></td><td style="vertical-align:top"><p>(n=521)</p></td><td style="vertical-align:top"><p>(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>p-value</p></td></tr><tr><td style="vertical-align:top"><p>Meeting&nbsp;relative indication for</p><p>chemotherapy&nbsp;<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>No</p></td><td style="vertical-align:top"><p>18/214</p></td><td style="vertical-align:top"><p>26/227</p></td><td style="vertical-align:top"><p>0.796&nbsp;(0.434-</p></td><td rowspan="2" style="vertical-align:top"><p>0.4593</p></td></tr><tr><td style="vertical-align:top"><p>(8.4%)</p></td><td style="vertical-align:top"><p>(11.5%)</p></td><td style="vertical-align:top"><p>1.459)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Yes</p></td><td style="vertical-align:top"><p>48/325</p></td><td style="vertical-align:top"><p>69/294</p></td><td rowspan="2" style="vertical-align:top"><p>0.606&nbsp;(0.42-0.877)</p></td><td rowspan="2" style="vertical-align:top"><p>0.0072</p></td></tr><tr><td style="vertical-align:top"><p>(14.8%)</p></td><td style="vertical-align:top"><p>(23.5%)</p></td></tr></tbody></table><p>TAC = docetaxel, doxorubicin and cyclophosphamide</p><p>FAC&nbsp;=&nbsp;5-fluorouracil,&nbsp;doxorubin&nbsp;and&nbsp;cyclophosphamide</p><p>CI = confidence interval; ER= estrogen receptor</p><p>PR&nbsp;=&nbsp;progesterone&nbsp;receptor</p><p><sup>a</sup>ER/PR-negative&nbsp;or&nbsp;Grade&nbsp;3&nbsp;or&nbsp;tumor&nbsp;size&nbsp;&gt;5&nbsp;cm</p><p>&nbsp;</p><p>The&nbsp;estimated&nbsp;hazard&nbsp;ratio&nbsp;was&nbsp;using&nbsp;Cox&nbsp;proportional&nbsp;hazard&nbsp;model&nbsp;with&nbsp;treatment&nbsp;group&nbsp;as&nbsp;the&nbsp;factor.</p><p>&nbsp;</p><p><em>Docetaxel&nbsp;as&nbsp;single&nbsp;agent</em></p><p>Two randomized phase III comparative studies, involving a total of 326 alkylating or 392 anthracycline failuremetastatic breast&nbsp;cancer&nbsp;patients,&nbsp;have&nbsp;been&nbsp;performed with&nbsp;docetaxel&nbsp;at&nbsp;the recommended dose&nbsp;and regimen of 100 mg/m&sup2; every 3 weeks.</p><p>&nbsp;</p><p>In alkylating-failure patients, docetaxel was compared to doxorubicin (75 mg/m&sup2; every 3 weeks). Without affecting overall survival time (docetaxel 15 months vs. doxorubicin 14 months, p=0.38) or time to progression&nbsp;(docetaxel&nbsp;27weeks&nbsp;vs.&nbsp;doxorubicin&nbsp;23&nbsp;weeks,&nbsp;p=0.54),&nbsp;docetaxel&nbsp;increased&nbsp;response&nbsp;rate&nbsp;(52% vs. 37%, p=0.01) and shortened time to response (12 weeks vs. 23 weeks, p=0.007). Three docetaxel&nbsp;patients (2%) discontinued the treatment due to fluid retention, whereas 15 doxorubicin patients (9%) discontinued due to cardiac toxicity (three cases of fatal congestive heart failure).</p><p>&nbsp;</p><p>In anthracycline-failure patients, docetaxel was compared to the combination of Mitomycin C and Vinblastine&nbsp;(12mg/m&sup2; every&nbsp;6&nbsp;weeks&nbsp;and&nbsp;6&nbsp;mg/m&sup2; every&nbsp;3&nbsp;weeks).&nbsp;Docetaxel&nbsp;increased&nbsp;response&nbsp;rate&nbsp;(33% vs. 12%, p &lt; 0.0001), prolonged time to progression (19 weeks vs. 11 weeks, p=0.0004) and prolonged overall survival (11 months vs. 9 months, p=0.01).</p><p>&nbsp;</p><p>During&nbsp;these&nbsp;two-phase&nbsp;III&nbsp;studies,&nbsp;the&nbsp;safety&nbsp;profile&nbsp;of&nbsp;docetaxel was&nbsp;consistent with&nbsp;the&nbsp;safety&nbsp;profile observed in phase II studies (see section 4.8).</p><p>&nbsp;</p><p>An open-label, multicenter, randomized phase III study was conducted to compare docetaxel monotherapy and paclitaxel in the treatment of advanced breast cancer in patients whose previous therapy should have included&nbsp;ananthracycline.&nbsp;A&nbsp;total of 449&nbsp;patients&nbsp;were&nbsp;randomized&nbsp;to&nbsp;receive&nbsp;either docetaxel monotherapy 100 mg/m&sup2; as a 1-hour infusion or paclitaxel 175 mg/m&sup2; as a 3 hour infusion. Both regimens were administered every 3 weeks.</p><p>Without affecting the primary endpoint, overall response rate (32% vs 25%, p=0.10), docetaxel prolonged median&nbsp;timeto&nbsp;progression&nbsp;(24.6&nbsp;weeks&nbsp;vs&nbsp;15.6&nbsp;weeks;&nbsp;p&nbsp;&lt;&nbsp;0.01) and&nbsp;median&nbsp;survival&nbsp;(15.3&nbsp;months&nbsp;vs&nbsp;12.7 months; p=0.03).</p><p>More&nbsp;grade&nbsp;3/4&nbsp;adverse&nbsp;events&nbsp;were&nbsp;observed&nbsp;for&nbsp;docetaxel&nbsp;monotherapy&nbsp;(55.4%)&nbsp;compared&nbsp;to&nbsp;paclitaxel&nbsp;(23.0%).</p><p>&nbsp;</p><p><em>Docetaxel&nbsp;in&nbsp;combination&nbsp;with&nbsp;doxorubicin</em></p><p>One&nbsp;large&nbsp;randomized&nbsp;phase&nbsp;III&nbsp;study,&nbsp;involving&nbsp;429&nbsp;previously&nbsp;untreated&nbsp;patients&nbsp;with&nbsp;metastatic&nbsp;disease, has been performed with doxorubicin (50 mg/m&sup2;) in combination with docetaxel (75 mg/m&sup2;) (AT arm) versus doxorubicin (60 mg/m&sup2;) in combination with cyclophosphamide (600 mg/m&sup2;) (AC arm). Both regimens were administered on day 1 every 3 weeks.</p><p>&nbsp;</p><p><img width="2" height="2" src="blob:https://sdi.sfda.gov.sa/c0de2887-2a36-4411-9583-a4d1a52e5210" />Time&nbsp;to&nbsp;progression&nbsp;(TTP)&nbsp;was&nbsp;significantly&nbsp;longer&nbsp;in&nbsp;the&nbsp;AT&nbsp;arm versus&nbsp;AC&nbsp;arm,&nbsp;p=0.0138.&nbsp;The&nbsp;median TTP was 37.3 weeks (95%CI :33.4 - 42.1) in AT arm and 31.9 weeks (95% CI: 27.4 - 36.0) in AC arm.</p><p><img width="2" height="2" src="blob:https://sdi.sfda.gov.sa/3a3e59b6-03b1-40f5-8c85-62816b3937dd" />Overall&nbsp;response&nbsp;rate&nbsp;(ORR)&nbsp;was&nbsp;significantly&nbsp;higher&nbsp;in&nbsp;the&nbsp;AT&nbsp;arm&nbsp;versus&nbsp;AC&nbsp;arm,&nbsp;p=0.009.&nbsp;The&nbsp;ORR was 59.3% (95%CI : 52.8 - 65.9) in AT arm versus 46.5% (95%CI : 39.8 - 53.2) in AC arm.</p><p>&nbsp;</p><p>In this study, AT arm showed a higher incidence of severe neutropenia (90% versus 68.6%), febrile neutropenia (33.3% versus 10%), infection (8% versus 2.4%), diarrhea (7.5% versus 1.4%), asthenia (8.5% versus 2.4%), and pain (2.8% versus 0%) than AC arm. On the other hand, AC arm showed a higher incidence&nbsp;of severe&nbsp;anemia&nbsp;(15.8% versus&nbsp;8.5%)than&nbsp;AT&nbsp;arm,&nbsp;and,&nbsp;in&nbsp;addition,&nbsp;a&nbsp;higher incidence&nbsp;of&nbsp;severe cardiac toxicity: congestive heart failure (3.8% versus 2.8%), absolute LVEF decrease &ge; 20% (13.1</p><p>% versus&nbsp;6.1%),&nbsp;absolute&nbsp;LVEF&nbsp;decrease&nbsp;&ge; 30%&nbsp;(6.2%&nbsp;versus&nbsp;1.1%).&nbsp;Toxic&nbsp;deaths&nbsp;occurred&nbsp;in&nbsp;1&nbsp;patient&nbsp;in the AT arm (congestive heart failure) and in 4 patients in the AC arm (1 due to septic shock and 3 due to congestive heart failure). In both arms, quality of life measured by the EORTC questionnaire was comparable and stable during treatment and follow-up.</p><p>&nbsp;</p><p><em>Docetaxel&nbsp;in&nbsp;combination&nbsp;with&nbsp;trastuzumab</em></p><p>Docetaxel in combination with trastuzumab was studied for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2, and&nbsp;who previously had not received&nbsp;chemotherapy&nbsp;for metastatic disease.&nbsp;Onehundred&nbsp;eighty-six&nbsp;patients&nbsp;were&nbsp;randomized&nbsp;to&nbsp;receive&nbsp;docetaxel&nbsp;(100&nbsp;mg/m<sup>2</sup>)&nbsp;with&nbsp;or&nbsp;without trastuzumab; 60% of patients received prior anthracycline based adjuvant chemotherapy. Docetaxel plus trastuzumab was efficacious in patients whether or not they had received prior adjuvant anthracyclines. The main&nbsp;test&nbsp;method&nbsp;used&nbsp;to&nbsp;determine&nbsp;HER2positivity&nbsp;in&nbsp;this&nbsp;pivotal&nbsp;study&nbsp;was&nbsp;immunohistochemistry&nbsp;(IHC). A minority of patients were tested using fluorescence in-situ hybridization (FISH). In this trial, 87% of patients&nbsp;had&nbsp;disease&nbsp;that was&nbsp;IHC&nbsp;3+,&nbsp;and&nbsp;95% of patients&nbsp;entered&nbsp;haddisease&nbsp;that&nbsp;was&nbsp;IHC&nbsp;3+&nbsp;and/or FISH positive. Efficacy results are summarized in the following table:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Parameter</p></td><td style="vertical-align:top"><p>Docetaxel&nbsp;plus&nbsp;trastuzumab<sup>1</sup></p><p>n=92</p></td><td style="vertical-align:top"><p>Docetaxel<sup>1</sup></p><p>n=94</p></td></tr><tr><td style="vertical-align:top"><p>Response&nbsp;rate (95% CI)</p></td><td style="vertical-align:top"><p>61%</p><p>(50-71)</p></td><td style="vertical-align:top"><p>34%</p><p>(25-45)</p></td></tr><tr><td style="vertical-align:top"><p>Median&nbsp;duration&nbsp;of&nbsp;response&nbsp;(months)</p><p>(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>11.4&nbsp;(9.2-</p><p>15.0)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>5.1&nbsp;(4.4-</p><p>6.2)</p></td></tr><tr><td style="vertical-align:top"><p>Median&nbsp;TTP&nbsp;(months) (95% CI)</p></td><td style="vertical-align:top"><p>10.6&nbsp;(7.6-</p><p>12.9)</p></td><td style="vertical-align:top"><p>5.7&nbsp;(5.0-</p><p>6.5)</p></td></tr><tr><td style="vertical-align:top"><p>Median&nbsp;survival&nbsp;(months) (95% CI)</p></td><td style="vertical-align:top"><p>30.5<sup>2</sup></p><p>(26.8-ne)</p></td><td style="vertical-align:top"><p>22.1<sup>2</sup></p><p>(17.6-28.9)</p></td></tr></tbody></table><p>TTP=time&nbsp;to&nbsp;progression;&nbsp;&ldquo;ne&rdquo;&nbsp;indicates&nbsp;that&nbsp;it&nbsp;could&nbsp;not&nbsp;be&nbsp;estimated,&nbsp;or&nbsp;it&nbsp;was&nbsp;not&nbsp;yet&nbsp;reached.</p><p><sup>1</sup>Full&nbsp;analysis&nbsp;set&nbsp;(intent-to-treat)</p><p><sup>2</sup>&nbsp;Estimated&nbsp;median&nbsp;survival</p><p>&nbsp;</p><p><em>Docetaxel&nbsp;in&nbsp;combination&nbsp;with&nbsp;capecitabine</em></p><p>Data from one multicenter, randomized, controlled phase III clinical study support the use of docetaxel in combination with capecitabine for treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy, including an anthracycline. In this study, 255 patients were randomized to treatment with docetaxel (75 mg/m<sup>2</sup>&nbsp;as a 1 hour intravenous infusion every 3 weeks) and capecitabine (1250 mg/m<sup>2</sup>&nbsp;twice daily for 2 weeks followed by 1-week rest period). 256 patients were randomized to treatment with docetaxel alone (100 mg/&nbsp;m<sup>2</sup>&nbsp;as a 1 hour intravenous infusion every 3 weeks). Survival was&nbsp;superior in&nbsp;the&nbsp;docetaxel&nbsp;+capecitabine&nbsp;combination&nbsp;arm(p=0.0126).&nbsp;Median&nbsp;survival was&nbsp;442 days (docetaxel + capecitabine) vs. 352 days (docetaxel alone). The overall objective response rates in the all-randomized population (investigator assessment) were 41.6% (docetaxel + capecitabine) vs. 29.7% (docetaxel alone); p = 0.0058. Time to progressive disease was superior in the docetaxel + capecitabine combination arm (p &lt; 0.0001). The median time to progression was 186 days (docetaxel + capecitabine) vs. 128 days (docetaxel alone).</p><p>&nbsp;</p><p><em>Non-small&nbsp;cell&nbsp;lung&nbsp;cancer</em></p><p><em>&nbsp;</em></p><p><em>Patients&nbsp;previously&nbsp;treated&nbsp;with&nbsp;chemotherapy&nbsp;with&nbsp;or&nbsp;without&nbsp;radiotherapy</em></p><p>In a phase III study, in previously treated patients, time to progression (12.3 weeks versus 7 weeks) and overallsurvival were&nbsp;significantly&nbsp;longer&nbsp;for docetaxel&nbsp;at 75&nbsp;mg/m&sup2; compared&nbsp;to&nbsp;Best Supportive&nbsp;Care.&nbsp;The 1-year survival rate was also significantly&nbsp;longer in docetaxel&nbsp;(40%)&nbsp;versus BSC&nbsp;(16%). There was&nbsp;less use of morphinic analgesic (p &lt; 0.01), non-morphinic analgesics (p &lt; 0.01), other disease related medications (p=0.06) and radiotherapy (p &lt; 0.01) in&nbsp;patients treated&nbsp;with docetaxel at 75&nbsp;mg/m&sup2; compared&nbsp;to&nbsp;those with&nbsp;BSC.</p><p>The&nbsp;overall&nbsp;response&nbsp;rate&nbsp;was&nbsp;6.8% in&nbsp;the&nbsp;evaluable&nbsp;patients,&nbsp;and&nbsp;the&nbsp;median&nbsp;duration&nbsp;of response&nbsp;was&nbsp;26.1&nbsp;weeks.</p><p>&nbsp;</p><p><em>Docetaxel&nbsp;in&nbsp;combination&nbsp;with&nbsp;platinum&nbsp;agents&nbsp;in&nbsp;chemotherapy-na&iuml;ve&nbsp;patients</em></p><p>In a Phase III study, 1218 patients with unresectable stage IIIB or IV NSCLC, with KPS of 70% or greater, and who did not receive previous chemotherapy&nbsp;for this condition, were randomized to&nbsp;either docetaxel (T) 75 mg/m<sup>2</sup>&nbsp;as a&nbsp;1 hour infusion immediately&nbsp;followed&nbsp;by cisplatin (Cis)&nbsp;75&nbsp;mg/&nbsp;m<sup>2</sup>&nbsp;over 30-60 minutes&nbsp;every 3 weeks, docetaxel 75 mg/ m<sup>2</sup>&nbsp;as a 1 hour infusion in combination with carboplatin (AUC 6 mg/ml&bull;min) over 30-60&nbsp;minutes&nbsp;every&nbsp;3&nbsp;weeks,&nbsp;or vinorelbine&nbsp;(V)&nbsp;25&nbsp;mg/&nbsp;m<sup>2</sup>&nbsp;administered&nbsp;over 6-10&nbsp;minutes&nbsp;on&nbsp;days&nbsp;1, 8, 15, 22 followed by cisplatin 100 mg/ m<sup>2</sup>administered on day 1 of cycles repeated every 4 weeks.</p><p>&nbsp;</p><p>Survival&nbsp;data,&nbsp;median&nbsp;time&nbsp;to progression and response&nbsp;rates&nbsp;for&nbsp;two arms of&nbsp;the&nbsp;study are illustrated&nbsp;in&nbsp;the following table:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>TCis&nbsp;n=408</p></td><td style="vertical-align:top"><p>VCis N=404</p></td><td style="vertical-align:top"><p>Statistical&nbsp;Analysis</p></td></tr><tr><td style="vertical-align:top"><p>Overall Survival (Primary&nbsp;end-point):</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median&nbsp;Survival&nbsp;(months)</p></td><td style="vertical-align:top"><p>11.3</p></td><td style="vertical-align:top"><p>10.1</p></td><td style="vertical-align:top"><p>Hazard&nbsp;Ratio:&nbsp;1.122</p><p>[97.2%&nbsp;CI:&nbsp;0.937;&nbsp;1.342]*</p></td></tr><tr><td style="vertical-align:top"><p>1-year&nbsp;Survival&nbsp;(%)</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>Treatment&nbsp;difference:&nbsp;5.4%</p><p>[95%&nbsp;CI:&nbsp;-1.1;&nbsp;12.0]</p></td></tr><tr><td style="vertical-align:top"><p>2-year&nbsp;Survival&nbsp;(%)</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>Treatment&nbsp;difference:&nbsp;6.2%</p><p>[95%&nbsp;CI:&nbsp;0.2;&nbsp;12.3]</p></td></tr><tr><td style="vertical-align:top"><p>Median&nbsp;Time&nbsp;to&nbsp;Progression</p><p>(weeks):</p></td><td style="vertical-align:top"><p>22.0</p></td><td style="vertical-align:top"><p>23.0</p></td><td style="vertical-align:top"><p>Hazard&nbsp;Ratio:&nbsp;1.032</p><p>[95%&nbsp;CI:&nbsp;0.876;&nbsp;1.216]</p></td></tr><tr><td style="vertical-align:top"><p>Overall&nbsp;Response&nbsp;Rate&nbsp;(%):</p></td><td style="vertical-align:top"><p>31.6</p></td><td style="vertical-align:top"><p>24.5</p></td><td style="vertical-align:top"><p>Treatment&nbsp;difference:&nbsp;7.1%</p><p>[95%&nbsp;CI:&nbsp;0.7;&nbsp;13.5]</p></td></tr></tbody></table><p>*:&nbsp;Corrected&nbsp;for&nbsp;multiple&nbsp;comparisons&nbsp;and&nbsp;adjusted&nbsp;for&nbsp;stratification&nbsp;factors&nbsp;(stage&nbsp;of&nbsp;disease&nbsp;and&nbsp;region&nbsp;of treatment), based on evaluable patient population.</p><p>&nbsp;</p><p>Secondary end-points included change of pain, global rating of quality of life by EuroQoL-5D, Lung Cancer Symptom Scale, and changes in Karnosfky performance status. Results on these end-points were supportive of the primary end-points results.</p><p>&nbsp;</p><p>For&nbsp;docetaxel/carboplatin&nbsp;combination,&nbsp;neither&nbsp;equivalent&nbsp;nor&nbsp;non-inferior&nbsp;efficacy&nbsp;could&nbsp;be&nbsp;proven compared to the reference treatment combination VCis.</p><p>&nbsp;</p><p><em>Prostate&nbsp;cancer</em></p><p><em>&nbsp;</em></p><p>The safety and efficacy of docetaxel in combination with prednisone or prednisolone in patients with hormonerefractory&nbsp;metastatic&nbsp;prostate&nbsp;cancer were&nbsp;evaluated&nbsp;in&nbsp;a&nbsp;randomized&nbsp;multicenter Phase&nbsp;III&nbsp;study.&nbsp;A total of 1006 patients with KPS &ge; 60 were randomized to the following treatment groups:</p><p><img width="2" height="27" src="blob:https://sdi.sfda.gov.sa/fe6fcede-90cf-484c-9cd8-eea84e8dadd9" />Docetaxel&nbsp;75&nbsp;mg/m<sup>2</sup>&nbsp;every&nbsp;3&nbsp;weeks&nbsp;for&nbsp;10&nbsp;cycles.</p><p>Docetaxel&nbsp;30&nbsp;mg/m<sup>2</sup>&nbsp;administered&nbsp;weekly&nbsp;for&nbsp;the&nbsp;first&nbsp;5&nbsp;weeks&nbsp;in&nbsp;a&nbsp;6&nbsp;week&nbsp;cycle&nbsp;for 5&nbsp;cycles. Mitoxantrone 12 mg/m<sup>2</sup>&nbsp;every 3 weeks for 10 cycles.</p><p>All 3&nbsp;regimens&nbsp;were&nbsp;administered&nbsp;in&nbsp;combination&nbsp;with&nbsp;prednisone&nbsp;or&nbsp;prednisolone&nbsp;5&nbsp;mg&nbsp;twice&nbsp;daily,&nbsp;continuously.</p><p>&nbsp;</p><p>Patients who received docetaxel every three weeks demonstrated significantly longer overall survival compared&nbsp;to&nbsp;thosetreated&nbsp;with&nbsp;mitoxantrone.&nbsp;The&nbsp;increase&nbsp;in&nbsp;survival&nbsp;seen&nbsp;in&nbsp;the&nbsp;docetaxel weekly&nbsp;arm was not statistically significant compared to the mitoxantrone control arm. Efficacy endpoints for the docetaxel arms versus the control arm are summarized in the following table:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Endpoint</em></p></td><td style="vertical-align:top"><p><em>Docetaxel&nbsp;every&nbsp;3&nbsp;weeks</em></p></td><td style="vertical-align:top"><p><em>Docetaxel&nbsp;every&nbsp;week</em></p></td><td style="vertical-align:top"><p><em>Mitoxantrone&nbsp;every&nbsp;3&nbsp;weeks</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Number of patients Median&nbsp;survival&nbsp;(months) 95%&nbsp;CI</em></p><p><em>Hazard&nbsp;ratio 95%&nbsp;CI</em></p><p><em>p-value<sup>&dagger;</sup>*</em></p></td><td style="vertical-align:top"><p><em>335</em></p><p><em>18.9&nbsp;(17.0-</em></p><p><em>21.2)</em></p><p><em>0.761&nbsp;(0.619-</em></p><p><em>0.936)</em></p><p><em>0.0094</em></p></td><td style="vertical-align:top"><p><em>334</em></p><p><em>17.4&nbsp;(15.7-</em></p><p><em>19.0)</em></p><p><em>0.912&nbsp;(0.747-</em></p><p><em>1.113)</em></p><p><em>0.3624</em></p></td><td style="vertical-align:top"><p><em>337</em></p><p><em>16.5&nbsp;(14.4-</em></p><p><em>18.6)</em></p><p><em>--</em></p><p><em>--</em></p><p><em>--</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Number of patients PSA**&nbsp;response&nbsp;rate&nbsp;(%) 95% CI</em></p><p><em>p-value*</em></p></td><td style="vertical-align:top"><p><em>291</em></p><p><em>45.4&nbsp;(39.5-</em></p><p><em>51.3)</em></p><p><em>0.0005</em></p></td><td style="vertical-align:top"><p><em>282</em></p><p><em>47.9&nbsp;(41.9-</em></p><p><em>53.9)</em></p><p><em>&lt;0.0001</em></p></td><td style="vertical-align:top"><p><em>300</em></p><p><em>31.7&nbsp;(26.4-</em></p><p><em>37.3)</em></p><p><em>--</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Number of patients Pain&nbsp;response&nbsp;rate&nbsp;(%) 95% CI</em></p><p><em>p-value*</em></p></td><td style="vertical-align:top"><p><em>153</em></p><p><em>34.6&nbsp;(27.1-</em></p><p><em>42.7)</em></p><p><em>0.0107</em></p></td><td style="vertical-align:top"><p><em>154</em></p><p><em>31.2&nbsp;(24.0-</em></p><p><em>39.1)</em></p><p><em>0.0798</em></p></td><td style="vertical-align:top"><p><em>157</em></p><p><em>21.7&nbsp;(15.5-</em></p><p><em>28.9)</em></p><p><em>--</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Number of patients Tumor&nbsp;response&nbsp;rate&nbsp;(%) 95% CI</em></p><p><em>p-value*</em></p></td><td style="vertical-align:top"><p><em>141</em></p><p><em>12.1&nbsp;(7.2-</em></p><p><em>18.6)</em></p><p><em>0.1112</em></p></td><td style="vertical-align:top"><p><em>134</em></p><p><em>8.2&nbsp;(4.2-</em></p><p><em>14.2)</em></p><p><em>0.5853</em></p></td><td style="vertical-align:top"><p><em>137</em></p><p><em>6.6&nbsp;(3.0-</em></p><p><em>12.1)</em></p><p><em>--</em></p></td></tr></tbody></table><p><em><sup>&dagger;</sup>Stratified&nbsp;log&nbsp;rank&nbsp;test</em></p><p><em>*Threshold&nbsp;for&nbsp;statistical&nbsp;significance=0.0175</em></p><p><em>**PSA:&nbsp;Prostate-Specific&nbsp;Antigen</em></p><p><em>&nbsp;</em></p><p>Given&nbsp;the&nbsp;fact&nbsp;that&nbsp;docetaxel&nbsp;every&nbsp;week&nbsp;presented&nbsp;a&nbsp;slightly&nbsp;better&nbsp;safety&nbsp;profile&nbsp;than&nbsp;docetaxel&nbsp;every&nbsp;3 weeks, it is possible that certain patients may benefit from docetaxel every week.</p><p>&nbsp;</p><p>No&nbsp;statistical&nbsp;differences&nbsp;were&nbsp;observed&nbsp;between&nbsp;treatment&nbsp;groups&nbsp;for&nbsp;Global&nbsp;Quality&nbsp;of&nbsp;Life.</p><p>&nbsp;</p><p><strong><em>Gastric&nbsp;adenocarcinoma</em></strong></p><p><em>&nbsp;</em></p><p>A&nbsp;multicenter,&nbsp;open-label,&nbsp;randomized&nbsp;study,&nbsp;was&nbsp;conducted&nbsp;to&nbsp;evaluate&nbsp;the&nbsp;safety&nbsp;and&nbsp;efficacy&nbsp;of&nbsp;docetaxel for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who had not received prior chemotherapy for metastatic disease. A total of 445 patients with KPS&gt;70 were treated with either docetaxel (T) (75 mg/m<sup>2</sup>&nbsp;on day 1) in combination with cisplatin (C) (75 mg/m<sup>2</sup>&nbsp;on day 1) and 5-fluorouracil (F) (750 mg/m<sup>2</sup>&nbsp;per day for 5 days) or cisplatin (100 mg/m<sup>2</sup>&nbsp;on&nbsp;day 1) and&nbsp;5-fluorouracil (1000&nbsp;mg/m<sup>2</sup>&nbsp;per day for 5 days). The length of a treatment cycle was 3 weeks for the TCF arm and 4 weeks for the CF arm. The median number of cycles administered per patient was 6 (with a range of 1-16) for the TCF arm compared to 4 (with a range of 1-12) for the CF arm. Time to progression (TTP) was the primary endpoint. The risk reduction of progression was 32.1% and was associated with a significantly longer TTP (p=0.0004) in favor of the TCF arm. Overall survival was also significantly longer (p=0.0201) in favor of the TCF arm with a risk reduction of mortality of 22.7%.</p><p>Efficacy&nbsp;results&nbsp;are&nbsp;summarized&nbsp;in&nbsp;the&nbsp;following&nbsp;table:</p><p><strong><u>Efficacy&nbsp;of&nbsp;docetaxel&nbsp;in&nbsp;the&nbsp;treatment&nbsp;of&nbsp;patients&nbsp;with&nbsp;gastric&nbsp;adenocarcinoma</u></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>TCF</strong></p><p>n=221</p></td><td style="vertical-align:top"><p><strong>CF</strong></p><p>N=224</p></td></tr><tr><td style="vertical-align:top"><p>Median&nbsp;TTP&nbsp;(months)</p></td><td style="vertical-align:top"><p>5.6</p></td><td style="vertical-align:top"><p>3.7</p></td></tr><tr><td style="vertical-align:top"><p>(95%CI)</p></td><td style="vertical-align:top"><p>(4.86-5.91)</p></td><td style="vertical-align:top"><p>(3.45-4.47)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard&nbsp;ratio</p></td><td colspan="2" style="vertical-align:top"><p>1.473</p></td></tr><tr><td style="vertical-align:top"><p>(95%CI)</p></td><td colspan="2" style="vertical-align:top"><p>(1.189-1.825)</p></td></tr><tr><td style="vertical-align:top"><p>*p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.0004</p></td></tr><tr><td style="vertical-align:top"><p>Median&nbsp;survival&nbsp;(months)</p></td><td style="vertical-align:top"><p>9.2</p></td><td style="vertical-align:top"><p>8.6</p></td></tr><tr><td style="vertical-align:top"><p>(95%CI)</p></td><td style="vertical-align:top"><p>(8.38-10.58)</p></td><td style="vertical-align:top"><p>(7.16-9.46)</p></td></tr><tr><td style="vertical-align:top"><p>2-year&nbsp;estimate&nbsp;(%)</p></td><td style="vertical-align:top"><p>18.4</p></td><td style="vertical-align:top"><p>8.8</p></td></tr><tr><td style="vertical-align:top"><p>Hazard&nbsp;ratio</p></td><td colspan="2" style="vertical-align:top"><p>1.293</p></td></tr><tr><td style="vertical-align:top"><p>(95%CI)</p></td><td colspan="2" style="vertical-align:top"><p>(1.041-1.606)</p></td></tr><tr><td style="vertical-align:top"><p>*p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.0201</p></td></tr><tr><td style="vertical-align:top"><p>Overall&nbsp;Response&nbsp;Rate&nbsp;(CR+PR)&nbsp;(%)</p></td><td style="vertical-align:top"><p>36.7</p></td><td style="vertical-align:top"><p>25.4</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.0106</p></td></tr><tr><td style="vertical-align:top"><p>Progressive&nbsp;Disease&nbsp;as&nbsp;Best&nbsp;Overall Response (%)</p></td><td style="vertical-align:top"><p>16.7</p></td><td style="vertical-align:top"><p>25.9</p></td></tr></tbody></table><p>*Unstratified&nbsp;logrank&nbsp;test</p><p>&nbsp;</p><p>Subgroup&nbsp;analyses&nbsp;across&nbsp;age,&nbsp;gender&nbsp;and&nbsp;race&nbsp;consistently&nbsp;favored&nbsp;the&nbsp;TCF&nbsp;arm&nbsp;compared&nbsp;to&nbsp;the&nbsp;CF&nbsp;arm.</p><p>&nbsp;</p><p>A survival update analysis conducted with a median follow-up time of 41.6 months no longer showed a statisticallysignificant&nbsp;difference&nbsp;although&nbsp;always&nbsp;in&nbsp;favors&nbsp;of&nbsp;the&nbsp;TCF&nbsp;regimen&nbsp;and&nbsp;showed&nbsp;that&nbsp;the&nbsp;benefit of TCF over CF is clearly observed between 18 and 30 months of follow up.</p><p>&nbsp;</p><p>Overall,&nbsp;quality&nbsp;of&nbsp;life&nbsp;(QoL) and&nbsp;clinical&nbsp;benefit&nbsp;results&nbsp;consistently&nbsp;indicated&nbsp;improvement&nbsp;in&nbsp;favor&nbsp;of&nbsp;the TCF arm. Patients treated&nbsp;with TCF had a longer time to 5% definitive deterioration of global health status on the QLQ-C30 questionnaire (p=0.0121) and a longer time to definitive worsening of Karnofsky performance status (p=0.0088) compared to patients treated with CF.</p><p>&nbsp;</p><p><em>Head&nbsp;and&nbsp;neck&nbsp;cancer</em></p><p><em>&nbsp;</em></p><p><img width="2" height="2" src="blob:https://sdi.sfda.gov.sa/3eb1c894-13e3-489a-89f6-25a614e5fb6a" />Induction&nbsp;chemotherapy&nbsp;followed&nbsp;by&nbsp;radiotherapy&nbsp;(TAX323)</p><p>The&nbsp;safety&nbsp;and&nbsp;efficacy&nbsp;of&nbsp;docetaxel in&nbsp;the&nbsp;induction&nbsp;treatment&nbsp;of patients&nbsp;with&nbsp;squamous&nbsp;cell carcinoma&nbsp;of the head and neck (SCCHN) was evaluated in a phase III, multicenter, open-label, randomized trial (TAX323). In this study, 358 patients with inoperable locally advanced SCCHN, and WHO performance&nbsp;status 0 or 1, were randomized to one of two treatment arms. Patients on the docetaxel arm received docetaxel (T) 75 mg/m<sup>2</sup>&nbsp;followed by cisplatin (P) 75 mg/m<sup>2</sup>&nbsp;followed by 5-fluorouracil (F) 750 mg/m<sup>2</sup>&nbsp;per day as a continuous infusion for 5 days. This regimen was administered every three weeks for 4 cycles in case&nbsp;at&nbsp;least&nbsp;a&nbsp;minor response&nbsp;(&ge; 25% reduction&nbsp;in&nbsp;bidimensional&nbsp;measured&nbsp;tumor&nbsp;size) was&nbsp;observed&nbsp;after 2 cycles. At the end of chemotherapy, with a minimal interval of 4 weeks and a maximal interval of 7 weeks, patients whose disease did not progress received radiotherapy (RT) according to institutional guidelines for&nbsp;7 weeks (TPF/RT). Patients on the comparator arm received cisplatin (P) 100 mg/m<sup>2</sup>&nbsp;followed by 5- fluorouracil (F) 1000 mg/m<sup>2</sup>&nbsp;per day for 5 days. This regimen was administered every three weeks for 4 cycles in case at least a minor response (&ge; 25% reduction in bidimensional measured tumor size) was observed after 2 cycles. At the end of chemotherapy, with a minimal interval of 4 weeks and a maximal interval of 7 weeks, patients whose disease did not progress received radiotherapy (RT) according to institutional guidelines for 7 weeks (PF/RT). Locoregional therapy with radiation was delivered either with&nbsp;a conventional fraction (1.8 Gy - 2.0 Gy once a day, 5 days per week for a total dose of 66 to 70 Gy), or accelerated/hyper fractionated regimens of radiation therapy (twice a day, with a minimum interaction interval of 6 hours, 5 days per week). A total of 70 Gy was recommended for accelerated regimens and 74 Gy for hyper fractionated schemes. Surgical resection was allowed following chemotherapy, before or after radiotherapy. Patients on the TPF arm received antibiotic prophylaxis with ciprofloxacin 500 mg orally twice daily for 10 days starting on day 5 of each cycle, or equivalent. The primary endpoint in this study, progression-free survival (PFS), was significantly longer in the TPF arm compared to the PF arm, p = 0.0042 (median PFS: 11.4 vs. 8.3 months respectively) with an overall median follow up time of 33.7 months. Median overall survival was also significantly longer in favor of the TPF arm compared to the PF arm (median OS: 18.6 vs. 14.5 months respectively) with a 28% risk reduction of mortality, p =0.0128.</p><p>Efficacy&nbsp;results&nbsp;are&nbsp;presented&nbsp;in&nbsp;the&nbsp;table&nbsp;below:</p><p>&nbsp;</p><p><strong>Efficacy&nbsp;of&nbsp;docetaxel&nbsp;in&nbsp;the&nbsp;induction&nbsp;treatment&nbsp;of&nbsp;patients&nbsp;with&nbsp;inoperable&nbsp;locally&nbsp;advanced SCCHN (Intent-to-Treat Analysis)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Docetaxel+ Cis+5-FU&nbsp;n=177</strong></p></td><td style="vertical-align:top"><p><strong>Cis+5-FU</strong></p><p><strong>&nbsp;</strong></p><p><strong>n=181</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median&nbsp;progression&nbsp;free&nbsp;survival&nbsp;(months)&nbsp;(95%CI)</p></td><td style="vertical-align:top"><p>11.4</p><p>(10.1-14.0)</p></td><td style="vertical-align:top"><p>8.3</p><p>(7.4-9.1)</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted&nbsp;Hazard&nbsp;ratio&nbsp;(95%CI)</p><p>*p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.70</p><p>(0.55-0.89)</p><p>0.0042</p></td></tr><tr><td style="vertical-align:top"><p>Median&nbsp;survival&nbsp;(months)&nbsp;(95%CI)</p></td><td style="vertical-align:top"><p>18.6</p><p>(15.7-24.0)</p></td><td style="vertical-align:top"><p>14.5</p><p>(11.6-18.7)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard&nbsp;ratio&nbsp;(95%CI)</p><p>**p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.72</p><p>(0.56-0.93)</p><p>0.0128</p></td></tr><tr><td style="vertical-align:top"><p>Best&nbsp;overall&nbsp;response&nbsp;to&nbsp;chemotherapy&nbsp;(%)(95%CI)</p></td><td style="vertical-align:top"><p>67.8</p><p>(60.4-74.6)</p></td><td style="vertical-align:top"><p>53.6</p><p>(46.0-61.0)</p></td></tr><tr><td style="vertical-align:top"><p>***p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.006</p></td></tr><tr><td style="vertical-align:top"><p>Best&nbsp;overall&nbsp;response&nbsp;to&nbsp;study&nbsp;treatment</p><p>[chemotherapy&nbsp;+/-&nbsp;radiotherapy]&nbsp;(%)&nbsp;(95%CI)</p></td><td style="vertical-align:top"><p>72.3</p><p>(65.1-78.8)</p></td><td style="vertical-align:top"><p>58.6</p><p>(51.0-65.8)</p></td></tr><tr><td style="vertical-align:top"><p>***p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.006</p></td></tr><tr><td style="vertical-align:top"><p>Median&nbsp;duration&nbsp;of&nbsp;response&nbsp;to&nbsp;chemotherapy&nbsp;&plusmn; radiotherapy (months)</p><p>(95%CI)</p></td><td style="vertical-align:top"><p>n=128&nbsp;15.7</p><p>(13.4-24.6)</p></td><td style="vertical-align:top"><p>n=106&nbsp;11.7</p><p>(10.2-17.4)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard&nbsp;ratio&nbsp;(95%CI)</p><p>**p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.72</p><p>(0.52-0.99)</p><p>0.0457</p></td></tr></tbody></table><p>A&nbsp;Hazard&nbsp;ratio&nbsp;of&nbsp;less&nbsp;than&nbsp;1&nbsp;favors&nbsp;docetaxel+Cisplatin+5-FU</p><p>*Cox&nbsp;model&nbsp;(adjustment&nbsp;for&nbsp;Primary&nbsp;tumor&nbsp;site,&nbsp;T&nbsp;and&nbsp;N&nbsp;clinical&nbsp;stages&nbsp;and&nbsp;PSWHO)</p><p>**Logrank&nbsp;test</p><p>***&nbsp;Chi-square&nbsp;test</p><p>&nbsp;</p><p><em>Quality&nbsp;of&nbsp;life&nbsp;parameters</em></p><p>Patients&nbsp;treated&nbsp;with&nbsp;TPF&nbsp;experienced&nbsp;significantly&nbsp;less&nbsp;deterioration&nbsp;of&nbsp;their&nbsp;Global&nbsp;health&nbsp;score&nbsp;compared to those treated with PF (p=0.01, using the EORTC QLQ-C30 scale).</p><p>&nbsp;</p><p><em>Clinical&nbsp;benefit&nbsp;parameters</em></p><p>The performance status scale, for head and neck (PSS-HN) subscales designed to measure understandability of speech,ability&nbsp;to eat&nbsp;in public, and&nbsp;normalcy&nbsp;of diet,&nbsp;was significantly&nbsp;in&nbsp;favor&nbsp;of TPF&nbsp;as&nbsp;compared&nbsp;to PF. Median time to first deterioration of WHO performance status was significantly longer in the TPF arm compared to PF. Pain intensity score improved during treatment in both groups</p><p>indicating&nbsp;adequate&nbsp;pain&nbsp;management.</p><p>&nbsp;</p><p><img width="2" height="2" src="blob:https://sdi.sfda.gov.sa/425118a9-9fc7-4bea-a357-f7ba33b084d0" />Induction&nbsp;chemotherapy&nbsp;followed&nbsp;by&nbsp;chemoradiotherapy&nbsp;(TAX324)</p><p>The safety and efficacy of docetaxel in the induction treatment of patients with locally advanced squamous cellcarcinoma&nbsp;of&nbsp;the&nbsp;head&nbsp;and&nbsp;neck&nbsp;(SCCHN)&nbsp;was&nbsp;evaluated&nbsp;in&nbsp;a&nbsp;randomized,&nbsp;multicenter&nbsp;open-label,&nbsp;phase III, study (TAX324). In this study, 501 patients, with locally advanced SCCHN, and a WHO performance status of 0 or 1, were randomized to one of two arms. The study population comprised patients with technically unresectable disease, patients with low probability of surgical cure and patients aiming at organ preservation. The efficacy and safety evaluation solely addressed survival endpoints and the success of&nbsp;organ preservation was not formally addressed. Patients on the docetaxel arm received docetaxel (T) 75 mg/m&sup2;&nbsp;by&nbsp;intravenous infusion on&nbsp;day 1&nbsp;followed&nbsp;by cisplatin (P) 100&nbsp;mg/m&sup2;administered as a 30-minute&nbsp;to three-hour intravenous infusion, followed by the continuous intravenous infusion of 5-fluorouracil (F) 1000 mg/m&sup2;/day from day 1 to day 4. The cycles were repeated every 3 weeks for 3 cycles. All patients who did not have progressive disease were to&nbsp;receive chemoradiotherapy (CRT) as per protocol (TPF/CRT). Patients on the comparator arm received cisplatin (P) 100 mg/m&sup2; as a 30-minute to three-hour intravenous infusion&nbsp;on day 1 followed by the continuous intravenous infusion of 5-fluorouracil (F) 1000 mg/m&sup2;/day from day 1 to day 5. The cycles were repeated every 3 weeks for 3 cycles. All patients who did not have progressive disease were to receive CRT as per protocol (PF/CRT).</p><p>Patients in both treatment arms were to receive 7 weeks of CRT following induction chemotherapy with a minimum interval of 3 weeks and no later than 8 weeks after start of the last cycle (day 22 to day 56 of last cycle).&nbsp;Duringradiotherapy,&nbsp;carboplatin&nbsp;(AUC&nbsp;1.5)&nbsp;was&nbsp;given&nbsp;weekly&nbsp;as&nbsp;a&nbsp;one-hour&nbsp;intravenous&nbsp;infusion&nbsp;for a maximum of 7 doses. Radiation was delivered with&nbsp;megavoltage equipment using once daily&nbsp;fractionation (2 Gy per day, 5 days per week for 7 weeks, for a total dose of 70-72 Gy). Surgery on the primary site of disease and/or neck could be considered at any time following completion of CRT. All patients on the docetaxel-containing arm of the study received prophylactic antibiotics. The primary efficacy endpoint in this study, overall survival (OS) was significantly longer (log-rank test, p = 0.0058) with the docetaxel- containing regimen compared to PF (median OS: 70.6 versus 30.1 months respectively), with a 30% risk reduction in mortality compared to PF (hazard ratio (HR) = 0.70, 95% confidence interval (CI) = 0.54-0.90) with an overall median follow up time of 41.9 months. The secondary endpoint, PFS, demonstrated a 29% risk reduction of progression or death and a 22-month improvement in median PFS (35.5 months for TPF and 13.1 for PF). This was also statistically significant with an HR of 0.71; 95% CI 0.56-0.90; log-rank test&nbsp;p = 0.004. Efficacy results are presented in the table below:</p><p>&nbsp;</p><p><strong>Efficacy&nbsp;of&nbsp;docetaxel&nbsp;in&nbsp;the&nbsp;induction&nbsp;treatment&nbsp;of&nbsp;patients&nbsp;with&nbsp;locally&nbsp;advanced&nbsp;SCCHN&nbsp;(Intent-to- Treat Analysis)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Docetaxel&nbsp;+&nbsp;Cis&nbsp;+&nbsp;5-U</strong></p><p>n=225</p></td><td style="vertical-align:top"><p><strong>Cis&nbsp;+&nbsp;5-FU</strong></p><p>n=246</p></td></tr><tr><td style="vertical-align:top"><p>Median&nbsp;overall&nbsp;survival&nbsp;(months)</p></td><td style="vertical-align:top"><p>70.6</p></td><td style="vertical-align:top"><p>30.1</p></td></tr><tr><td style="vertical-align:top"><p>(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>(49.0-NA)</p></td><td style="vertical-align:top"><p>(20.9-51.5)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard&nbsp;ratio</p></td><td colspan="2" style="vertical-align:top"><p>0.70</p></td></tr><tr><td style="vertical-align:top"><p>(95%&nbsp;CI)</p></td><td colspan="2" style="vertical-align:top"><p>(0.54-0.90)</p></td></tr><tr><td style="vertical-align:top"><p>*p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.0058</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:448px"><tbody><tr><td style="vertical-align:top; width:202px"><p>Median&nbsp;PFS&nbsp;(months)</p></td><td style="vertical-align:top; width:156px"><p>35.5</p></td><td style="vertical-align:top; width:87px"><p>13.1</p></td></tr><tr><td style="vertical-align:top; width:202px"><p>(95%&nbsp;CI)</p></td><td style="vertical-align:top; width:156px"><p>(19.3-NA)</p></td><td style="vertical-align:top; width:87px"><p>(10.6-20.2)</p></td></tr><tr><td style="vertical-align:top; width:202px"><p>Hazard&nbsp;ratio</p></td><td style="vertical-align:top; width:156px"><p>0.71</p></td><td style="vertical-align:top; width:87px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:202px"><p>(95%&nbsp;CI)</p></td><td style="vertical-align:top; width:156px"><p>(0.56-0.90)</p></td><td style="vertical-align:top; width:87px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:202px"><p>**p-value</p></td><td style="vertical-align:top; width:156px"><p>0.004</p></td><td style="vertical-align:top; width:87px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:202px"><p>Best&nbsp;overall&nbsp;response&nbsp;(CR+PR)&nbsp;to</p></td><td style="vertical-align:top; width:156px"><p>71.8</p></td><td style="vertical-align:top; width:87px"><p>64.2</p></td></tr><tr><td style="vertical-align:top; width:202px"><p>chemotherapy&nbsp;(%)</p></td><td style="vertical-align:top; width:156px"><p>(65.8-77.2)</p></td><td style="vertical-align:top; width:87px"><p>(57.9-70.2)</p></td></tr><tr><td style="vertical-align:top; width:202px"><p>(95%&nbsp;CI)</p></td><td style="vertical-align:top; width:156px"><p>&nbsp;</p></td><td style="vertical-align:top; width:87px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:202px"><p>***p-value</p></td><td colspan="2" style="vertical-align:top; width:243px"><p>0.070</p></td></tr><tr><td style="vertical-align:top; width:202px"><p>Best&nbsp;overall&nbsp;response&nbsp;(CR+PR)&nbsp;to</p></td><td style="vertical-align:top; width:156px"><p>76.5</p></td><td style="vertical-align:top; width:87px"><p>71.5</p></td></tr><tr><td style="vertical-align:top; width:202px"><p>study&nbsp;treatment&nbsp;[chemotherapy&nbsp;+/-</p></td><td style="vertical-align:top; width:156px"><p>(70.8-81.5)</p></td><td style="vertical-align:top; width:87px"><p>(65.5-77.1)</p></td></tr><tr><td style="vertical-align:top; width:202px"><p>chemoradiotherapy]&nbsp;(%)</p></td><td style="vertical-align:top; width:156px"><p>&nbsp;</p></td><td style="vertical-align:top; width:87px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:202px"><p>(95%&nbsp;CI)</p></td><td style="vertical-align:top; width:156px"><p>&nbsp;</p></td><td style="vertical-align:top; width:87px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:202px"><p>***&nbsp;p-value</p></td><td colspan="2" style="vertical-align:top; width:243px"><p>0.209</p></td></tr></tbody></table><p>A&nbsp;Hazard&nbsp;ratio&nbsp;of&nbsp;less&nbsp;than&nbsp;1&nbsp;favors&nbsp;docetaxel +&nbsp;cisplation&nbsp;+&nbsp;fluorouracil</p><p>*un-adjusted&nbsp;log-rank&nbsp;test</p><p>**un-adjusted&nbsp;log-rank&nbsp;test,&nbsp;not&nbsp;adjusted&nbsp;for&nbsp;multiple&nbsp;comparisons</p><p>***Chi&nbsp;square&nbsp;test,&nbsp;not&nbsp;adjusted&nbsp;for&nbsp;multiple&nbsp;comparisons NA &ndash; not applicable</p><p>&nbsp;</p><p><u>Pediatric&nbsp;population</u></p><p>&nbsp;</p><p>The&nbsp;European&nbsp;Medicines&nbsp;Agency&nbsp;has&nbsp;waived&nbsp;the&nbsp;obligation&nbsp;to&nbsp;submit&nbsp;the&nbsp;results&nbsp;of studies&nbsp;with&nbsp;docetaxel in all subsets of the paediatric population in breast cancer, non-small cell lung cancer, prostate cancer, gastric carcinoma and head and neck cancer, not including type II and III less differentiated nasopharyngeal carcinoma (see section 4.2 for information on pediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>The pharmacokinetics of docetaxel have been evaluated in cancer patients after administration of 20-115 mg/m<sup>2</sup>&nbsp;in Phase I studies. The kinetic profile of docetaxel is dose independent and&nbsp;consistent with a three- compartmentpharmacokinetic&nbsp;model with&nbsp;half-lives&nbsp;for the&nbsp;&alpha;,&nbsp;&beta;&nbsp;and&nbsp;&gamma; phases&nbsp;of&nbsp;4&nbsp;min,&nbsp;36&nbsp;min&nbsp;and&nbsp;11.1&nbsp;h, respectively. The late phase is due, in part, to a relatively slow efflux of docetaxel from the peripheral&nbsp;compartment.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Following&nbsp;the&nbsp;administration&nbsp;of&nbsp;a&nbsp;100&nbsp;mg/m<sup>2</sup>&nbsp;dose&nbsp;given&nbsp;as&nbsp;a&nbsp;one-hour&nbsp;infusion&nbsp;a&nbsp;mean&nbsp;peak&nbsp;plasma&nbsp;level&nbsp;of</p><p>3.7 &micro;g/ml was obtained with a corresponding AUC of 4.6 h.&micro;g/ml. Mean values for total body clearance and steady-state volume of distribution were 21 l/h/m<sup>2</sup>&nbsp;and 113 l, respectively. Inter individual variation in total body clearance was approximately 50%. Docetaxel is more than 95% bound to plasma proteins.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>A study of&nbsp;<sup>14</sup>C-docetaxel has been conducted in three cancer patients. Docetaxel was eliminated in both the urine and fecal following cytochrome P450-mediated oxidative metabolism of the tert-butyl ester group, within seven days, the urinary and fecal excretion accounted for about 6% and 75% of the administered radioactivity, respectively. About 80% of the radioactivity recovered in fecal is excreted during the first 48 hours&nbsp;as&nbsp;one&nbsp;major&nbsp;inactive&nbsp;metabolite&nbsp;and&nbsp;3&nbsp;minorinactive&nbsp;metabolites&nbsp;and&nbsp;very&nbsp;low&nbsp;amounts&nbsp;of unchanged medicinal product.</p><p>&nbsp;</p><p><u>Special&nbsp;populations</u></p><p>&nbsp;</p><p><em>Age&nbsp;and&nbsp;gender</em></p><p>A&nbsp;population&nbsp;pharmacokinetic&nbsp;analysis&nbsp;has&nbsp;been&nbsp;performed&nbsp;with&nbsp;docetaxel&nbsp;in&nbsp;577&nbsp;patients.&nbsp;Pharmacokinetic parameters estimated by the model were very close to those estimated from Phase I studies. The pharmacokinetics of docetaxel were not altered by the age or sex of the patient.</p><p>&nbsp;</p><p><em>Hepatic&nbsp;impairment</em></p><p>In a small number of patients (n=23) with clinical chemistry data suggestive of mild to moderate liver functionimpairment&nbsp;(ALT,&nbsp;AST&nbsp;&ge; 1.5&nbsp;times&nbsp;the&nbsp;ULN&nbsp;associated&nbsp;with&nbsp;alkaline&nbsp;phosphatase&nbsp;&ge;&nbsp;2.5&nbsp;times&nbsp;the ULN), total clearance was lowered by 27% on average (see section 4.2).</p><p>&nbsp;</p><p><em>Fluid&nbsp;retention</em></p><p>Docetaxel&nbsp;clearance&nbsp;was&nbsp;not modified&nbsp;in&nbsp;patients&nbsp;with&nbsp;mild&nbsp;to&nbsp;moderate&nbsp;fluid&nbsp;retention&nbsp;and&nbsp;there&nbsp;are&nbsp;no&nbsp;data available in patients with severe fluid retention.</p><p>&nbsp;</p><p><u>Combination&nbsp;therapy</u></p><p>&nbsp;</p><p><em>Doxorubicin</em></p><p>When&nbsp;used&nbsp;in&nbsp;combination,&nbsp;docetaxel&nbsp;does&nbsp;not&nbsp;influence&nbsp;the&nbsp;clearance&nbsp;of&nbsp;doxorubicin&nbsp;and&nbsp;the&nbsp;plasma&nbsp;levels of doxorubicinol (a doxorubicin metabolite). The pharmacokinetics of docetaxel, doxorubicin and cyclophosphamide were not influenced by their coadministration.</p><p>&nbsp;</p><p><em>Capecitabine</em></p><p>Phase I study evaluating the effect of capecitabine on the pharmacokinetics of docetaxel and vice versa&nbsp;showed&nbsp;noeffect&nbsp;by&nbsp;capecitabine&nbsp;on&nbsp;the&nbsp;pharmacokinetics&nbsp;of&nbsp;docetaxel&nbsp;(Cmax&nbsp;and&nbsp;AUC)&nbsp;and&nbsp;no&nbsp;effect&nbsp;by&nbsp;docetaxel on the pharmacokinetics of a relevant capecitabine metabolite 5&rsquo;-DFUR.</p><p>&nbsp;</p><p><em>Cisplatin</em></p><p>Clearance of docetaxel in combination therapy with cisplatin was similar to that observed following monotherapy.&nbsp;Thepharmacokinetic&nbsp;profile&nbsp;of&nbsp;cisplatin&nbsp;administered&nbsp;shortly&nbsp;after&nbsp;docetaxel&nbsp;infusion&nbsp;is similar to that observed with cisplatin alone.</p><p>&nbsp;</p><p><em>Cisplatin&nbsp;and&nbsp;5-fluorouracil</em></p><p>The&nbsp;combined&nbsp;administration&nbsp;of docetaxel,&nbsp;cisplatin&nbsp;and&nbsp;5-fluorouracil&nbsp;in&nbsp;12&nbsp;patients&nbsp;with&nbsp;solid&nbsp;tumors&nbsp;had no influence on the pharmacokinetics of each individual medicinal product.</p><p>&nbsp;</p><p><em>Prednisone&nbsp;and&nbsp;dexamethasone</em></p><p>The&nbsp;effect&nbsp;of&nbsp;prednisone&nbsp;on&nbsp;the&nbsp;pharmacokinetics&nbsp;of&nbsp;docetaxel&nbsp;administered&nbsp;with&nbsp;standard&nbsp;dexamethasone premedication has been studied in 42 patients.</p><p>&nbsp;</p><p><em>Prednisone</em></p><p>No&nbsp;effect&nbsp;of&nbsp;prednisone&nbsp;on&nbsp;the&nbsp;pharmacokinetics&nbsp;of&nbsp;docetaxel&nbsp;was&nbsp;observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The&nbsp;carcinogenic&nbsp;potential&nbsp;of&nbsp;docetaxel&nbsp;has&nbsp;not&nbsp;been&nbsp;studied.</p><p>&nbsp;</p><p>Docetaxel has been shown to be mutagenic in the&nbsp;<em>in vitro&nbsp;</em>micronucleus and chromosome aberration test in CHO-K1cells&nbsp;and&nbsp;in&nbsp;the&nbsp;<em>in&nbsp;vivo&nbsp;</em>micronucleus&nbsp;test&nbsp;in&nbsp;the&nbsp;mouse.&nbsp;However,&nbsp;it did&nbsp;not induce&nbsp;mutagenicity&nbsp;in the Ames test or the CHO/HGPRT gene mutation assay. These results are consistent with the pharmacological activity of docetaxel.</p><p>&nbsp;</p><p>Undesirable&nbsp;effects&nbsp;on&nbsp;the&nbsp;testis&nbsp;observed&nbsp;in&nbsp;rodent toxicity&nbsp;studies&nbsp;suggest that docetaxel&nbsp;may&nbsp;impair&nbsp;male&nbsp;fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Citric&nbsp;acid&nbsp;anhydrous</p><p>&nbsp;Povidone</p><p>Polysorbate 80</p><p>Ethanol absolute</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This&nbsp;medicinal&nbsp;product&nbsp;must&nbsp;not&nbsp;be&nbsp;mixed&nbsp;with&nbsp;other&nbsp;medicinal&nbsp;products&nbsp;except&nbsp;those&nbsp;mentioned&nbsp;in&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial:
24 months.

After opening of the vial:
Each vial is for single use and should be used immediately after opening. If not used immediately, in-use storage times and conditions are the responsibility of the user.

Once added to the infusion bag:
From a microbiological point of view, reconstitution/dilution must take place in controlled and aseptic conditions and the medicinal product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.

Once added as recommended into the infusion bag, the docetaxel infusion solution, if stored below 25°C, in non-PVC bags, is stable for 8 hours. It should be used within 8 hours (including the one hour infusion intravenous administration).

In addition, physical and chemical in-use stability of the infusion solution prepared as recommended has been demonstrated for 3 days when stored between 2 to 8°C protected from light.

Docetaxel infusion solution is supersaturated, therefore may crystallize over time. If crystals appear, the solution must no longer be used and shall be discarded.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store&nbsp;below&nbsp;30&deg;C.</p><p>Store&nbsp;in&nbsp;the&nbsp;original&nbsp;package&nbsp;in&nbsp;order&nbsp;to&nbsp;protect&nbsp;from&nbsp;light. Do not refrigerate or freeze.</p><p>For&nbsp;storage&nbsp;conditions&nbsp;after&nbsp;opening&nbsp;of&nbsp;the&nbsp;vials&nbsp;and&nbsp;of&nbsp;the&nbsp;diluted&nbsp;medicinal&nbsp;product,&nbsp;see&nbsp;section&nbsp;6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Colourless&nbsp;glass&nbsp;vial&nbsp;(type&nbsp;I) closed&nbsp;with&nbsp;a&nbsp;bromobutyl&nbsp;rubber stopper&nbsp;(type&nbsp;I) sealed&nbsp;with&nbsp;aluminium&nbsp;cap with polypropylene disc. Vial will be packed with or without a protective plastic overwrap.</p><p>&nbsp;</p><p><em>Pack&nbsp;sizes:</em></p><p>1&nbsp;x&nbsp;4&nbsp;ml&nbsp;into&nbsp;8&nbsp;ml&nbsp;vial&nbsp;(S.&nbsp;C.&nbsp;Sindan-Pharma&nbsp;S.R.L) 1 x 4 ml into 10 ml vial (Actavis Italy S.p.A.)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Docadex is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing Docadex solutions. Cytotoxic agents should be prepared for administration only by personnel who have been trained in the safe handling of such preparations. Refer to local cytotoxic guidelines before commencing. The use of gloves is recommended. If Docadex concentrate or infusion solution should come into contact with skin, wash immediately and thoroughly with soap and water.&nbsp;If Docadex&nbsp;concentrate&nbsp;or infusion&nbsp;solution&nbsp;shouldcome&nbsp;into&nbsp;contact with&nbsp;mucous&nbsp;membranes,&nbsp;wash immediately and thoroughly with water.</p><p>&nbsp;</p><p><em>Preparation&nbsp;of&nbsp;the&nbsp;solution&nbsp;for&nbsp;infusion</em></p><p>More than one vial of Docadex 20 mg/ml concentrate for solution for infusion may be necessary to obtain the required dose for individual patients. Based on the required dose for the patient expressed in mg, aseptically&nbsp;withdraw&nbsp;thecorresponding&nbsp;volume&nbsp;of 20&nbsp;mg/ml docetaxel&nbsp;from&nbsp;the&nbsp;appropriate&nbsp;number&nbsp;of vials using graduated syringes fitted with a needle. For example, a dose of 140 mg docetaxel would require 7 ml of Docadex 20 mg/ml concentrate for solution for infusion.</p><p>&nbsp;</p><p>For doses below 192 mg of docetaxel, inject the required volume of Docetaxel 20 mg/ml concentrate for solution&nbsp;for infusion&nbsp;into&nbsp;a&nbsp;250&nbsp;ml infusion&nbsp;bag&nbsp;or bottle&nbsp;containing&nbsp;either&nbsp;250&nbsp;ml&nbsp;of 50&nbsp;mg/ml (5%) glucose solution for infusion or 9 mg/ml (0.9%) sodium chloride solution for infusion. For doses exceeding 192 mg of docetaxel more than 250 ml of the infusion solution is required, as the maximum concentration of docetaxel is 0.74 mg per ml of infusion solution.</p><p>&nbsp;</p><p>Mix the infusion bag or bottle manually using a rocking motion. The diluted solution should be used within 8&nbsp;hoursand&nbsp;should&nbsp;be&nbsp;aseptically&nbsp;administered&nbsp;as&nbsp;a&nbsp;1-hour infusion&nbsp;at&nbsp;room temperature&nbsp;and&nbsp;normal&nbsp;lighting&nbsp;conditions.</p><p>&nbsp;</p><p><em>Administration</em></p><p>For&nbsp;instructions&nbsp;on&nbsp;administration&nbsp;see&nbsp;Section&nbsp;4.2.</p><p>&nbsp;</p><p>As&nbsp;with&nbsp;all parenteral&nbsp;products,&nbsp;this&nbsp;medicinal product&nbsp;should&nbsp;be&nbsp;visually&nbsp;inspected&nbsp;prior&nbsp;to&nbsp;use&nbsp;and solutions containing a precipitate should be discarded.</p><p>&nbsp;</p><p>Any&nbsp;unused&nbsp;product&nbsp;or&nbsp;waste&nbsp;material&nbsp;should&nbsp;be&nbsp;disposed&nbsp;of&nbsp;in&nbsp;accordance&nbsp;with&nbsp;local&nbsp;requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tadawy Biomedical company 
Olaya st
Riyadh 
Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                XXXX
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>